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Abstract 
G protein-coupled receptors (GPCRs) play an essential role in cell communications and 
sensory functions. Consequently, they are involved in wide variety of diseases and are targets for 
many drug therapies. Particularly important is the large number of orphan GPCRs, which may 
play important, albeit unknown, functions in various cells. To understand their respective 
physiological roles, it is important to identify their endogenous ligands, and to find small 
molecule ligands that would serve as selective agonists or antagonists. The mas-related gene G 
protein-coupled receptors (Mrg receptors) belong to the orphan GPCR family, which is expressed 
in a specific subset of sensory neurons known to detect painful stimuli, suggesting that they could 
be involved in pain sensation or modulation.  
The primary focus of this thesis is to predict the 3D structure and binding site of Mrg 
receptors and to identify novel ligands that would be potential agonists or antagonists. We predict 
the 3D structure for the mouse MrgC11 (mMrgC11) and the binding site for five chiral FMRF-
NH2 ligands. We correctly predict the relative binding observed for these five ligands. We find 
that Tyr110 (TM3), Asp161 (TM4), and Asp179 (TM5) are particularly important to binding the 
ligands. Subsequently, we carry out mutagenesis experiments followed by intracellular calcium 
release assays that demonstrate the dramatic decrease in activity for the Y110A, D161A, and 
D179A mutants predicted by our model.  
The all-atom molecular dynamics simulation of the mMrgC11/F-(D)M-R-F-NH2 complex 
structure in explicit water and infinite lipid membrane system shows that some conformational 
fluctuations are present, but no significant instability is detected, thus validating our structure 
prediction method. 
The virtual screening with the combination of QSPR and docking methods is carried out 
for the predicted mMrgC11 receptor. The compounds showing the antagonistic effect are 
 vi
identified by competitive functional assays. These hit compounds are certainly good staring 
points in designing better agonists or antagonists.  
The binding site of rat MrgA receptor that shows differential binding between adenine and 
guanine is also predicted. The predicted binding affinity correlates with the availability of the 
hydrogen bonds to two Asn residues, which would be primary mutation candidates to validate the 
structure. 
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Chapter 1  
Introduction 
Cells and organelles are bounded by membranes, which are composed of lipids and 
proteins. The lipids form a bilayered structure that is hydrophilic on its two outer surfaces and 
hydrophobic in between, and proteins are embedded in this layer. These membrane proteins can 
be classified into two broad categories—integral and peripheral—based on the protein-membrane 
interactions[1]. Most integral membrane proteins span the entire membrane (i.e., transmembrane 
protein). The regions of the protein that are actually crossing the bilayer are in most cases α 
helices, but are in some cases mutiple β strands as in porins. Although some proteins only pass 
through the membrane once as an α helix, others may be multipass, having several 
transmembrane α helices connected by hydrophilic loops. Some of integral proteins are anchored 
to the membrane by one α helix parallel to the plane of the membrane. Peripheral membrane 
proteins are usually bound to the membrane indirectly by non-covalent interactions with integral 
membrane proteins or directly by interactions with lipid polar head groups.  
The transmembrane proteins play a role as active mediators between the cell and its 
environment or the interior of an organelle and the cytosol. They catalyze specific transport of 
ions across the membrane barriers (e.g., ion channels). They convert the energy of sunlight into 
chemical and electrical energy (e.g., photosynthetic reaction centers). They serve as signal 
receptors, for example, the G protein-coupled receptors (GPCRs) that are the main subject in this 
thesis, and transduce signals across the membrane. The signals can be neurotransmitters, growth 
factors, hormones, light or chemotactic stimuli.  
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In this chapter we outline GPCRs, one of important transmembrane receptor families, on 
the structural and functional aspects, and discuss orphan GPCRs and an effort to identify their 
endogenous ligands and physiological functions (deorphanization). Lastly, the principles of 
molecular modeling are explained, focusing on the techniques used in our studies for the 
structural and functional prediction of GPCRs. 
1.1 G protein-coupled receptors 
GPCRs comprise a large and diverse family of proteins whose primary function is to 
induce extracellular stimuli into intracellular signals. These stimuli include light, 
neurotransmitters, odorants, biogenic amines, lipids, proteins, amino acids, hormones, nucleotides, 
and chemokines. They are among the largest and most diverse protein families in mammalian 
genomes[2]. The common structural feature is that they have seven transmembrane-spanning α-
Figure 1.1 Various ways in which membrane proteins associate with the lipid bilayer. Most trans-
membrane proteins are thought to extend across the bilayer (1) as a single α helix, (2) as multiple α
helices, or (3) as a rolled-up β sheet (a β barrel). Some of these "single-pass" and "multipass" proteins 
have a covalently attached fatty acid chain inserted in the cytosolic lipid monolayer (1). Other membrane 
proteins are exposed at only one side of the membrane. (4) Some of these are anchored to the cytosolic 
surface by an amphipathic a helix that partitions into the cytosolic monolayer of the lipid bilayer through 
the hydrophobic face of the helix. (5) Others are attached to the bilayer solely by a covalently attached 
lipid chain – either a fatty acid chain or a prenyl group in the cytosolic monolayer or, (6) via an 
oligosaccharide linker, to phosphatidylinositol in the noncytosolic monolayer. (7, 8) Finally, many proteins 
are attached to the membrane only by noncovalent interactions with other membrane proteins[1]. 
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helical segments connected by alternating intracellular and extracellular loops, with the amino 
terminus located on the extracellular side and the carboxyl terminus on the intracellular side (fig. 
1.2). GPCRs can be divided into three major subfamilies; rhodopsin-like family (family A), 
glucagon receptor-like family (family B) and metabotropic neurotransmitter/calcium receptors 
(family C)[3]. The family A has the largest number of receptors including biogenic amine 
receptors (adrenergic, serotonin, dopamine, muscarinic, histamine), neurotensin receptors, 
chemokine receptors, opioid receptors, and olfactory receptors. In a recent analysis of the GPCRs 
in the human genome more than 800 human GPCRs were listed[4]. Among them a total of 701 
receptors belong to the rhodopsin-like family and, of these, 241 are non-olfactory. 
GPCRs have been named based on their ability to recruit and regulate the activity of 
intracellular heterotrimeric G proteins (α, β and γ subunits)[3]. The extracellular signaling (ligand 
binding) is followed by a change in the conformation of the receptor. This activated receptor 
induces a conformational change in the associated G protein α subunit, leading to release of a 
guanosine diphosphate (GDP) followed by binding of a guanosine triphosphate (GTP). 
Subsequently, the GTP-bound form of the α subunit dissociates from the receptor as well as from 
COO-
NH3+
Exterior
Cytosol
TM1 TM2 TM3 TM4 TM5 TM6 TM7
EC1
EC2
EC3
IC1 IC2
IC3
Figure 1.2 Schematic diagram of the general structure of G protein-coupled receptors. All receptors of 
this type contain seven transmembrane α-helical regions. The loop between α helices 5 and 6, and in 
some cases the loop between helices 3 and 4, which face the cytosol, are important for interactions with 
the coupled G protein. TM1–TM7 = transmembrane domains; EC1–EC3 = extracellular loops; IC1–IC3 = 
intracellular loops. 
 4
the stable βγ-dimer. Both the GTP-bound α subunit and the free βγ-dimer modulate several 
intracellular signaling pathways. These include stimulation or inhibition of adenylate cyclase and 
activation of phospholipases, in addition to regulation of potassium and calcium channel 
activity[5]. This variety of intracellular signaling pathways is dictated by the different G protein 
types in α, β and γ subunits and multiplicity in G protein coupling, that is, the simultaneous 
functional coupling of GPCRs with distinct unrelated G proteins[6]. There are at least 18 different 
human Gα proteins, at least 5 types of Gβ subunits and at least 11 types for Gγ subunits.  
Signaling is then attenuated (desensitized) by GPCR internalization, which is facilitated by 
arrestin binding[7]. Arrestins bind specifically to GPCRs phosphorylated by G protein-coupled 
receptor kinases (GRKs) and lead to an interaction which participates in the desensitization of the 
receptor by disturbing their coupling to G proteins. Arrestins also target the receptors for 
internalization by means of their ability to interact with clathrin. Thus signaling, desensitization 
and eventual resenstization are regulated by complex interactions of various intracellular domains 
of the GPCRs with numerous intracellular proteins.  
1.2 Orphan GPCRs and deorphanization 
Although the biology of GPCRs is certainly intriguing, their ultimate importance is 
underscored by the fact that approximately 25% of the top 200 best-selling drugs target GPCRs 
(http://www.mindbranch.com/products/R359-0071.html) although only 10% of non-sensory 
GPCRs are known drug targets, emphasizing the potential of the remaining 90% of the GPCR 
superfamily for the treatment of human disease[8]. Among the non-sensory  approximately 360 
GPCR genes, the endogenous ligands have been identified for around 210 receptors leaving ~150 
receptors for which the ligands remain unknown (“orphan receptors”)[9]. These orphan receptors 
may play important, albeit unknown, functions in various cells, so that some of them may be 
potential candidates for new drug targets. 
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Discovery of the endogenous ligand for an orphan receptor is the preferred strategy in 
deorphanization process since it provides additional biological information derived from the 
ligand that might give initial clues to the utility of receptor in disease and address 
pharmacological anomalies. The orphan receptor strategy has been developed with the aim of 
discovering novel natural ligands[10]. In this strategy, the cloned orphan GPCR is transfected in 
cells, which are then exposed to a tissue extract. Activation of the orphan GPCR is monitored by 
second messenger response. The tissue extract is fractionated and isolated to determine the 
chemical structure of the active compound. Melanin concentrating hormone (MCH), urotensin II 
and neuromedin U are example peptide ligands paired with orphan GPCRs through this strategy. 
In the reverse pharmacology strategy, orphan GPCRs are screened using mixtures of 
synthetic ligands (naturally occurring). This approach can be extended with use of small-
molecule focused libraries designed using known GPCR modulators (agonists or antagonists) as 
templates.  
The widely used cell-based screening assays are based on calcium ion mobilization or 
modulation of intracellular cyclic adenosine monophosphate (cAMP) level. The calcium ion is 
naturally produced in cells upon activation of GPCRs coupled to α subunits belonging to Gq 
family (fig. 1.3)[11]. The release α subunit couples to phosphoinositidases of the phospholipase β 
class (PLCβ). Activation of PLCβ induces the formation of inositol-triphosphate and 
diacylglycerol from phosphatidylinositol diphosphate. Inositol-triphosphate in turn stimulates the 
release of intracellular calcium from endoplasmic reticulum. The heterologous expression of a 
member of the Gαq family, Gα15 or Gα16, can allow coupling of a wide range of GPCRs to PLCβ 
activity through an alternative pathway. Therefore it is possible to force a receptor to response to 
an agonist via PLCβ activation, thus considerably broadening the range of receptors that will give 
a measurable calcium mobilization response.  
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Recently Dong et al.[12] and Lembo et al.[13] have identified a novel family of GPCRs 
called the Mas-related gene (Mrg) receptor for mouse or the sensory neuron specific receptor 
(SNSR) in mice and human. A subset of these receptors including mouse MrgA1 (mMrgA1) and 
mouse MrgC11 (mMrgC11) is distributed mainly to isolectin B4+, small diameter nociceptors in 
the dorsal root ganglia (DRG), which are suggested to be involved in pain sensation or 
modulation. Mrg receptors have been paired with structurally diverse transmitter peptides and 
provide a daunting case for deorphanization[14]. Although these receptors remain orphans, and 
their precise physiological function remains unknown, distinct and selective peptides activating 
some of these receptors have been identified:  
COO-
NH3+
Gαq β
γGDPCOO-
NH3+
Gαq β
γGTP
Gαq
β
γ
PLCβ
Inositol-triphosphate ↑
Ca2+ ↑
Cell response
Agonist
Figure 1.3 Classical examples of GPCR signalling. After agonist binding, a transient high-affinity complex 
of agonist, activated receptor and G protein is formed. GDP is released from the G protein and is 
replaced by GTP. This leads to dissociation of the G-protein complexes into a subunits and bg dimers, 
which both activate several effectors. Gaq, for instance, couples to phosphoinositidases of the 
phospholipase beta class (PLCb), which leads to an increase in inositol-triphosphate. Inositol-
triphosphate in turn stimulates the release of intracellular calcium.  
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• BAM22 derived from preproenkephalin A, one of endogenous opioid peptides activates 
SNSR3 (EC50 ~ 13 nM) or SNSR4 (EC50 ~ 16 nM)[13]. 
• The neuropeptide RF amides are potent for mouse Mrg receptors, for example, NPFF for 
MrgA1 (EC50 ~ 200 nM) and MrgC11 (EC50 ~ 54 nM) and NPAF for MrgA4 (EC50 ~ 60 nM)[12, 
15].  
• In addition, adenine shows high affinity (Ki ~ 18 nM) and potency for rat MrgA 
receptor[16].  
• Cortistatin has been identified to activate potently human MrgX2 (EC50 ~ 25 nM)[17]. 
• More recently Grazzini et al. have observed that γ2-MSH is highly potent in rat MrgC 
receptor and the active moiety recognized by rat MrgC receptor is the C-terminal RF-amide motif 
of γ2-MSH[18].  
• Recent studies also show that MrgD receptors specifically respond to β-alanine with 
micromolar concentration[19]. 
Our studies aimed to contribute to deorphanization of Mrg receptors, especially focusing 
on mMrgC11, mMrgA1 and rat MrgA, by characterizing the active site and screening the 
chemical libraries to search for the potential agonist or antagonists.  
1.3 The 3D structure of GPCR and molecular modeling 
Clearly it would be most useful to have the three-dimensional (3D) structure of the receptor 
to help select the most promising new ligands for experimental assays. Moreover the structural 
information is essential in designing receptor subtype-specific drugs. However, GPCRs, like other 
membrane proteins, are difficult to crystallize. Membrane proteins, which have both hydrophobic 
and hydrophilic regions on their surfaces, are not soluble in aqueous buffer and denature in 
organic solvent. In addition, because membrane proteins are typically produced in a 
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heterogeneous manner by cells with substantial variability in glycosylation, obtaining high-
quantity and high-purity GPCR proteins is very challenging[20]. All GPCRs are known to have a 
common motif of seven transmembrane helical structures, but the only GPCR crystal structure 
published at atomic resolution is of inactive conformation of rhodopsin[21]. Here comes the 
demand for prediction of the 3D structures of GPCRs. The low (<25 %) sequence homology with 
rhodopsin sheds some uncertainties on the accuracy of a 3D structure constructed by using the 
comparative homology modeling method. Clearly, then it is necessary to devise a general method 
that predicts more reliable structures.  
Recently MembStruk computational method to predict the 3D structure of GPCRs has been 
developed in Goddard’s group[22]. It includes prediction of transmembrane (TM) α helices using 
hydrophobicity profile with a set of homologous sequences, subsequent optimization in relative 
orientations of helices and then conformational optimization of the entire receptor structure using 
molecular mechanics (MM) and molecular dynamics (MD). The binding site of the GPCR is 
further predicted using the HierDock method to validate the predicted protein structure, and the 
binding modes of the ligand are suggested. In our study of Mrg receptors, we also applied the 
Membstruk method in prediction of their 3D structures and the HireDock method in 
characterization of the binding site. Chapter 2 describes the details in each step of the procedure.  
In the following sections, the basic principles of molecular modeling are explained with 
specific technique used in prediction of the 3D GPCR structure and the binding site. 
1.3.1 Hydrophobicity scale: TM prediction from the primary sequence 
The membrane helices are embedded in a hydrophobic environment and are built up from 
continuous regions of predominantly hydrophobic amino acids. Thus from the amino acid 
sequences, the regions that comprise the TM helices can be predicted with reasonable confidence. 
In order to determine whether the segment of amino acid sequences is likely to be a TM helix, we 
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need to measure the amount of hydrophobicity. The numerical hydrophobicity scales of each 
amino acid have been derived in several groups on the basis of solubility measurements of the 
amino acids in different solvents, vapor pressure of side-chain analogs, analysis of side-chain 
distributions within soluble proteins, and theoretical energy calculations. These values generally 
correspond to the free energy of transfer of the side chain of the amino acid from water to a 
nonpolar environment. In our study, we used the “consensus” hydrophobicity scale that Eisenberg 
et al. introduced by averaging the normalized hydrophobicities for each residue over the five 
known scales[23]. The hydrophobicity values of 20 amino acids in the Eisenberg scale are shown 
in table 1.1. 
With the given hydrophobicity scale, the hydropathy index, the mean value of the 
hydrophobicity of the amino acids within a window (12 to 20 residues long in MembStruk), is 
calculated for each position in the sequence.  In MembStuck, the hydropathy plot, the curve of the 
hydropathy indices against residue numbers is evaluated from the multiple sequence alignment of 
the set of homologous sequences with a target protein sequence[22]. First, the hydrophobicity at 
each residue position is averaged over all the sequences in the multiple sequence alignment. Then 
we calculate the mean hydrophobicity over a window size of residues around every residue 
position. Figure 1.4 shows one example of a hydropathy plot obtained from MembStruk. 
1.3.2 Force field 
The molecular state can be accurately described by solving the Schrödinger equation: 
Table 1.1 Eisenberg hydrophobicity scale
-0.07
P
0.73
I
-0.18
T
0.61
F
-0.26
S
0.54
V
-0.40
H
0.53
L
-0.62
E
0.37
W
-0.64
N
0.26
M
-0.69
Q
0.25
A
-0.72
D
0.16
G
-1.1
K
0.04
C
-1.8
R
0.02
Y
Hydrophobicity
Amino acid
Hydrophobicity
Amino acid
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),(),(),( rRrRErRH Ψ=Ψ ,        (1.1) 
where H is the Hamiltonian for the system, Ψ is the wavefunction, and E is the energy. In general, 
Ψ is a function of the coordinates of the nuclei (R) and of the electrons (r). Although this equation 
is quite general, it is too complex for any practical use, so approximations are made. Based on the 
Born-Oppenheimer approximation that the electrons are several thousands of times lighter than 
the nuclei and therefore move much faster, the motion of the electrons can be decoupled from that 
of the nuclei, giving two separate equations. The first equation describes the electronic motion:  
);()();()( RrRURrVH elelNNel ψψ =+ ,      (1.2) 
where the purely electronic Hamiltonian Hel includes nuclear repulsion VNN. It depends only 
parametrically on the positions of the nuclei. This equation defines the energy, U(R), which is a 
function of only the coordinates of the nuclei. This energy is usually called the potential energy 
surface.  
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Figure 1.4 Hydrophobicity profile for mouse MrgC11 sequence set (window size = 12) 
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The second equation then describes the motion of the nuclei on this potential energy 
surface U(R):  
)()( RERH NNN Φ=Φ .        (1.3) 
In principle, (1.2) could be solved for the potential energy U, and then (1.3) could be solved. 
However, the effort required to solve (1.2) is extremely large, so usually an empirical fit to the 
potential energy surface, commonly called the forcefield (V), is used. Since the nuclei are 
relatively heavy objects, quantum mechanical effects are often insignificant, in which case (1.3) 
can be replaced by Newton's equation of motion: 
2
2
dt
Rdm
dR
dV =− .         (1.4) 
The solution of (1.4) using an empirical fit to the potential energy surface U(R) is called 
“molecular dynamics”. Molecular mechanics ignores the time evolution of the system and instead 
focuses on finding particular geometries and their associated energies or other static properties.  
The potential energy is expressed as a sum of valence interaction, nonbonded interaction 
and additional terms such as constraints. The valence interactions consist of bond stretching (Ebond, 
two-body), bond angle bending (Eangle, three-body), dihedral angle torsion (Etorsion, four-body) and 
inversion (Einversion, four-body), that are in nearly all force fields of covalent systems plus cross- 
terms that are included in more sophisticated force fields developed to produce accurate 
vibrational frequencies. The nonbonded interactions are composed of van der Waals or dispersion 
(Evdw), electrostatic (Ecoulomb) and explicit hydrogen bonds (Ehbond) terms. Figure 1.5 shows the 
schematic representation of these valence and nonbonded interactions with the functional forms 
of potentials used in DREIDING force field[24]. 
1.3.3 Molecular mechanics 
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The potential energy of a system of N particles, U=U(r1, r2, …,rN), is minimized with the 
respect to their positions ri (and, possibly, some other internal coordinates). After an initial 
configuration has been specified, the positions of particles are adjusted using an iterative 
computational method until the minimum energy configuration is attained. It should be 
emphasized that U, which is a function of 3N variables, may possess a number of minima. No 
method guarantees that the lowest energy minimum will be found. 
All minimization methods pursue the following algorithm: if in the mth iteration the system 
of particles is described by position vectors ri(m) then in the (m + 1)th interation the position 
vectors are 
)()()1( m
i
m
i
m
i rrr Δ+=+ ,        (1.5) 
where Δri(m) is determined so as to decrease the potential energy and approach, eventually, a 
minimum of U(r1, r2, …,rN). Different molecular mechanics (MM) methods of relaxation differ in 
the way Δri(m) is determined. There are three commonly used methods for finding minima: 
steepest descent, Newton’s method and conjugate gradient. Here the conjugate gradient method 
that we used is explained briefly. The conjugate gradient method is based on the idea that the 
convergence to the energy minimum could be accelerated if we minimize a function (here U) 
over the hyperplane that contains all previous search directions. In steepest descent, the position 
vectors ri are being adjusted in proportion to the negative gradient of U, that is, the force Fi at any 
given iteration. However, in the conjugate gradient the directions of the displacements of the (m + 
1)th iteration are not determined only on the basis of the forces calculated in the mth iteration but 
also using values of the forces found in previous iterations. This is carried out as follows: 
The increment of the 3N dimensional vector }{ αir=R  is  
∑
=
Φ=Δ
N
k
kkR
3
1
λ ,         (1.6) 
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where Φk are 3N vectors in the 3N-dimensional space that have been gradually constructed in the 
previous 3N iterations. In the first iteration Φ1 = F(1), where F(1) is the 3N-dimensional vector of 
forces evaluated in the first iteration, and all other vectors Φk for k > 1 are set to zero. In the 
second iteration the vector Φ2 is constructed as Φ2 = F(2), similarly as in the first iteration; all 
other vectors Φk for k > 2 are set to zero. In the following iterations the recursive formula 
1)2()2(
)1()1(
)(
−−−
−−
Φ+=Φ mmmT
mmT
m
m FF
FFF        (1.7) 
is used to construct gradually additional vectors Φk; T denotes the transpose of the corresponding 
vector. Thus in every iteration, m, a new vector Φk is added until 3N vectors have been 
constructed in the first 3N iterations. At this point these 3N vectors are used to determine ΔR(3N+1) 
in the 3N+1 iteration according to (1.7). When the number of iterations, M, is larger than 3N, then 
3N vectors constructed in the previous 3N iterations are used in determining ΔR(M+1) in the M+1 
iteration. 
1.3.4 Molecular dynamics 
In molecular dynamics (MD) that investigates the motion of atoms in time as discussed in 
section 1.3.2, successive configurations of a system are generated by integrating Newton’s law of 
motion, hence resulting in a trajectory that specifies the positions and velocities of the atoms as 
function of time. In (1.4), the accelerations of atoms are determined from the gradient of the 
potential energy and therefore their velocities can be derived, resulting in new positions of the 
atoms.  
The approach taken by MD is to solve the equations of motion numerically on a computer. 
The most widely used algorithm of integrating the equations of motion is Verlet algorithm. It uses 
the positions and acceleration (= Fi/mi) at time t and the positions from the previous step, ri(t-Δt), 
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to calculate the new positions at t+Δt, ri(t+Δt). Using the central difference method for numerical 
evaluation of the second derivative, the equation of motion for ri can be written as 
)(1)]()(2)([
)(
1)(
22
2
tF
m
ttrtrttr
tdt
trd
i
i
iii
i =Δ−+−Δ+Δ= ,    (1.8) 
and therefore 
)()()()(2)(
2
tF
m
tttrtrttr i
i
iii
Δ+Δ−−=Δ+ .      (1.9) 
The basic recurrent formula for the MD simulation proceeds as follows: 
The forces Fi(JΔt) are first evaluated at the time step J. 
Positions ri((J+1)Δt) at the time step J+1 are calculated using (1.9) 
Velocities vi(JΔt) at the time step J+1 may be calculated as 
t
ttrttrtv iii Δ
Δ−−Δ+=
2
)()()(  .       (1.10) 
Implementation of the Verlet algorithm is straightforward and the storage requirements are 
modest, comprising two sets of positions and the force. One of its drawbacks is that the positions 
ri(t+Δt) are obtained by adding a small term (Δt)2Fi/mi to the difference of two much larger terms, 
2ri(t) and ri(t-Δt). This may lead to a loss of precision. Some other disadvantages are that it does 
not have an explicit velocity term in the equation and indeed velocities are not available until the 
positions have been computed at the next step. Moreover it is not a self-starting algorithm; the 
new positions are calculated from the current positions ri(t) and the previous time step, ri(t-Δt). 
The velocity Verlet method is one of the variations on the Verlet algorithm. It gives 
positions, velocities and forces at the same time and does not compromise precision. The MD 
simulation then proceeds as follows: 
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The forces Fi(JΔt) are first evaluated at the time step J. 
Positions ri((J+1)Δt) and velocities at the time step J+1 are evaluated as 
)(
2
)()()())1((
2
tJF
m
ttJtvtJrtJr i
i
iii ΔΔ+ΔΔ+Δ=Δ+      (1.11) 
))())1(((
2
)()())1(( tJFtJF
m
ttJvtJv ii
i
ii Δ+Δ+Δ+Δ=Δ+ .    (1.12) 
In the above formalism, the coupling of the system with a heat bath is not considered yet. 
Actually in the ensemble such as the canonical ensemble or the isobaric-isothermal ensemble 
where the temperature, T is kept constant, that is, the kinetic energy of the system should be 
constant, the scaling of the velocity is necessary during MD simulation. The simplest approach is 
to first compute the instantaneous kinetic energy ∑
=
N
i
iivm
1
2
2
1 from the velocities obtained from 
(1.10) or (1.12) and then scale velocities by a factor λ chosen such as to preserve the temperature 
T 
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TNkλ .         (1.13) 
The more sophisticated schemes are Anderson thermostat and Nose-Hoover thermostat in which 
the exchange of heat with a bath is explicitly included. 
1.3.5 Molecular docking 
In molecular docking, we attempt to predict the structure of the intermolecular complex 
formed between two molecules. Most docking cases target at the identification of the low-energy 
binding modes of a small molecule (a ligand) within the active site of a macromolecule such as a 
protein receptor, whose structure is known. Therefore solving a docking problem computationally 
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requires an accurate description of the molecular energetics (scoring function) as well as an 
efficient algorithm to search for the potential binding modes.  
The docking problem involves many degrees of freedom; three translational and three 
rotational freedom of one molecule relative to the other as well as the conformational degrees of 
freedom for each molecule. In reality, it is almost impossible to consider all possible degrees of 
freedom since one of the molecules in the docking problems is a macromolecule. Therefore the 
simplest algorithms treat the two molecules as rigid bodies and explore the six degrees of 
translational and rotational freedom. A well-known example is the DOCK program of Kuntz and 
co-workers[25]. DOCK is based on the shape complementarity between a ligand and the pocket 
in a receptor that forms the binding site. To describe the shape of the binding site in a receptor, 
the molecular surface is calculated first. The molecular surface is divided into two classes; the 
contact surface and the reentrant surface. The contact surface is the part of the van der Waals 
surface that can be touched by a probe sphere. The reentrant surface consists of the inward-facing 
Figure 1.6 Construction of molecular surface in 2D. The filled circles (cyan) correspond to the van der 
Waals spheres of the atoms. The molecular surface is obtained with a spherical probe and the contact 
surface is in magenta and the reentrant surface is in blue. Actually the molecular surface is a collection of 
points and vectors normal to the surface at each point. 
Probe sphere
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part of the probe sphere when it is in contact with more than one atom. The surface can only be 
defined completely with reference to a probe object of some form, and indeed depend on the 
probe size (the probe radius for a spherical probe). A spherical probe of radius 1.4Å to 
approximate a water molecule is most commonly used. In the diagram of figure 1.6 where the 
molecular surface is obtained with a spherical probe the contact surface is in magenta and the 
reentrant surface is in blue. 
Next a collection of overlapping spheres of varying radii filling the binding pocket is 
generated. Each sphere touches the molecular surface at two points (i, j) and has its center on the 
surface normal from point i and lies on the outside of the receptor surface (“negative image”). 
Ligand atom are matched to the sphere centers to find matching sets in which all the distances 
between the ligand atoms in the set are equal to the corresponding sphere center-sphere center 
distances within some tolerance (1 to 2Å). Actually matching four pairs is sufficient to determine 
the rigid docking. Then the ligand is positioned within the site by performing the least square fits 
of the atoms to the sphere centers, as shown in figure 1.8. The orientation may be checked to 
make sure that there is no unacceptable steric interaction between the ligand and the receptor. If 
the ligand orientation is acceptable, the interaction energy is calculated to give the “score” for that 
binding mode. The DOCK uses the grid-based energy evaluation in which the receptor-dependent 
terms in the potential function are pre-calculated at points on a 3D grid in order to minimize the 
i
j
Figure 1.7 A binding site represented as a collection of overlapping spheres. Each sphere touches the 
molecular surface at two points. 
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overall computational costs of evaluation[26]. Grid-based scoring can be accomplished when the 
ligand and receptor terms in the evaluation function are separable. It could be achieved in the 
following ways. The energy scores are calculated as a sum of van der Waals and electrostatic 
components:  
∑∑
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where each term is a double sum over ligand atoms i and receptor atoms j, Aij and Bij are van der 
Waals repulsion and attraction parameters, rij is the distance between atoms i and j, qi and qj are 
the point charges on atoms i and j, D is the dielectric constant and 332.0 is a factor that converts 
the electrostatic energy into kcal/mol. By using a geometric mean approximation, the van der 
Waals parameters Aij and Bij can be expressed with the single-atom-type parameters as follows: 
jjiiij AAA =  and jjiiij BBB = .       (1.15) 
Therefore Eq. 1.14 can be rewritten as: 
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Three values are stored for every grid point k, each a sum over receptor atoms that are within a 
user-defined distance of the point: 
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The final scoring function can be expressed in the multiplication of these values (which is may be 
values at the nearest point from the corresponding ligand atom or the results of trilinearly 
interpolating the values for the eight surrounding points) by the appropriate ligand values: 
[ ]∑
=
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iiiii esvalqbvalBavalAE
1
)()()(  .      (1.18) 
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Figure 1.8 Matching algorithm in DOCK. Atoms are matched to spheres centers and then molecule is 
placed in the binding pocket (Reproduced from [27]). 
New orientations are generated by matching different sets of ligand atoms and sphere centers and 
then scored. The top-scoring orientations are retained for subsequent analysis.  
To perform the flexible docking, the conformational degrees of freedoms should be 
considered. Most of the methods including DOCK take into account only the conformational 
space of the ligand and assume that the receptor is fixed. In DOCK, the rotatable bonds are 
defined with the possible discrete torsion angles based on the hybridizations of two atoms in the 
bond. The conformations of a ligand are searched or relaxed by modifying only the torsion angles 
with the bond lengths or angles fixed. DOCK uses two search strategies: incremental construction 
and random conformation search.  
To briefly explain, in the incremental construction (anchor and grow) technique a rigid 
portion of the ligand, the anchor, is first identified and docked using a geometrical matching 
procedure[28]. To select the anchor, all rotatable bonds in the ligand are identified and the ligand 
molecule is divided into rigid, overlapping segments, then the anchor segment is selected (fig. 
1.8). Usually the largest overlapping segment is chosen as the anchor. In the next step, the 
molecular atoms of the ligand organized into non-overlapping segments arranged concentrically 
around anchor. In the conformation search step, the remaining molecular segments are added to 
the docked anchor starting from the inner layer. On each cycle, a molecular segment is added to 
the current set of partial binding configurations and sampling the appropriate torsion positions of 
N
HO
N
HO
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the intervening rotatable bond. The set of partial binding configurations are pruned based on 
score and positional diversity to avoid the exponential growth of a systematic conformation 
search.  
When the conformational freedom is given to flexible ligand molecules during construction, 
the intramolecular energy term of the ligand should be considered in scoring. In addition to 
prevention of internal clash, the van der Waals and coulombic energies are computed for 
interaction between atoms in different rigid segments in DOCK. Atoms within a rigid segment 
are excluded because their contribution is a constant. The overall scoring includes both the 
intramolecular energy and the intermolecular energy between the ligand and the receptor 
discussed earlier. 
N
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N
O
N
O
N
N
O
O
N
A. Identify rotatable bonds.
B. Divide into overlapping rigid segments. Identify anchors. 
C. Divide into non-overlapping rigid segments. Organize by layer. 
Figure 1.9 Atom pre-organization and anchor selection[27]. 
Anchor
Layer1
Layer2
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The HierDock protocol[29] used in our study applies more sophisticated scoring method to 
the set of configurations generated from the DOCK run in order to complement the crude scoring 
function in DOCK. The selection of the top configurations proceeds in the hierarchical way; 
along with scoring steps the number of selected configurations decreases, and on the other hand 
the more degrees of freedom are taken into account in the energy scoring. Moreover the recent 
development of MSCDock (a new version of HierDock) incorporates the diversity and 
enrichment scheme into DOCK 4.0 to enhance the completeness in the conformation search. All 
the details are described in the next chapter. 
1.4 Outline of Thesis 
The following part of the thesis is composed of four chapters: 
• In chapter 2, we predict the 3D structure of the mMrgC11 and mMrgA1 receptors using the 
MembStruk computational method. We also predict the binding sites of the di- and tetra-
peptide ligands containing the RF amide motif that have been identified as agonists for these 
receptors. The subsequent mutagenesis experiments validate our prediction of the binding site 
in the mMrgC11 receptor. 
• Chapter 3 describes the all-atom MD simulation of mMrgC11/F-(D)M-R-F-NH2 complex in 
the explicit lipid and water environment.  
• In chapter 4, the virtual ligand screening for the predicted binding site of mMrgC11 receptor 
is carried out as an effort to identify novel non-peptide ligands.  
• In chapter 5, the 3D structure and the binding site of rat MrgA receptor are predicted using 
the homology modeling and docking method. 
In appendix A, the quantum mechanics and molecular dynamics study of the 5-
formyluracil, which was my earlier PhD subject, is discussed. 
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Chapter 2 
Prediction of the 3D Structure for FMRF-amide Peptides Bound to 
Mouse MrgC11 Receptor with Subsequent Experimental 
Verification1 
2.1 Introduction 
G protein-coupled receptors (GPCRs) play an essential role in cell communications and 
sensory functions as mentioned in chapter 1. Consequently they are involved in wide variety of 
diseases and are targets for many drug therapies. Particularly important is the large number of 
orphan GPCRs (for which the native ligands remain unknown), which may play important, albeit 
unknown, functions in various cells. To understand their respective physiological roles, it is 
important to identify their endogenous ligands, and to find small molecule ligands that would 
serve as selective agonists or antagonists. One example here is the family of GPCRs called the 
Mas-related gene (Mrg) receptor for mouse or the sensory neuron specific receptor (SNSR) in 
mouse and human[1, 2]. A subset of these receptors including mMrgC11 and mMrgA1 is 
localized mainly to isolectin B4+, the small diameter nociceptors in the dorsal root ganglia 
(DRG). Dong et al. showed that some of these receptors were activated by RFamide 
neuropeptides such as NPFF and NPAF and suggested them to be involved in pain sensation or 
modulation[1]. These Mrg receptors have been paired with structurally diverse transmitter 
peptides[3].  
                                                 
1 Portions of this chapter have been submitted to the Journal of Medical Chemistry for publication. 
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Clearly deorphanization would be greatly aided by having three-dimensional (3D) 
structures of the orphan receptors to help select the most promising new ligands for experimental 
assays, but it is not yet possible to obtain experimental 3D structures for human GPCRs. 
Consequently our group developed the MembStruk computational method[4, 5] to predict such 
structures and we demonstrate in this study that the predicted structures are sufficiently accurate 
to predict binding sites and relative binding energies. Previously MembStruk was applied to 
several GPCRs, obtaining ligand binding sites in excellent agreement with experiments. However 
in these studies the structural data were known prior to our calculations. Although any 
experimental data were not utilized in making our predictions, such validations are not 
completely convincing. We undertook this study on mMrgC11 and mMrgA1 receptors for the 
specific purpose of validating the MembStruk method. Thus prior to our calculations there were 
no data on how mutations affect binding. In addition the experiments had shown that the F-M-R-
F-NH2, (D)F-M-R-F-NH2 and F-(D)M-R-F-NH2 tetrapeptides activate mMrgC11 receptor at ~100 
nM concentration, while F-M-(D)R-F-NH2 and F-M-R-(D)F-NH2 are inactive (>10 μM). We 
assumed that explaining such an effect of chirality on binding should provide a strong test of the 
predicted structures.  
2.2 Computational methods 
All energy and force calculations were done using DREIDING force field (FF)[6] with the 
charges from CHARMM22[7] FF and were executed in the molecular dynamics program, 
MPSIM[8]. The cell multipole method[9] was used for the calculation of nonbond interaction. 
Unless otherwise specified all simulations were performed in gas phase with the dielectric 
constant of 2.5. 
2.2.1 Structure predictions of the Mrg receptor 
The 3D structure of the mMrgC11 and mMrgA1 receptors were predicted independently 
using MembStruk (version 4.05)[10]. The details of the MembStruk (version 3.5) were described  
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mMrgC11 MDPTISSHDTESTPLN-ETGHPNCTPILTLSFLVLITTLVGLAGNTIVLWLLGFRMRRKA 59 
mMrgA1  --------------MDNTIPGGINITILIPNLMIIIFGLVGLTGNGIVFWLLGFCLHRNA 46
mMrgC11 ISVYILNLALADSFFLCCHFIDSLLRIIDFYGLYAHKLSKDILGNAAIIPYISGLSILSA 119
mMrgA1  FSVYILNLALADFFFLLGHIIDSILLLLNVF--YP-ITFLLCFYTIMMVLYIAGLSMLSA 103
mMrgC11 ISTERCLCVLWPIWYHCHRPRNMSAIICALIWVLSFLMGILDWF-SGFLGETHHH-LWKN 177 
mMrgA1  ISTERCLSVLCPIWYHCHRPEHTSTVMCAVIWVLSLLICILNSYFCGFLNTQYKNENGCL 163
mMrgC11 -VDFIITAFLIFLFMLLSGSSLALLLRILCGPRRKPLSRLYVTIALTVMVYLICGLPLGL 236 
mMrgA1  ALNFFTAAYLMFLFVVLCLSSLALVARLFCGTGQIKLTRLYVTIILSILVFLLCGLPFGI 223 
mMrgC11 YLFLLYWFGVHLHYPFCHIYQVTAVLSCVNSSANPIIYFLVGSFRQHRKHRSLKRVLKRA 296 
mMrgA1  HWFLLFKIKDDFHVFDLGFYLASVVLTAINSCANPIIYFFVGSFRHRLKHQTLKMVLQNA 283 
mMrgC11 LEDTPEEDEYTDSHLHKTTEISESRY 322 
mMrgA1  LQDTPET---AKIMVEMSRSKSEP–– 304
TM1
TM2 TM3
TM4
TM5 TM6
TM7
 
Figure 2.1 Predicted transmembrane (TM) regions. The sequence alignment of mMrgC11 and mMrgA1 is 
based on the alignment with the entire set of sequences obtained by BLAST search with the mMrgC11 
sequence (see Fig. S2.1). The hydrophobic center of each TM is indicated with an arrow. The residues 
involved in the mutagenesis experiment are highlighted. 
 
in reference 10.  Here we outline the procedure, highlighting aspects also relevant to Mrg 
receptors or that were improved in version 4.05.  
Prediction of transmembrane regions 
The transmembrane (TM) regions and the hydrophobic maximum for each TM helix were 
predicted using the TM2ndS method[5]. We used NCBI BLAST[11] to search the non redundant 
protein database to find sequences homologous to the mMrgC11 receptor with bit scores greater 
than 200. These 27 sequence hits had sequence identities to mMrgC11 ranging from 41% to 88%. 
This set of sequences included the mMrgA1 receptor whose sequence identity to mMrgC11 is 
44%. Twenty-two of these 27 sequences belong to Mrg receptor family, with remaining 5 
corresponding to unnamed GPCRs. We then carried out a multiple sequence alignment with these 
27 sequences using ClustalW[12]. These results (Fig. S2.1) were used as input to TM2ndS. The 
hydrophobicity profile (Fig. S2.2) resulting from TM2ndS had no clear separation between TM2 
and TM3, leading to uncertainty in the boundaries between TM2 and TM3. A similar ambiguity 
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was observed between TM6 and TM7. To eliminate such problems, the MembStruk 4.05 
procedure calculates the hydrophobicity profile from a second round of seven TM predictions in 
which each sequence of the core of the seven TM (15 amino acids around the hydrophobic center) 
was used as a template. This second set of independent BLAST searches was executed under high 
gap penalty with each TM core. Here we selected GPCR sequences with sequence identities of 
>50% (the identity with the entire sequence of mMrgC11 was as low as 23%), see table S1. Then 
a second round of TM predictions was performed using the multiple sequence alignment of these 
7 sets of sequences, see Table S1. The final refined TM region and its hydrophobic center for 
each of the 7 TM domains were determined from this second round of prediction. For mMrgA1 
we used the same TM regions as assigned from alignment with mMrgC11. 
Assembly of TM helical bundle 
For each TM domain we built canonical α-helices with fully extended conformation of side 
chains. These were assembled such that the 7 predicted hydrophobic centers are all in the xy  
plane with the x and y coordinates adapted from the 7.5 Å electron density map of frog 
rhodopsin[13]. Each helix oriented about its axis so that its hydrophobic moment pointed away 
from the center of the seven helices (toward the membrane). The tilt of each helix with respect to 
the z axis and its azimuthal angle were adapted from the 7.5 Å electron density map of frog 
rhodopsin[13]. 
Then we carried out 200 ps of molecular dynamics (MD) at 300 K without solvent or lipid, 
but with charged side chains neutralized by adding Na+ or Cl- ions. This allows the conformation 
of each individual helix to bend or kink as appropriate. We then selected the snapshot with the 
lowest potential energy from the last 100 ps of the MD trajectory and the net hydrophobic 
moment was calculated for the middle 15 residues around the hydrophobic center for each helix 
using this conformation. Each helix was rotated again so that its hydrophobic moment faces 
toward the membrane. This hydrophobicity-based rotation works well for the six TM helices with 
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extensive contacts to lipid bilayers. Moreover, since the optimal orientation of a helix depends on 
the relative orientations of the neighboring helices, we often carry out a combinatorial rotation of 
the 7 helices. However we found that the structure predicted by the above process placed the 
highly conserved Asn44-Asp71 pair between TM1 and TM2 and the Asn66-Trp151 pair between 
TM2 and TM4 close enough to form hydrogen bonds (based only on the coarse hydrophobicity-
based rotation step). Therefore we carried out extensive 360º rotational orientation optimization 
only for TM3, TM5 and TM6. Here the rotational angle of TM3 was scanned for 360 º (in 30 º 
increments) because TM3 has the least surface area exposed to lipid, but TM5 and 6 were rotated 
only over the range of -60º to 60º since the orientation had already been optimized roughly using 
the hydrophobic moment. For every rotation we reassigned the side chain conformation using 
SCWRL3.0[14] before energy-minimization. The orientation with the best energy was then 
selected. The results of these scans are shown in Table S2. The rotational orientation of TM7 was 
scanned over 360º in 5º increments, where for each angle all atoms were optimized. In fact the 
initial orientation showed the best energy. 
Rigid body dynamics in lipid bilayers and addition of loops 
Next we added two layers of explicit lipid molecules (52 molecules of 
dilauroylphosphatidyl choline (DPC) lipid) surrounding the TM bundle. The initial structures for 
the lipid DPC these were based on the crystal structure in Cambridge Structural Database (ID: 
LAPETM10). To achieve proper packing of the TM helices, the 7-helix-lipid complex was 
optimized using rigid body MD for 50 ps where each helix and lipid molecule was treated as a 
rigid body, with just 6 degrees of freedom (translation and rotation).  
The conformation of each TM helix was further optimized in the lipid environment with 
full atom Cartesian MD simulation for 50 ps while the coordinates of lipid molecules were kept 
fixed. Then we carried out an additional equilibration of the whole system for 40 ps and selected 
the structure with the lowest potential energy. For this structure each side chain conformation was 
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re-assigned using SCWRL and the bundle (helices plus lipid) was minimized to an RMS force of 
0.5 (kcal/mol)/Å using conjugate gradients. 
The loops were added to the helices using MODELLER6v2[15]. The side chains were re-
assigned using SCWRL and subsequently a full atom conjugate gradient minimization of the 
receptor was performed.  
In many GPCRs (including bovine rhodopsin and the catechol amine receptors, such as 
dopamine and adrenergic receptors) there are conserved cysteines near the top of TM3 and in the 
second extracellular loop (EC2) that are expected to form a disulfide bond leading to a closed 
loop. However the mMrgC11 and mMrgA1 receptors do not contain such cysteines so the loops 
were allowed to remain in an open conformation. From five loop structures generated with 
MODELLER6v2 we selected the one with the lowest internal strain and then optimized the 
coordinates using annealing MD while keeping the coordinates of TM helices fixed. In this 
process the system was heated from 50 K to 600 K and cooled down back to 50 K in 50 K steps, 
with 1 ps of equilibration between the temperature jumps. At the end of the annealing cycle the 
structure was fully optimized using the conjugate gradients. This final structure shown in Figure 
2.3 (top and side views) was used for all docking studies. 
2.2.2 Docking predictions with peptide ligands 
Using the 3D structure of the mMrgC11 structure we used a refined version (MSCDock) of 
the docking procedure described in Cho et al.[16]. Since peptide ligands are highly flexible we 
modified the step in HierDock2.0 (described in Vaidehi et al.[4]), involving scan of the entire 
receptor with RFa to locate the binding site. This hierarchical docking protocol to predict the 
binding sites for various ligands as used in this study is described below.  
Scanning of the binding sites 
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Figure 2.2 The scanning regions used to determine the binding sites for the mMrgC11 receptor. (a) The 
9186 Spheres generated with SPHGEN to fill the void spaces of the receptor. The 40 cubic boxes used for 
docking are shown. (b) The four regions pre-selected for the docking studies. The region enclosed by the 
dotted circle was identified as the best site.  
 
The entire receptor structure was scanned with the Arg-Phe-NH2 (RFa) dipeptide known to 
agonize the receptor (EC50 = 460 nM) to locate the putative binding site. First, the molecular 
surface was created using the autoMS utility in DOCK4.0[17] with the default values for surface 
density (3.0dots/Å2) and probe radius (1.4Å). Then we generated spheres from each that filled the 
void space in the receptor. To do this we used SPHGEN in DOCK4.0. We then constructed a total 
of 40 cubic boxes (sides of 10Å) and spaced by 8Å that covered this set of spheres. Assuming 
that the ligand binds inside the TM bundle from the extracellular region, we analyzed these 
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spheres using a buried surface criterion to pre-select four non-peripheral regions, located on the 
upper half of the receptor as shown in Figure 2.2. The spheres inside each box were used to 
define the docking region as input to DOCK4.0. 
The RFa ligand was docked independently into each of the four regions as follows. Since 
the peptide ligands have a significant number of independent dihedral angles (the smallest 
dipeptide, RFa, contains 10 torsions), we wanted to ensure that this extensive conformation space 
is sampled in the docking. Thus for each peptide ligand we used the Metropolis Monte Carlo 
(MC) Method in Cerius2[18] (with a MC temperature of 5000 K in vacuum) to generate a set of  
1,000 low energy conformations having a diversity of CRMS = 1.0 Å.  
Level0: Then for each of the 1,000 conformers we used DOCK4.0 to generate a set of 3,000 
configurations within each of the four binding regions of the receptor. From these we selected the 
100 best configurations for each of the 1,000 conformers based on the DOCK score. This led to a 
total of 100*1000 = 100,000 configurations which were combined together and saved for the next 
scoring step. In these configurational searches, the rigid ligand and torsion drive options in 
DOCK4.0 were used. The bump filter option was turned on (maximum bump = 10) and the 
reduced (to 75%) van der Waals radius was used.  
Level1: The configurations from level0 with a ligand-buried surface area below 65% were 
discarded and the remaining configurations were ranked by the number of hydrogen bonds 
between receptor and ligand, then by the percentage of buried surface area, and then by DOCK4.0 
energy score. This ordered list was trimmed using a diversity criterion of CRMS = 0.6 Å and the 
top 100 configurations selected. Each of these was minimized in MPSIM using 100 steps of 
conjugate gradient method, while the receptor coordinates were fixed. 
Level2: The 10 best configurations by energy were selected from level1 and the full ligand-
protein complex was minimized in MPSIM with 100 steps. The side chain rotamers for all the 
residues within 5 Å of the ligand were reassigned using the SCREAM side chain replacement 
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program [Kam, Vaidehi and Goddard unpublished], which uses a side chain rotamer library of 
1,478 rotamers with a diversity of 1.0 Å in coordinates. 
Level3: The binding energies were then calculated for these 10 optimized ligand-receptor 
complex configurations. The calculated binding energy (BE) is defined by  
BE = E (ligand in fixed protein) – E (ligand in water)  
where the E (ligand in fixed protein is the potential energy of the ligand calculated in the ligand-
receptor complex with the coordinates of the receptor fixed. This potential energy includes the 
internal energy of the ligand and the interaction energy of the ligand with the receptor. E (ligand 
in water) is the potential energy of the free ligand in its docked conformation (snap bind energy) 
and its solvation energy calculated using the analytical volume generalized born (AVGB) 
continuum solvation method[19]. In these calculations the dielectric constant was set to 78.2 for 
the exterior region and to 1.3 for the interior region. The final best ligand-receptor structure was 
selected as the one with the most negative binding energy. 
 Among four regions we found that the RFa ligand had the best binding energy in the 
region involving TM3, 4, 5 and 6 (blue in Fig. 2.2(b)), which we call the putative binding site. 
The best structure of the RFa-receptor complex was further refined using one cycle of annealing 
MD heating from 50 K to 600 K and cooling down back to 50 K in 50 K steps, with 1 ps of 
equilibration between the temperature jumps. Here only the ligand and the residues within 10 Å 
of the binding pocket (including backbone atoms) were allowed to move during the annealing 
cycle. At the end of the annealing cycle, the system was minimized to an RMS force of 0.3 
(kcal/mol)/Å and the side chains of the residues in the receptor within 4 Å from the ligand was 
reassigned again with SCREAM. The spheres for docking other peptide ligands were defined 
with this final optimized RFa-receptor complex.  
Docking of other peptide ligands 
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For the five F-M-R-F tetra-peptide stereoisomers, we first docked the R-F amide part of the 
C-terminal. This motif is common to most peptide agonists of mMrgC11[20]. Indeed the efficacy 
results for the five chirally modified F-M-R-F-amides (see Fig. 2.11) show that the chirality of 
the R-F part dramatically affects activation. Therefore we first docked the three dipeptides: 
acetylated R-F-NH2, (D)R-F-NH2 and R-(D)F-NH2. Then we used these as an anchor in building 
the remaining F-M amino acids to construct the docked tetrapeptide. 
For docking the three dipeptides, we used the Dock-Diversity Completeness protocol 
(DDCP) described in Cho et al.[16] to generate a set of diverse configurations and improve 
completeness in searching the configurations in DOCK (Level0). Briefly, DDCP attempts to 
generate a complete set of ligand configurations families with a fixed coordinate diversity (1.0 Å). 
Completeness is defined as the point where the fraction of new configuration that belong to 
previously generated families to the fraction that leads to a new family is 2.2 (but restricted the 
list to 5000 families). Then we selected the 50 families with the best energies (by DOCK4.0 
energy score) and continued generating configurations while keeping only those that belonged to 
one of these 50 families until there was an average of six members in each family. Then 50 
family heads (best energy in each family) were conjugate gradient minimized (100 steps or 0.1 
kcal/mol/Å of RMS force) with the ligand atoms movable and the receptor atoms fixed. Then the 
10 best scoring ligands (one from each family by binding energy) were selected for further side 
chain optimization. Here the binding energy was calculated as the difference between the energy 
of the ligand in the fixed receptor and the energy of the ligand in solution. The energy of the free 
ligand was calculated for the docked conformation and its solvation energy was calculated using 
surface generalized Born model (SGB)[21]. The side chain rotamers of the residues in the 
receptor within 5 Å of the bound ligand were reassigned by using the SCREAM side chain 
replacement program. After side chain optimization, the final 10 complex structures were 
minimized (100 steps or 0.1 kcal/mol/Å of RMS force) with all atoms movable.  
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The above docking procedure was applied to each of the 1,000 conformers of each peptide 
ligand generated using the MC Method in Cerius2 (with a MC temperature of 5,000 K in vacuum) 
using diversity of CRMS = 2.0 Å. Prior to docking the structures of the 1,000 conformers were 
minimized in gas phase and ordered by energy. Then they were re-clustered with the diversity of 
2.0 Å and the conformer of each family head (the best energy among the family) was chosen for 
docking. This led at least 10 family heads for the R-F dipeptides and over 20 family heads for 
acetylated R-F dipeptides.  
For each such structure the docking process ends up with 10 structures for the 
ligand/protein complex. Thus we obtained ~100 structures for the dipeptide and ~200 for 
acetylated peptides. The number of hydrogen bonds (intermolecular between receptor and ligand 
and intramolecular for a ligand) was calculated for each structure of each ligand/protein complex. 
This was combined with the binding energy and the number of hydrogen bonds to select the final 
best structure.  
The final structure of ligand-receptor complex obtained from the hierarchical docking 
procedure was further refined by annealing MD as described in section 2.1.3. Here only the 
ligand and the side chains of residues within 3.5 Å of the binding pocket were allowed to move. 
At the end of the annealing cycle, the system was minimized to an RMS force of 0.1 (kcal/mol)/Å. 
Building the terminal F-M residues from the bound acetylated R-F-NH2 
The conformations of the terminal F-M residues were sampled using moleculeGL, a 
recursive, Metropolis Monte Carlo-based rotamer design technique [Kekenes-Huskey, Vaidehi 
and Goddard in preparation] from the R-F-NH2 dipeptide docked in mMrgC11 receptor where the 
extracellular loops were removed. Either the psi angle of Met or the phi angle of Arg is defined as 
an anchor. We used moleculeGL to generate 1000 structures for the terminal FM, using a 
diversity of 1.0. Then we selected the lowest energy conformation and minimized the ligand 
structure (0.3 kcal/mol/Å of RMS force) with the coordinates of receptor fixed. Then the side 
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chain rotamers of residues within 5 Å of the ligand were assigned using SCREAM and the 
structure of the whole complex was minimized. The final best structure was refined by annealing 
as described in previous section.  
2.3 Experimental procedures 
2.3.1 In vitro mutagenesis 
The point mutation was incorporated into mMrgC11-GFP coding sequence in 
pcDNA3.1/Zeo (+) plasmid (Invitrogen) using the QuickChange site-directed mutagenesis kit 
(Stratagene, La Jolla, CA). The mutagenic oligonucleotide primers were synthesized and purified 
in the oligonucleotide synthesis center of Caltech. All mutant constructs were verified by DNA 
sequencing. Later the wild type and mutant gene in pcDNA3.1/Zeo (+) were sub-cloned into 
pcDNA5/FRT expression vector (Invitrogen) for stably expressing cell lines. 
2.3.2 Cell culture and transfection 
Flp-In™-293 cells (Invitrogen) were co-transfected with mMrgC11-GFP gene in 
pcDNA5/FRT vector and pOG44 plasmid (Invitrogen) using FuGENE-6 reagent (Roche Applied 
Science) according to the manufacturer’s instructions. The cells were maintained in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 
penicillin/streptomycin and L-glutamine. The cells were split into fresh medium 48 h after 
transfection and then selected with 400 μg/ml of hygromycin. After two weeks of selection period 
the hygromycin-resistant clones were picked and then maintained in the selective medium with 
200 μg/ml of hygromycin. 
2.3.3 Biotinylation and immunoprecipitation 
Flp-In™-293 cells stably expressing wild type and mutant receptors were placed into 10 
cm culture dish coated with poly-L-lysine and cultured for 24h. The cells were washed twice with 
ice-cold PBS and incubated with 3 mL of 0.5 mg/mL Sulfo-NHS-LC-Biotin (Pierce 
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Biotechnology) in PBS supplemented with 0.1 mM HEPES, pH 7.5 at room temperature for 30 
min. The biotinylation reaction was quenched by washing cells three times with Tris-buffered 
saline (10 mM Tris pH 7.5, 154 mM NaCl). The washed cells were incubated with 5 mL of cold 
lysis buffer (10 mM HEPES, pH 7.4, 1 mM EGTA) supplemented with 100 μM 4-(2-
aminoethyl)-benzene sulfonyl fluoride hydrochloride at 4 °C for 15 min. Cells were scraped from 
the dish and homogenized with a Dounce homogenizer (20-25 strokes with a tight pestle). The 
cell lysate was centrifuged at 750x g for 10min at 4 °C to remove the nuclei and cell debris. The 
resulting supernatant was centrifuged at 75,000x g for 30 min at 4 °C. The membrane pellet was 
solubilized in 500 μL of ice-cold TX/G buffer (300 mM NaCl, 1% TX-100, 10% Glycerol, 1.5 
mM MgCl2, 1 mM CaCl2, 50 nM Tris pH 7.4, 0.5 mM PMSF, protease inhibitor cocktail) and 
incubated with gentle mixing at 4 °C for 1h. Insoluble material was removed by centrifugation at 
10,000x g for 15 min at 4 °C. The protein concentration was estimated using the DC Protein 
Assay Kit (Bio-Rad). 
The solubilized protein was incubated with 50 μL of streptavidin-agarose (Pierce 
Biotechnology) overnight at 4 °C on an inversion wheel. The streptavidin-agarose was washed 
four times with ice-cold TX/G buffer in absence of protease inhibitor and then twice with ice-cold 
PBS. The precipitates were resuspended with protein sample buffer and then boiled for 15 min. 
The protein sample was analyzed by SDS-PAGE and transferred to nitrocellulose membrane. The 
membrane was blocked in Tris-buffered saline with 0.1% Tween 20 containing 5% non-fat milk 
for 1h. GFP-tagged mMrgC11 receptors were detected by blotting with anti-GFP polyclonal 
primary antibody (Molecular Probes) in blocking solution followed by anti-rabbit horseradish 
peroxidase-conjugated secondary antibody and an ECL detection kit (Amersham Biosciences). 
2.3.4 Intracellular calcium assay 
The cells were placed into 96-well cell culture plate coated with MATRIGEL matrix (BD 
Biosciences). After 16-24 h, the cells were washed twice with Hank’s balanced salt solution 
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supplemented with 10 mM D-glucose, 20 mM HEPES and 1.6 mM NaOH (assay buffer) and 
loaded with 2 μM fura-2/AM (Molecular Probes) in assay buffer at room temperature for 20min. 
Then the cells were washed four times with assay buffer to get rid of the residual fura-2/AM 
present outsides cell membranes. The fluorometric imaging plate reader (FLIPR) assay was 
carried out at various concentrations of peptide ligands (1 nM to 10 μM) with the FlexStation II 
system (Molecular Devices). The fluorescence emitted from the excitation at 340 nm and 380 nm 
was measured respectively along the time and the ratio of emission at two excitation wavelengths 
was evaluated together. The difference between maximum and minimum value of the ratio was 
plotted along with the logarithm of the ligand concentration. The curve was fitted with 
ORIGIN6.0 software to compute EC50 value. 
2.4 Results and discussion 
2.4.1 Characteristics of the predicted mMrgC11 receptor structure 
The predicted TM regions for mMrgC11 are given in Figure 2.1 and the predicted 3D 
structure of the mMrgC11 receptor is shown in Figure 2.3. TM6 is bent by 28º at Pro233 and 
TM7 is bent by 15º at Pro271. These two prolines are highly conserved over all family A GPCRs 
including rhosopsin (in rhodopsin TM 6 and TM7 are bent by 24º and 33º, respectively). 
Moreover, Pro109 in the middle of TM3 leads to bending of 23º (in rhodopsin TM3 is bent by 
13º). We find that these distortions lead to a cavity lined by TM3, TM5, and TM6 that provides 
the space required for binding our tetrapeptides. The remaining four TMs have relatively straight 
α-helical conformations.  
The predicted 3-D structure of mMrgC11 receptor is superimposed with the 2.2 Å X-ray 
crystal structure of bovine rhodopsin[22] in Figure 2.3. Here each TM between mMrgC11 and 
rhodopsin was aligned separately with Clustal-W, imposing a high gap penalty and only the TM  
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Figure 2.3 Comparison of the predicted 3D structure for the RFa/mMrgC11 complex (green) with the X-ray 
crystal structure of retinal/rhodopsin (PDB code: 1U19, 2.2 Å resolution). The RFa dipeptide is colored red 
while the retinal is blue.  (a) top view (from extracellular region);  (b) side view (with EC at the top). As 
expected by the low sequence identity (22% for the TM regions) there are significant differences. The CRMS 
difference in the Cα atoms is 3.75 Å. 
regions were fitted with each other for superposition. The sequence identity between the TM 
regions is ~22%, averaged over the seven TM region sequences. The RMSD in coordinates 
(CRMSD) of the Cα atoms in the TM regions between bovine rhodopsin and mMrgC11 is 3.75 Å. 
As expected from the low sequence identity the structures are rather different, but they share such 
structural features as the kink in the TM6 and TM7 helices. Indeed TM3 of rhodopsin has a slight 
kink at the two consecutive glycines present at the same position as the proline in mMrgC11. 
Several conserved residues participate in the inter-helical hydrogen bonds that maintain the 
stability of the mMrgC11 receptor structure just as in the rhodopsin crystal structure. Thus Asn44 
(TM1) (highly conserved in the family A GPCRs) forms a hydrogen bond with the Ser268 
carbonyl group of the backbone in TM7 as shown in Figure 2.4. Asp71 (TM2) forms an 
interhelical hydrogen bond with this Asn in rhodopsin is in the proximity, but is not in hydrogen 
bond contact in the mMrgC11 receptor. Such differences are plausible since Miura and Karnik 
reported TM2 movement from activation in angiotensin II type 1 receptor (using substituted  
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Figure 2.4 Interhelical hydrogen bond networks in the mMrgC11 receptor. The interhelical hydrogen bonds 
(dashed lines) are specified with residues participating in hydrogen bonds. The highly conserved residues in 
the family A of GPCRs that form interhelical hydrogen bonds in rhodopsin are colored by yellow. (a) Viewed 
from the intracellular region. (b) Viewed from the extracellular region. The HBPLUS[23] program was used to 
calculate hydrogen bonds (maximum D-A distance = 3.9 Å, minimum D-H-A angle = 90.0°). 
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cystein accessibility mapping)[24]. Thus Asp in TM2 might interact differently, compared to one 
in the inactive rhodopsin structure. The Asn66 (TM2)–Trp151 (TM4) pair does form a hydrogen 
bond just like the analogous pair in rhodopsin. 
Important points to note in the structure are:  
Tyr63 (TM2) (one of residues conserved in the Mrg receptor family (with 39 sequences 
available on Swiss-Prot and TrEMBL)) participates in hydrogen bonding with Ser112 (TM3) as 
shown in Figure 2.4. 
Another conserved residue, Ser143 (TM4) forms a hydrogen bond with the hydroxyl group 
in Thr122 (TM3) as shown in Figure 2.4. 
Arg215 (TM6) contacts with the backbone carbonyl group of Val277 in TM7, as shown in 
Figure 2.4. 
Asp179 (TM5), which is identified as a key residue for the ligand binding in this study is in 
contact with Lys99 (TM3) in the apo protein. Asp161 (TM4) also interacts with Thr183 (TM5) in 
the absence of a ligand. 
Several other inter-helical hydrogen bonds are formed with non-conserved hydrophilic 
residues. Most of these are found in the regions of the TM regions near the intracellular loop. 
These regions pack more compactly than the near-extracellular regions as appropriate for ligand 
binding.  
No direct contact between TM3 and TM6 or between TM3 and TM7 is found in the TM 
regions. However, these TM helices interact with each other through well-stacked aromatic rings 
as shown in Figure 2.5. Tyr110 (TM3), one of the aromatic residues participating in these 
interactions is conserved through the Mrg receptors (5 of 39 have Phe at this position instead of 
Tyr). Also Trp265 in TM6 known to be responsible in activating rhodopsin is replaced with Gly  
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Figure 2.5 Aromatic interactions in TM regions of mMrgC11 receptor. Aromatic residues involved in the π-
stacking through TM3, 5, 6 and 7 are shown with the closest C–C distance between two benzyl rings (Å). 
 
in the mMrgC11 receptor. Thus activation in mMrgC11 might involve a different mechanism. As 
discussed in section 4.2 we find that the agonists to MrgC11 bind in the pocket located between 
TM3, 4, 5 and 6, which might affect the aromatic–aromatic interactions to help induce activation. 
2.4.2 Description of the peptide binding sites 
The predicted RFa binding site is located between TM3, TM4, TM5 and TM6 as shown in 
Figure 2.3. In contrast to 11-cis retinal in rhodopsin, we find that RFa orients vertically in the 
binding pocket. As seen in Figure 2.3, the aromatic rings stacked between TM3 and TM6 
confines the ligand to the region between TM3, TM4, TM5 and TM6. A similar binding 
orientation has been suggested for the formylated peptide, fMLF[25], which binds parallel to the 
helix in the formyl peptide receptor (FPR). Since RFa is a small peptide ligand (like fMLF) it can 
be placed parallel in the pocket but for longer peptides, the additional amino acids might be 
kinked towards TM2 and TM7, having contact with these TMs mainly in the loop regions. 
Predicted binding site of the dipeptides 
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Figure 2.6 Predicted 5 Å binding pocket of the RFa and RF dipeptide agonists. The intermolecular hydrogen 
bonds calculated with explicit hydrogens using the same criteria as in Figure 2.4 are indicated by the dotted 
lines. A residue whose side chain participates in the hydrogen bond is specified in red, while one whose 
backbone is involved is in blue. The residues showing good hydrophobic interactions are specified in black. 
The top of the picture corresponds to the extracellular regions.  
 
The detailed interactions of bound dipeptides with mMrgC11 receptors are described in 
Figure 2.6. The binding mode of R-F-OH (RF) is similar to R-F-NH2 (RFa) although the side 
chain rotamers of certain residues are different. The common features are that the positively 
charged moieties are stabilized through the salt bridges and other hydrophilic interactions. Thus 
the Arg has a good electrostatic interaction with Asp179 (TM5) and the N-terminus has good 
electrostatic interaction with Asp161 (TM4). The N-terminus of RFa also forms a hydrogen bond 
with the hydroxyl group of Thr183 (TM5). In addition the C-terminus of RFa makes a hydrogen 
bond with the hydroxyl group of Tyr110 (TM3). 
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Figure 2.7 Predicted 3D structure for the FMRFa/mMrgC11 complex. The Cα atoms in the TM regions are 
traced in cartoon while the three key residues (Y110, D161, and D179) are shown in stick. The top view is 
from extracellular (EC) region and in the side view the EC region is at the top. 
 
The phenyl group of the Phe is stabilized by several aromatic residues present in the 
binding pocket. Tyr110 interacts most closely with Phe of both dipeptides. For RFa the phenyl 
ring is in a sandwiched geometry with Tyr110 while for RF these two rings have the displaced T-
shape. Phe190 (TM5) also has a good π-π interaction with Phe of the ligand, while Leu186 (TM5) 
also contributes a good hydrophobic environment for Phe. 
Predicted binding sites of the tetrapeptide agonists, F-M-R-F-NH2, (D)F-M-R-F-NH2 and F-
(D)M-R-F-NH2 
 Three tetra-peptides known to be good agonists for mMrgC11[20] were docked into the 
binding region identified for RFa. The common C-terminal dipeptide part, which is parallel to the 
average helical axis with the C-terminus of the peptide toward the intracellular region, is bound 
similarly to RFa (or RF). The extra F-M peptide stretches out horizontally toward TM6 as shown 
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in Figure 2.7 for the F-(D)M-R-F-NH2 (FdMRFa) case, where the chirality of Met is modified to 
be left-handed. In FdMRFa, the amide group of the C-terminus forms hydrogen bonds with the 
side chain of Asp161 (TM4) and the backbone carbonyl group of Gly158 (TM4). Phe at the C-
terminus resides in good aromatic and hydrophobic environment formed by Tyr110 (TM3), 
Phe190 (TM5) and Leu186 (TM5). Arg is stabilized through the electrostatic interactions with 
Asp161 (TM4) and Asp179 (TM5). Thr183 (TM5) also interacts with the side chain of Arg. 
Asp161 (TM4) forms a hydrogen bond with a nitrogen atom of the backbone. Met located in the 
peripheral region between TM5 and TM6 is nearby such hydrophobic residues as Leu238 (TM6), 
Phe239 (TM6) and Ile187 (TM5), but has no specific interaction. The N-terminal Phe is 
sandwiched between Trp162 (TM4) and Tyr237 (TM6), leading to good aromatic interactions. 
The N-terminus is exposed to the extracellular region. Thus for longer peptide agonists the extra 
residues might be added starting from this N-terminal position. This might account for the 
binding of Met-Enk-RF-amide. This is all shown in Figure 2.8. 
In F-M-R-F-NH2 (FMRFa), the overall binding mode is similar to FdMRFa. Some 
differences are that Thr183 (TM5) no longer participates in the hydrogen bonding with the 
peptide and the side chain of the right-handed Met is closer to TM5 and interacts at the edge of 
aromatic ring of Phe180 (S–C distance = 4.0 Å). The preference of S atoms at the edge of 
aromatic ring has been observed in the study of the non-bond interaction involving sulfur atom of 
Met by analyzing the protein crystal structures[26]. 
(D)F-M-R-F-NH2 (dFMRFa) shows similar interactions. Although the N-terminal Phe has 
a different chirality from the previous two ligands, it has a similar conformation of the side chain 
and fits in between Trp162 (TM4) and Tyr237 (TM6). In this case the Met leads to an intra-
residue S…O interaction and an inter-residue interaction with Leu240, where the sulfur atom 
behaves as an electrophile [26]. 
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Figure 2.8 Predicted 5 Å binding site to mMrgC11 of the agonist tetra-peptides, F-(D)M-R-F-NH2, F-M-R-F-
NH2 and (D)F-M-R-F-NH2.  
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Figure 2.9 Predicted 5 Å binding pocket of the non-agonist tetra-peptides, F-M-(D)R-F-NH2 and F-M-R-(D)F-
NH2 (neither case was observed experimental to bind even at 30 μM). 
 
We calculate FdMRFa to bind strongest, with FMRFa and dFMRFa having binding 
energies just 7% and 11% weaker. 
Predicted binding sites of the non-agonists, F-M-(D)R-F-NH2 and F-M-R-(D)F-NH2  
The two other chirally modified FMRFa peptides, FMdRFa and FMRdFa, do not agonize 
mMrgC11. Our predicted 5 Å binding sites for them are shown in Figure 2.9. In both cases, the 
C-terminal Phe interacts with Tyr110 (TM3) and Phe190 (TM5) as seen for other agonists.  
In F-M-(D)R-F-NH2 (FMdRFa) the side chain of Arg is located near Asp161 (TM4) and 
Asp179 (TM5), with good electrostatic interactions. However the contact is less tight and the 
non-bond interaction energies with Asp161 and Asp179 decrease by 41% and 12% respectively, 
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compared with FdMRFa. We see the intra-residue S…O interaction for Met in this case. The N-
terminal Phe loses π-π interaction with Trp162 (TM4). 
In the other non-agonist, F-M-R-(D)F-NH2 (FMRdFa), the side chain of Arg is between 
Asp161 (TM4) and Asp179 (TM5) and the interaction is weaker than in FdMRFa. The sulfur of 
Met shows the interaction with the backbone carbonyl group of Asp179. The N-terminal Phe is 
sandwiched with Trp162 (TM4) and Tyr237 (TM6). Overall these two non-agonist peptides show 
the similar binding characteristics to the agonist peptides, but the interaction energy is much 
weaker by 34% for FMdRFa and by 32% for FMRdFa, compared with FdMRFa.   
Summary of binding sites  
This study identified several residues critical for peptide binding in mMrgC11. The two 
aspartic acids, Asp161 (TM4) and Asp179 (TM5) contribute to good electrostatic interactions for 
the electropositive groups of the ligands; Arg for tetrapeptides and Arg and N-terminus for 
dipeptides. Several aromatic residues contribute to good π-π interactions. Tyr110 (TM3) and 
Phe190 (TM5) contact with the common C-terminal Phe of all five agonists. Tyr110 is highly 
conserved across MRG family of receptors. In the tetrapeptide agonists, the additional phenyl 
group interacts with Trp162 (TM4) and Tyr237 (TM6). As mentioned previously, these aromatic 
residues are well stacked in the receptor in the absence of a ligand and provide the interhelical 
interactions among TM3, TM5, TM6 and TM7. This coupling with two phenyl groups of the 
tetrapeptide ligand along with the strong electrostatic interaction of Arg with Asp161 (TM4) and 
Asp179 (TM5) is likely to induce the conformational change responsible for the activation. 
2.4.3 Mutagenesis experimental results 
Based on the predictions described above, we expect that Tyr110 (TM3) (highly conserved 
aromatic residue among Mrg family), Asp161 (TM4), and Asp179 (TM5) are all critical to 
binding. Thus we embarked on a series of mutation experiments to validate theses predictions. 
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Figure 2.10 The expression of mMrgC11 wild type and mutant receptors in the Flp-In293 cells. (a) GFP 
images of wild type and mutant cells. The GFP was fused into the C-terminus of the receptor. (b) 
Biotinylation of the cell surface where receptors are localized and folded. The biotinylated cell extract is 
blotted with anti-GFP after immunoprecipitation (IP) with streptavidin. Lanes 1-5 are before IP and Lanes 6-
10 are after IP. The molecular weight markers are shown on the left in kDa. 
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398 ± 189
292 ± 19
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666 ± 228
682 ± 186
1255 ± 239
EC50, nM
54 ± 5
11 ± 5
17 ± 3
53 ± 2
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inactive
11 ± 4
108 ± 1
114 ± 32
544 ± 117
460 ± 35
632 ± 124
Han et. al[20]
FMRFFMRF
FMRF-NH2FMRFa
(D)F-M-R-F-NH2dFMRFa
F-(D)M-R-F-NH2FdMRFa
F-M-(D)R-F-NH2FMdRFa
F-M-R-(D)F-NH2FMRdFa
RF-NH2RFa
RFRF
FLFQPQRF-NH2NPFF
YVMGHFRWDRFGγ2-MSH
YVMGHFRWDRF-NH2γ1-MSH
VGRPEWWMDYQKRYGBam15
SequencePeptide
Inactive means that no activation was detected up to the highest concentration tested, 10μM. 
Data represent the mean (±SEM) of four independent experiments.
Table 2.1 The EC50 values of various peptide ligands determined by the intracellular calcium release 
assay with Flp-In293 cells expressing mMrgC11 receptor
 
Expression and localization of mMrgC11 wild type and mutant receptors 
Based on the predictions, we carried out three sets of experiments in which key residues 
were mutated to alanine – Tyr110Ala, Asp161Ala and Asp179Ala. Figure 2.10(a) shows the GFP 
images for mMrgC11 wild type and for the three mutant receptors. All mutant cells show 
fluorescence signals as intense as the wild type and the cell boundaries are clearly identified. 
These images indicate that the mutant receptors are expressed at level similar to the wild type and 
are well localized at the cell membranes. 
To determine whether the mutants properly fold across the cell membrane, we combined 
immunoprecipitation (IP) experiments with biotinylation. Lanes 1-5 in Figure 2.10(b) show total 
mMrgC11 receptor proteins including ones that are not biotinylated but present in cytosol and 
those that have not crossed properly through the membranes. These blots indicate again that all 
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three mutants are well expressed in the cells, although the expression levels of D161A and 
D179A mutants seem slightly lower. The results of blots after IP with streptavidin (lanes 6-10) 
show that the mutant receptors localized on the cell membranes take apical positions at similar 
amounts to the wild type. Since the band corresponding to the non-specific binding of 
streptavidin (lane 6) is much weaker, we conclude that the major portions of blots in lane 7-10 
come from the biotin-specific binding. This suggests the mutant proteins folds properly on the 
membranes as well as the wild type protein. 
Dose-dependent intracellular calcium release assay with stably expressed MrgC11 receptors 
 Table 2.1 shows the EC50 values of various peptide ligands determined by intracellular 
calcium assay experiment with Flp-In293 cells expressing the mMrgC11 receptor. The di- and 
tetra-peptides and some longer peptide agonists were selected from the ligands previously 
identified by Han et al.[20]. We obtained slightly higher EC50 values in our cellular system, 
compared to the previous measurements. This difference might result from a variety of sources 
such as different coupling efficiencies, different expression levels of receptor, and different 
cellular environment[27]. Nonetheless, the selectivity observed in this study is consistent with the 
previous results– for example; FMdRFa and FMRdFa still show no activity. 
Out of the twelve ligands tested for the wild type receptor, we selected the six most potent 
ligands to measure the potencies for Y110A, D161A and D179A mutant receptors, as shown in 
Table 2.2.  
We find that the Y110A mutant is not activated by any of the six tested ligands up to a 
concentration of 33 μM, indicating that Y110 is critical for binding and activation.  
The D179A mutants show no potency for the three tetrapeptide ligands, while the other 
three are activated only under 10 times higher concentration of the ligand. 
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Table 2.2 Binding constants (EC50 values in nM) of mutant mMrgC11 receptors from intracellular calcium 
assays
>1000068%FMRdFa
>1000067%FMdRFa
349 (1.0)340 (1.0)+ (2000)+ (33000)>33000340 ± 66γ2-MSH
302 (0.8)331 (0.8)+ (3000)>33000>33000398 ± 189γ1-MSH
1713 (5.9)749 (2.6)+ (3000)>33000>33000292 ± 19Bam15
1513 (5.5)1500 (5.4)>33000>33000>33000276 ± 5688%dFMRFa
1531 (9.1)1795 (10.7)>33000+ (18000)>33000168 ± 2693%FMRFa
334 (3.0)714 (6.3)>33000>33000>33000113 ± 18100%FdMRFa
Y110WcY110FcD179AbD161AbY110AbWild TypeBindinga


a Calculated binding energy relative to FdMRFa (absolute value = 117kcal/mol). b + means that activation 
starts at a given concentration. c Numbers in parentheses are the ratio with respect to the EC50 values of 
WT.  
For mutants D161A we find that 4 of the 6 ligands no longer activate while that other two 
only activate for 100 times the concentration.  
These results that mutation of Tyr110, Asp161 and Asp179 very strongly reduce or 
eliminate the activity of mMrgC11 receptor validate the predictions that these residues are 
involved in the ligand binding.  
For a positive control experiment, the mutant of Asp81 in TM2 to Ala was transiently 
expressed in HEK293 cells along with the Y110A, D161A, and D179A mutant receptors also 
transiently expressed under the same condition. Then the intracellular calcium assay experiment 
was carried out with 0.33 μM of FMRFa. Except for the D81A mutant, the other three showed no 
activity.  
We investigated the implication of the hydroxyl group on the Tyr110 in ligand recognition 
by replacing this tyrosine with phenylalanine or tryptophan. The potencies of γ1-MSH and γ2-
MSH ligands are not affected by the absence of the hydroxyl group, indicating that the hydroxyl 
group does not contribute to ligand activation for these ligands. For the three tetrapeptide agonists 
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the Y110F or Y110W mutations leads to a factor of 5 to 10 reduction in the potency. This is 
consistent with our predicted structure (Figures 2.7 and 2.8) which does not have the hydroxyl 
group of Tyr110 interacting with the ligand, but instead forms a hydrogen bond with the carbonyl 
group of the backbone. The missing hydroxyl group should results in a dangling hydrogen bond 
donor which might induce an overall conformational change in the binding pocket to explain the 
loss in activity. Since mutation of Tyr110 to Ala totally extinguishes the activity for all six 
ligands, we conclude that the aromatic ring must be significant for all six cases. 
To investigate whether the two non-agonist tetrapeptides, FMdRFa and FMRdFa are 
antagonists or weak binders (or non-binders), we saturated the receptors either with FMdRFa or 
with FMRdFa in three concentrations, 3.3, 16 and 33 μM and then measured the EC50 value for 
FdMRFa. The intensity of calcium signal remained on the same level as in the absence of 
FMdRFa or FMRdFa and the EC50 values did not change much (within standard deviation). This 
result shows that FMdRFa and FMRdFa do not block the efficacy of FdMRFa and at best bind 
only weakly to the receptor.  
Summarizing, the experimental results show that Tyr110 (TM3), Asp161 (TM4) and 
Asp179 (TM5) are possibly in the binding site in agreement with the predictions. These predicted 
mutations focused on the dipeptide binding region. Using the binding region for the tetrapeptide, 
we now suggest that mutations of Trp162 (TM4), Phe190 (TM5), and Tyr237 (TM6) to Ala 
would also dramatically decrease binding. Additional validations could be to mutate either the 
receptor or the peptide ligand and to carry out other cell assay experiments such as radiolabelled 
ligand binding assays. Such studies should further improve our understanding of the structure and 
ligand binding site.  
2.4.4 Prediction of the structure of the mMrgA1 receptor and the binding site for ligands 
 The 3D structure of mMrgA1 was predicted using MembStruk procedure described in 
this chapter. The CRMSD of Cα atoms between mMrgC11 and mMrgA1 is 2.49Å in the TM  
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Figure 2.11 Comparison between mMrgC11 and mMrgA binding sites. (a) The electrostatic potential map of 
the binding pocket in mMrgC11 and mMrgA1. The residues within 5 Å from RFa ligand were selected for 
visualization. Asp161, Asp179 and Lys99 of mMrgC11 are specified in stick and Asn145 of mMrgA1 in stick. 
The electrostatic potential was computed using APBS and visualized on PyMOL. The van der Waals radii of 
DREIDING forcefield were used for APBS calculation. (b) The predicted 5 Å binding pocket of RFa in 
mMrgC11 and mMrgA1 receptor. 
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regions and 4.94 Å if the loops are included. The sequence identity between them is 53% for the 
TM regions and 46% for the entire sequence. It was observed experimentally that mMrgA1 
receptor is activated much less potently by tetra-peptide ligands containing the RF-amide motif as 
compared to the mMrgC11 receptor, and that neither the amide nor acidic form of RF di-peptide 
activates mMrgA1[20].  
We docked the RFa ligand into the mMrgA1 receptor by superimposing it with RFa-bound 
mMrgC11 receptor. The side chains of residues within 5 Å were reassigned using SCREAM and 
then the potential energy of the ligand-receptor complex structure was minimized. We found that 
Tyr94 (TM3), F177 (TM5) and L173 (TM5) (homologous residues of Tyr110, Phe190 and 
Leu186 in mMrgC11) form a hydrophobic pocket for Phe as in mMrgC11, but they are located 
slightly farther (the closet C–C distance between aromatic rings is 4 to 5 Å). Asn145 (TM4), the 
homologous residue of Asp161 in mMrgC11, is involved in the hydrogen bonding with the N-
terminus. The Arg side chain of the peptide is surrounded with hydrophobic residues and does not 
have any favorable interaction with receptor. The calculated binding energy (positive value) 
predicts that it does not bind to mMrgA1 receptor.  
Figure 2.11 shows the electrostatic potential maps of the binding pocket in mMrgC11 and 
of the corresponding region in mMrgA1. The electrostatic potential was calculated for the entire 
receptor using adaptive Poisson-Boltzmann solver (APBS)[28]. The binding pocket within 5 Å 
from RFa docked in mMrgC11 receptor is selectively presented here. We can see that the pocket 
of mMrgA1 is more hydrophobic than that of mMrgC11. In mMrgC11, two aspartic acids 
(Asp161 and Asp179) are located in the spot showing the fairly negative potential. We observed 
that in mMrgC11 the positively charged side chain of Arg and the N-terminus are favored in this 
region. In the absence of the ligand, Lys in TM3 (Lys99) compensates for this highly negative 
potential. For mMrgA1 these Asp residues are replaced by Asn. We expect that highly polar 
ligands such as a peptide containing an Arg residue might be unfavorable for the hydrophobic 
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character of the pocket in mMrgA1. This might explain why this ligand fails to bind strongly to 
the mMrgA1 receptor, explaining the low potency for RFa ligand to mMrgA1. This provides 
additional confirmation of our predicted binding site and protein structure for mMrgC11. We 
expect that the potency for these ligands to mMrgA1 might increase if these Asn residues are 
mutated to Asp, an experiment we intend to do soon.  
2.4.5 Comparison of Mrg sequences 
The 39 verified Mrg sequences were aligned using Clustal-W (v. 1.83) with the default 
parameters (protein gap open penalty = 10.0, protein gap extension penalty = 0.2, protein matrix 
= Gonnet) as shown in Figure S2.4. It includes 19 mouse, 13 rat, 1 monkey and 6 human Mrg 
receptors. The sequence identities range from 21% to 97 %. The mouse MrgF and rat MrgF have 
the highest sequence identity. The human MrgF also shows the relatively high sequence identity 
with rat and mouse orthologs (85% and 86% respectively). Across the 39 sequences we examined 
the sequence variations in the six key residues (Tyr110, Phe190, Asp161, Asp179, Trp162 and 
Tyr256) that we identified in this study. As mentioned before, Tyr110 is conserved throughout 
the Mrg sequences except for the 5 Mrgs that have the homologous Phe at the same position. 
Other five residues show various range of alteration; 
• D161: 14 D or E, 7 N, 5 L, 2 A, 3 H, 2 P, 2 T, 1 Q, 1 K, 1 V and 1 Y.  
• W162: 6 W, 14 G, 8 S, 4 N, 3 R, 2 A, 1 M and 1 E.  
• D179: 14 D, 10 N, 5 I, 3 M, 2 A, 2 H, 2 W and 1 S. 
• F190: 20 F, 8 C, 3 T, 2 M, 2 S, 1 A, 1 I, 1 L and 1 V. 
• Y256: 20 Y or F, 3 C, 3 D, 3 Q, 2 H, 2 L, 2 N, 2 I, 1 S, and 1 T.  
We observed that only rat MrgC has all six residues conserved and mouse MrgB1, mouse MrgB2 
and rat MrgB2 have Tyr110, Asp161, Asp179, Phe190 and Y256 at their homologous positions. 
Trp162 are replaced with Gly for these MrgB receptors. It has been shown that γ2-MSH is the 
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most potent at activating rat MrgC and the active moiety recognized by rat MrgC is the C-
terminal of γ2-MSH, F-R-W-D-R-F-G[29]. The rat MrgC also binds Met-Enkephalin RF-amide 
with F-M-R-F-NH2 at the C-terminus. These experimental results suggest the similar 
characteristics in the binding site of rat MrgC receptor to that of mMrgC11, further supporting 
our predictions.   
2.5 Summary and conclusions 
 We predicted the 3D structure of the mMrgC11 receptor and used it to predict the binding 
sites for a number of di- and tetra-peptide ligands. We find that in each case the peptide ligand 
binds in a pocket among TM3, 4, 5 and 6 oriented parallel to the helical axis. These predictions 
suggested that three residues (Tyr110 (TM3), Asp161 (TM4) and Asp179 (TM5) in the binding 
pocket) play a key role in the binding.  
To test these predictions, we carried out several mutagenesis experiments. For 6 ligands 
exhibiting EC50 of 100 to 400 nM in wild type, we find that the EC50 for the Y110A, D161A 
and D179A mutant receptors are higher than 33 μM for 14 of 18 combinations and 50 to 100 
times higher for the other 4 combinations.  This validates the implication of these residues for the 
activation or binding of the ligand. 
Since the peptide forms a zwitterion at pH 7 giving it relatively polar character and since 
the ligands that bind to MrgC11 contain an Arg whose side chain is positively charged at pH 7, it 
is plausible that the two aspartic acids in the binding pocket participate. On the other hand, 
mMrgA1 has increased hydrophobic character in the corresponding region (these Asp are 
replaced by Asn). This might be responsible for the low efficacy of the ligand. 
Our predicted binding site also suggests additional mutation candidates to be tested, 
especially residues involving hydrophobic interaction such as Trp162, Leu186, Phe190, Tyr237, 
and Leu238.  
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 This study indicates how collaboration between theory and experiment can provide 
insight into the structural characterization of these Mrg receptors to determine how they are 
related with function. This could lead to the design of small molecule antagonists to selectively 
inhibit these receptors as candidate drugs for treating pain. Such studies would be equally 
valuable for many other GPCR receptors, indicating that a systematic combination of 
computational tools along with biochemical experiments can provide an increased understanding 
membrane protein receptors and their activation. 
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Supporting figures and tables 
mMrgC11                   --------------MDPTISSHDTESTPLN-ETGHPNCTPILTLSFLVLITTLVGLAGNT 45
tr|Q91YB7                 -MGESFTGTGFINLNTSASTIAVTTTNPMDKTIPGSFNGRTLIPNLLIIISGLVGLIGNA 59
tr|Q7TN49                 ----------------------------MDKTIPGSFNSRTLIPNLLIIISGLVGLTGNA 32
tr|Q91WW5                 ----------------------------MDNTIPGGINITILIPNLMIIIFGLVGLTGNG 32
tr|Q91ZC6                 ----------------------------MHRSIS----IRILITNLMIVILGLVGLTGNA 28
tr|Q91WW3                 ----------------------------MNETIPGSIDIETLIPDLMIIIFGLVGLTGNA 32
tr|Q8R4G1                 MVCVLRDTTGRFVSMDPTISSLSTESTTLN-KTGHPSCRPILTLSFLVPIITLLGLAGNT 59
tr|Q7TN42                 --------------MDPTISSLSTESTTLN-KTGHPSCRPILTLSFLVPIITLLGLAGNT 45
tr|Q96LB0                 --------------MDSTIPVLGTELTPINGREETPCYKQTLSFTGLTCIVSLVALTGNA 46
gp|AX923125|40216229      --------------MDSTIPVLGTELTPINGREETPCYKQTLSFTGLTCIVSLVALTGDA 46
gp|AX647081|28800069      --------------MDSTIPVLGTELTPINGREETPCYKQTLSFTGLTCIVSLVALTGNA 46
tr|Q8TDE1                 --------------MDPTIPVLGTELTPINGREETPCYKQTLSFTGLTCIVSLVALTGNA 46
tr|Q8TDE0                 --------------MDPTVPVLGTELTPINGREETPCYKQTLSFTGLTCIVSLVALTGNA 46
gp|AX657514|29160254      ------------------------------------CYKQTLSFTGLTCIVSLVALTGNA 24
tr|Q96LB2                 --------------MDPTISTLDTELTPINGTEETLCYKQTLSLTVLTCIVSLVGLTGNA 46
tr|Q8TDD8                 --------------MDPTVSTLDTELTPINGTEETLCYKQTLSLTVLTCIVSLVGLTGNA 46
tr|Q8TDD9                 --------------MDPTVSTLDTELTPINGTEETLCYKQTLSLTVLTCIVSLVGLTGNA 46
tr|Q96LA9                 --------------MDPTVPVFGTKLTPINGREETPCYNQTLSFTVLTCIISLVGLTGNA 46
gp|AX646849|28799318      --------------MDPTVPVFGTKLTPINGREETPCYNQTLSFTVLTCIISLVGLTGNA 46
tr|Q8TDD6                 --------------MDPTVPVFGTKLTPINGREETPCYNQTLSFTVLTCIISLVGLTGNA 46
tr|Q8TDD7                 --------------MDPTVPVLGTKLTPINGREETPCYKQTLSFTVLTCIISLVGLTGNA 46
gp|AX657510|29160250      ------------------------------------CYNQTLSFTVLTCIISLVGLTGNA 24
tr|Q7TN45                 -----------MSPTTQAWSINNTVVKENYYTEILSCITTFNTLNFLIVIISVVGMAGNA 49
tr|Q91ZC0                 -----------MGTTTLAWNINNTAENG-SYTEMFSCITKFNTLNFLTVIIAVVGLAGNG 48
tr|Q91ZC3                 -----------MDLVIQDWTINITALKESNDNGISFCEVVSRTMTFLSLIIALVGLVGNA 49
tr|Q7TN48                 ---------------------------------MSFCEVVSCAIILLSLIIALVGLVGNG 27
tr|Q91ZC2                 ----MSGDFLIKNLSTSAWKTNITVLNGSYYIDTSVCVTRNQAMILLSIIISLVGMGLNA 56
tr|Q8CDY4                 ----MSGDFLIKNLSTSAWKTNITVLNGSYYFDTSVCVTRNQAMILLSIIISLVGMGLNA 56
:  *  ::.:  : 
mMrgC11                   IVLWLLGFRMRRKAISVYILNLALADSFFLCCHFIDSLLRIIDFYGLYAHKLSKDILGNA 105
tr|Q91YB7                 MVFWLLGFRLARNAFSVYILNLALADFLFLLCHIIDSTLLLLKFS--YPNIIFLPCFNTV 117
tr|Q7TN49                 MVFWLLGFRLARNAFSVYILNLALADFLFLLCHIIDSTLLLLKFS--YPNIIFLPCFNTV 90
tr|Q91WW5                 IVFWLLGFCLHRNAFSVYILNLALADFFFLLGHIIDSILLLLNVF--YP-ITFLLCFYTI 89
tr|Q91ZC6                 IVFWLLLFRLRRNAFSIYILNLALADFLFLLCHIIASTEHILTFS--SPNSIFINCLYTF 86
tr|Q91WW3                 IVFWLLGFRMHRTAFLVYILNLALADFLFLLCHIINSTVDLLKFT--LPKGIFAFCFHTI 90
tr|Q8R4G1                 IVLWLLGFRMRRKAISVYVLNLSLADSFFLCCHFIDSLMRIMNFYGIYAHKLSKEILGNA 119
tr|Q7TN42                 IVLWLLGFRMRRKAISVYVLNLSLADSFFLCCHFIDSLMRIMNFYGIYAHKLSKEILGNV 105
tr|Q96LB0                 VVLWLLGCRMRRNAVSIYILNLVAADFLFLSGHIICSPLRLINIR----HPISK-ILSPV 101
gp|AX923125|40216229      VVLWLLGCRMRRNAVSIYILNLVAADFLFLSGHIICSPLRLINIR----HPISK-ILSPV 101
gp|AX647081|28800069      VVLWLLGCRMRRNAVSIYILNLVAADFLFLSGHIICSPLRLINIR----HPISK-ILSPV 101
tr|Q8TDE1                 VVLWLLGCRMRRNAVSIYILNLVAADFLFLSGHIICSPLRLINIR----HPISK-ILSPV 101
tr|Q8TDE0                 VVLWLLGCRMRRNAVSIYILNLVAADFLFLSGHIICSPLRLINIS----HPISK-ILSPV 101
gp|AX657514|29160254      VVLWLLGCRMRRNAVSIYILNLVAADFLFLSGHIICSPLRLINIR----HPISK-ILSPV 79
tr|Q96LB2                 VVLWLLGCRMRRNAFSIYILNLAAADFLFLSGRLIYSLLSFISIP----HTISK-ILYPV 101
tr|Q8TDD8                 VVLWLLGCRMRRNAFSIYILNLAAADFLFLSGRLIYSLLSFISIP----HTISK-ILYPV 101
tr|Q8TDD9                 VVLWLLGCRMRRNAFSIYILNLAAADFLFLSGRLIYSLLSFISIP----HTISK-ILYPV 101
tr|Q96LA9                 VVLWLLGYRMRRNAVSIYILNLAAADFLFLSFQIIRSPLRLINIS----HLIRK-ILVSV 101
gp|AX646849|28799318      VVLWLLGYRMRRNAVSIYILNLAAADFLFLSFQIIRLPLRLINIS----HLIRK-ILVSV 101
tr|Q8TDD6                 VVLWLLGYRMRRNAVSIYILNLAAADFLFLSFQIIRSPLRLINIS----HLIRK-ILVSV 101
tr|Q8TDD7                 VVLWLLGCRMRRNAVSIYILNLAAADFLFLSFQIIRSPLRLINIS----HLIRK-ILVSV 101
gp|AX657510|29160250      VVLWLLGYRMRRNAVSIYILNLAAADFLFLSFQIIRLPLRLINIS----HLIRK-ILVSV 79
tr|Q7TN45                 TVLWLLGFHMHRNAFSVYVLNLAGADFLYLCAQTVYSLECVLQFDN-----SYFYFLLTI 104
tr|Q91ZC0                 IVLWLLAFHLHRNAFSVYVLNLAGADFLYLFTQVVHSLECVLQLDN-----NSFYILLIV 103
tr|Q91ZC3                 TVLWFLGFQMSRNAFSVYILNLAGADFVFMCFQIVHCFYIILDIYF--IPTNFFSSYTMV 107
tr|Q7TN48                 TVFWLLGFQMRRNAFSVYILNLAGADFLFMCFQIVYCSHIMLDMYY--IPIKFPLFSIVV 85
tr|Q91ZC2                 IVLWFLGIRMHTNAFTVYILNLAMADFLYLCSQFVICLLIAFYIFYS-IDINIPLVLYVV 115
tr|Q8CDY4                 IVLWFLGIRMHTNAFTVYILNLAMADFLYLCSQFVICLLIAFYIFYS-IDINIPLVLYVV 115
*:*:*   :  .*. :*:***  ** .::  : :   : .                
Figure S2.1 Multiple sequence alignment for mMrgC11 with 27 homologous sequences.  
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mMrgC11                   AIIPYISGLSILSAISTERCLCVLWPIWYHCHRPRNMSAIICALIWVLSFLMGILDWF-S 164
tr|Q91YB7                 MMVPYIAGLSMLSAISTERCLSVVCPIWYRCRRPKHTSTVMCSAIWVLSLLICILNRYFC 177
tr|Q7TN49                 MMVPYIAGLSMLSAISTERCLSVVCPIWYRCRRPKHTSTVMCSAIWVLSLLICILNRYFC 150
tr|Q91WW5                 MMVLYIAGLSMLSAISTERCLSVLCPIWYHCHRPEHTSTVMCAVIWVLSLLICILNSYFC 149
tr|Q91ZC6                 RVLLYIAGLSMLSAISIERCLSVMCPIWYRCHSPEHTSTVMCAMIWVLSLLLCILYRYFC 146
tr|Q91WW3                 KRVLYITGLSMLSAISTERCLSVLCPIWYHCRRPEHTSTVMCAVIWVLSLLICILDGYFC 150
tr|Q8R4G1                 AIIPYISGLSILSAISTERCLSVLWPIWYHCHRPRNMSAIICVLIWVLSFLMGILDWFFS 179
tr|Q7TN42                 AFIPYISGLSILSAISTERCLSVLWPIWYHCHRPRNMSAIICVLIWVLSFLMGILDWFFS 165
tr|Q96LB0                 MTFPYFIGLSMLSAISTERCLSILWPIWYHCRRPRYLSSVMCVLLWALSLLRSILEWMFC 161
gp|AX923125|40216229      MTFPYFIGLSMLSAISTERCLSILWPIWYHCRRPRYLSSVMCVLLWALSLLRSILEWMFC 161
gp|AX647081|28800069      MTFPYFIGLSMLSAISTERCLSILWPIWYHCRRPRYLSSVMCVLLWALSLLRSILEWMFC 161
tr|Q8TDE1                 MTFPYFIGLSMLSAISTERCLSILWPIWYHCRRPRYLSSVMCVLLWALSLLRSILEWMFC 161
tr|Q8TDE0                 MTFPYFIGLSMLNAISTERCLSILWPIWYHCRRPRYLSSVMCVLLWAPSLLRSILEWMFC 161
gp|AX657514|29160254      MTFPYFIGLSMLSAISTERCLSILWPIWYHCRRPRYLSSVMCVLLWALSLLRSILEWMFC 139
tr|Q96LB2                 MMFSYFAGLSFLSAVSTERCLSVLWPIWYRCHRPTHLSAVVCVLLWALSLLRSILEWMLC 161
tr|Q8TDD8                 MMFSYFAGLSFLSAVSTERCLSVLWPIWYRCHRPTHLSAVVCVLLWALSLLRSILEWMLC 161
tr|Q8TDD9                 MMFSYFAGLSFLSAVSTERCLSVLWPIWYRCHRPTHLSAVVCVLLWALSLLRSILEWMLC 161
tr|Q96LA9                 MTFPYFTGLSMLSAISTERCLSVLWPIWYRCRRPTHLSAVVCVLLWGLSLLFSMLEWRFC 161
gp|AX646849|28799318      MTFPYFTGLSMLSAISTERCLSVLWPIWYRCRRPTHLSAVVCVLLWGLSLLFSMLEWRFC 161
tr|Q8TDD6                 MTFPYFTGLSMLSAISTERCLSVLWPIWYRCRRPTHLSAVVCVLLWGLSLLFSMLEWRFC 161
tr|Q8TDD7                 MTFPYFTGLSMLSAISTERCLSVLWPIWYRCRRPTHLSAVVCVLLWGLSLLFSMLEWRFC 161
gp|AX657510|29160250      MTFPYFTGLSMLSAISTERCLSVLWPIWYRCRRPTHLSAVVCVLLWGLSLLFSMLEWRFC 139
tr|Q7TN45                 LMFNYLAGFCMIAAISTERCLSVTWPIWYHCQRPRHTSATVCALFWAFSLLLSLLLGQGC 164
tr|Q91ZC0                 TMFAYLAGLCMIAAISAERCLSVMWPIWYHCQRPRHTSAIMCALVWVSSLLLSLVVGLGC 163
tr|Q91ZC3                 LNIAYLSGLSILTVISTERFLSVMWPIWYRCQRPRHTSAVICTVLWVLSLVLSLLEGKEC 167
tr|Q7TN48                 LNIGYLCGMSILSAISIERCLSVMWPIWYRCQRPRHTSAVICTLLWVLALVWSLIEGKEC 145
tr|Q91ZC2                 PIFAYLSGLSILSTISIERCLSVIWPIWYRCKRPRHTSAITCFVLWVMSLLLGLLEGKAC 175
tr|Q8CDY4                 PIFAYLSGLSILSTISIERCLSVIWPIWYRCKRPRHTSAITCFVLWVMSLLLGLLEGKAC 175
. *: *:.:: .:* ** *.:  ****:*: *   *:  *  .*  :::  ::    .
mMrgC11                   GFLGETHHH-LWKN-VDFIITAFLIFLFMLLSGSSLALLLRILCGPRRKPLSRLYVTIAL 222
tr|Q91YB7                 GFLDTKYEKDNRCLASNFFTAACLIFLFVVLCLSSLALLVRSFCGAGRMKLTRLYATIML 237
tr|Q7TN49                 GFLDTKYEKDNRCLASNFFTAACLIFLFVVLCLSSLALLVRLFCGAGRMKLTRLYATIML 210
tr|Q91WW5                 GFLNTQYKNENGCLALNFFTAAYLMFLFVVLCLSSLALVARLFCGTGQIKLTRLYVTIIL 209
tr|Q91ZC6                 GFLDTKYEDDYGCLAMNFLTTAYLMFLFVVLCVSSLALLARLFCGAGRMKLTRLYVTITL 206
tr|Q91WW3                 GYLDNHYFNYSVCQAWDIFIGAYLMFLFVVLCLSTLALLARLFCGARNMKFTRLFVTIML 210
tr|Q8R4G1                 GFLGETHHH-LWKN-VDFIVTAFLIFLFMLLFGSSLALLVRILCGSRRKPLSRLYVTISL 237
tr|Q7TN42                 GFLGETHHH-LWKN-VDFIVTAFLIFLFMLLFGSSLALLVRILCGSRRKPLSRLYVTISL 223
tr|Q96LB0                 DFLFSGADS-VWCETSDFITIAWLVFLCVVLCGSSLVLLVRILCGSRKMPLTRLYVTILL 220
gp|AX923125|40216229      DFLFSGADS-VWCETSDFITIAWLVFLCVVLCGSSLVLLVRILCGSRKMPLTRLYVTILL 220
gp|AX647081|28800069      DFLFSGANS-VWCETSDFITIAWLVFLCVVLCGSSLVLLVRILCGSRKMPLTRLYVTILL 220
tr|Q8TDE1                 DFLFSGANS-VWCETSDFITIAWLVFLCVVLCGSSLVLLVRILCGSRKMPLTRLYVTILL 220
tr|Q8TDE0                 DFLFSGADS-VRCETSDFITIAWLVFLRVVLCGSSLVLLVRILCGSRKMPLTRLYVTILL 220
gp|AX657514|29160254      DFLFSGANS-VWCETSDFITIAWLVFLCVVLCGSSLVLLVRILCGSRKMPLTRLYVTILL 198
tr|Q96LB2                 GFLFSGADS-AWCQTSDFITVAWLIFLCVVLCGSSLVLLIRILCGSRKIPLTRLYVTILL 220
tr|Q8TDD8                 GFLFSGADS-AWCQTSDFITVAWLIFLCVVLCGSSLVLLIRILCGSRKIPLTRLYVTILL 220
tr|Q8TDD9                 GFLFSGADS-AWCQTSDFITVAWLIFLCVVLCGSSLVLLIRILCGSRKIPLTRLYVTILL 220
tr|Q96LA9                 DFLFSGADS-SWCETSDFIPVAWLIFLCVVLCVSSLVLLVRILCGSRKMPLTRLYVTILL 220
gp|AX646849|28799318      DFLFSGADS-SWCETSDFIPVAWLIFLCVVLCVSSLVLLVRILCGSRKMPLTRLYVTILL 220
tr|Q8TDD6                 DFLFSGADS-SWCETSDFIPVVWLIFLCVVLCVSSLVLLVRILCGSRKMPLTRLYVTILL 220
tr|Q8TDD7                 DFLFSGADS-SWCETSDFIPVAWLIFLCVVLCVSSLVLLVRILCGSRKMPLTRLYVTILL 220
gp|AX657510|29160250      DFLFSGADS-SWCETSDFIPVAWLIFLCVVLCVSSLVLLVRILCGSRKMPLTRLYVTILL 198
tr|Q7TN45                 GFLFSKFDY-SFCRYCNFIATAFLIVIFMVLFVSSLALLAKIICGSHRIPVTRFYVTIAL 223
tr|Q91ZC0                 GFLFSYYDY-YFCITLNFITAAFLIVLSVVLSVSSLALLVKIVWGSHRIPVTRFFVTIAL 222
tr|Q91ZC3                 GFLYYTSGP-GLCKTFDLITTAWLIVLFVVLLGSSLALVLTIFCGLHKVPVTRLYVTIVF 226
tr|Q7TN48                 GFLFDTNGP-GWCETFDLIATAWLIVLIVVLLGSSLALVINIFCGLYRIPVTRLYVTIVF 204
tr|Q91ZC2                 GLLFNSFDS-YWCETFDVITNIWSVVFFGVLCGSSLTLLVRIFCGSQRIPMTRLYVTITL 234
tr|Q8CDY4                 GLLFNSFDS-YWCETFDVITNIWSVVFFGVLCGSSLTLLVRIFCGSQRIPMTRLYVTITL 234
. *             :.:     :.:  :*  *:*.*:   . *  .  .:*::.** :
Figure S2.1 (continued)  
 
 65
Figure S2.1 (continued)  
 
mMrgC11                   TVMVYLICGLPLGLYLFLLYWFGVHLHYPFCHIYQVTAVLSCVNSSANPIIYFLVGSFRQ 282 
tr|Q91YB7                 TVLVFLLCGLPFGIHWFLLIWIKIDYGKFAYGLYLAALVLTAVNSCANPIIYFFVGSFRH 297
tr|Q7TN49                 TVLVFLLCGLPFGIHWFLLIWIKIDYGKFAYGLYLAALVLTAVNSCANPIIYFFVGSFRH 270
tr|Q91WW5                 SILVFLLCGLPFGIHWFLLFKIKDDFHVFDLGFYLASVVLTAINSCANPIIYFFVGSFRH 269
tr|Q91ZC6                 TLLVFLLCGLPCGFYWFLLSKIKNVFTVFEFSLYLASVVLTAINSCANPIIYFFVGSFRH 266
tr|Q91WW3                 TVLVFLLCGLPWGITWFLLFWIAPGVFVLDYS---PLLVLTAINSCANPIIYFFVGSFRQ 267
tr|Q8R4G1                 TVMVYLICGLPLGLYLFLLYWFGIHLHYPFCHIYQVTVLLSCVNSSANPIIYFLVGSFRH 297
tr|Q7TN42                 TVMVYLICGLPLGLYLFLLYWFGIHLHYPFCHIYQVTVLLSCVNSSANPIIYFLVGSFRH 283
tr|Q96LB0                 TVLVFLLCGLPFGIQWALFSRIHLDWKVLFCHVHLVSIFLSALNSSANPIIYFFVGSFRQ 280
gp|AX923125|40216229      TVLVFLLCGLPFGIQWALFSRIHLDWKVLFCHVHLVSIFLSALNSSANPIIYFFVGSFRQ 280
gp|AX647081|28800069      TVLVFLLCGLPFGIQWALFSRIHLDWKVLFCHVHLVSIFLSALNSSANPIIYFFVGSFRQ 280
tr|Q8TDE1                 TVLVFLLCGLPFGIQWALFSRIHLDWKVLFCHVHLVSIFLSALNSSANPIIYFFVGSFRQ 280
tr|Q8TDE0                 TVLVFLLCGLPFGIQWALFSRIHLDWKVLFCHVHLVSIFLSALNSSANPIIYFFMGSFRQ 280
gp|AX657514|29160254      TVLVFLLCGLPFGIQWALFSRIHLDWKVLFCHVHLVSIFLSALNSSANPIIYFFVGSFRQ 258
tr|Q96LB2                 TVLVFLLCGLPFGIQFFLFLWIHVDREVLFCHVHLVSIFLSALNSSANPIIYFFVGSFRQ 280
tr|Q8TDD8                 TVLVFLLCGLPFGIQFFLFLWIHVDREVLFCHVHLVSIFLSALNSSANPIIYFFVGSFRQ 280
tr|Q8TDD9                 TVLVFLLCGLPFGIQFFLFLWIHVDREVLFCHVHLVSIFLSALNSSANPIIYFFVGSLRQ 280
tr|Q96LA9                 TVLVFLLCGLPFGILGALIYRMHLNLEVLYCHVYLVCMSLSSLNSSANPIIYFFVGSFRQ 280
gp|AX646849|28799318      TVLVFLLCGLPFGILGALIYRMHLNLEVLYCHVYLVCMSLSSLNSSANPIIYFFVGSFRQ 280
tr|Q8TDD6                 TVLVFLLCGLPFGILGALIYRMHLNLEVLYCHVYLVCMSLSSLNSSANPIIYFFVGSFRQ 280
tr|Q8TDD7                 TVLVFLLCGLPFGILGALIYRMHLNLEVLYCHVYLVCMSLSSLNSSANPIIYFFVGSFRQ 280
gp|AX657510|29160250      TVLVFLLCGLPFGILGALIYRMHLNLEVLYCHVYLVCMSLSSLNSSANPIIYFFVGSFRQ 258
tr|Q7TN45                 TVLVFIFFGLPIGICVFLLPWIHMMLSSFF---YEMVTLLSCVNSCANPIIYFFVGSIRH 280
tr|Q91ZC0                 TVVVFIYFGMPFGICWFLLSRIMEFDSIFFNNVYEIIEFLSCVNSCANPIIYFLVGSIRQ 282
tr|Q91ZC3                 TVLVFLIFGLPYGIYWFLLEWIREFHDNKPCGFRNVTIFLSCINSCANPIIYFLVGSIRH 286
tr|Q7TN48                 TVLVFLLCGLPYGIYWFLLEWTEKFNYNLPCGFHPVTVLLSCVNSCANPIIYFLVGSIRH 264
tr|Q91ZC2                 TVLVFLIFGLPFGIYWILYQWISNFYYVEICNFYLEILFLSCVNSCMNPIIYFLVGSIRH 294
tr|Q8CDY4                 TVLVFLIFGLPFGIYWILYQWISNFYYVEICNFYLEILFLSCVNSCMNPIIYFLVGSIRH 294
:::*::  *:* *:   *                    *:.:**. ******::**:*:
mMrgC11                   H-RKHRSLKR---VLKRALEDTPEEDEYTDSHL-HKTTEISESRY---------- 322
tr|Q91YB7                 --QKHQTLKM---VLQRALQDTPETAEN--------TVEMSSSKVEP-------- 331
tr|Q7TN49                 --QKHQTLKM---VLQRALQDTPETAEN--------TVEMSSSKVEP-------- 304
tr|Q91WW5                 R-LKHQTLKM---VLQNALQDTPETAKI--------MVEMSRSKSEP-------- 304
tr|Q91ZC6                 R-LKHQTLKM---VLQSALQDTPETPEN--------MVEMSRNKAEL-------- 301
tr|Q91WW3                 R-LNKQTLKM---VLQKALQDTPETPEN--------MVEMSRNKAEP-------- 302
tr|Q8R4G1                 R-KKHRSLKM---VLKRALEETPEEDEYTDSHV-QKPTEISERRC---------- 337
tr|Q7TN42                 R-KKHRSLKM---VLKRALEETPEEDEYTDSHV-QKPTEISERRC---------- 323
tr|Q96LB0                 R-QNRQNLKL---VLQRALQDTPEVDEGGGWLP-QETLELSGSRLEQ-------- 322
gp|AX923125|40216229      R-QNRQNLKL---VLQRALQDTPEVDEGGGWLP-QETLELSGSRLEQ-------- 322
gp|AX647081|28800069      R-QNRQNLKL---VLQRALQDTPEVDEGGGWLP-QETLELSGSRLEQ-------- 322
tr|Q8TDE1                 R-QNRQNLKL---VLQRALQDTPEVDEGGGWLP-QETLELSGSKLEQ-------- 322
tr|Q8TDE0                 L-QNRKTLKL---VLQRDLQDTPEVDEGGWWLP-QETLELSGSRLEQ-------- 322
gp|AX657514|29160254      R-QNRQNLKLDSMCRRTALYKTIRSRESYSLSREQQREDPTHDSILS-------- 304
tr|Q96LB2                 R-QNRQNLKL---VLQRALQDASEVDEGGGQLP-EEILELSGSRLEQ-------- 322
tr|Q8TDD8                 R-QNRQNLKL---VLQRALQDASEVDEGGGQLP-EEILELSGSRLEQ-------- 322
tr|Q8TDD9                 R-QNRQNLKL---VLQRALQDTPEVDEGGGWLP-QETLELSGSRLEQ-------- 322
tr|Q96LA9                 R-QNRQNLKL---VLQRALQDKPEVDKGEGQLP-EESLELSGSRLGP-------- 322
gp|AX646849|28799318      R-QNRQNLKL---VLQRALQDKPEVDKGEGQLP-EESLELSGSRLGP-------- 322
tr|Q8TDD6                 R-QNRQNLKL---VLQRALQDKPEVDKGEGQLP-EESLELSGSKLGP-------- 322
tr|Q8TDD7                 R-QNRQNLKL---VLQRALQDKPEVDKGEGQLP-EESLELSGRRLGP-------- 322
gp|AX657510|29160250      R-QNRQNLKL---VLQRALQDKPEVDKASATRS-RTRTTSTSSASTPPRPT---- 304
tr|Q7TN45                 HRLQRQTLKL---LLQRAMQDTPEEE-GGERGPSQKSEDLEVVRCSS-------- 323
tr|Q91ZC0                 HRLRWQSLKL---LLQRAMQDTPEEE-SGERGPSQRSGELETV------------ 321
tr|Q91ZC3                 HRFQRKTLKL---LLQRAMQDSPEEEECGEMGSSRRPREIKTVWKGLRAALIRHK 338
tr|Q7TN48                 HRFQRKTLKL---LLQKAMQDTPEEEECGEMGS---------------------- 294
tr|Q91ZC2                 RRFRRKTLKL---LLQRAMQDTPEEEQSGNKSSSEHPEELETVQSCS-------- 338
tr|Q8CDY4                 RRFRRKTLKL---LLQRAMQDTPEEEQSGNKSSSEHPEELETVQSCS-------- 338
. :.**      :  : .  .              
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Figure S2.2 Hydrophobicity profile for mMrgC11 sequence set (window size = 12). 
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Figure S2.3 Multiple alignment of 39 verified Mrg sequences, including 19 mouse (orange), 13 rat 
(navy), 1 monkey and 6 human (violet) receptors. The positions of six key residues are specified in red 
boxes. 
 68
MrgB1
MrgB2
MrgB3
MrgB4
MrgB5
MrgB8
MrgB1
MrgB2
MrgB4
MrgB5
MrgB6
MrgB8
MrgC
MrgH
MrgB1
MrgB2
MrgB3
MrgB4
MrgB5
MrgB8
MrgB1
MrgB2
MrgB4
MrgB5
MrgB6
MrgB8
MrgC
MrgH
Figure S2.3 (continued) 
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Figure S2.3 (continued) 
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xxxxxxx44tr|Q91ZC3
xxxx48tr|Q7TN48
xxxx42tr|Q91ZC2
xxxx42tr|Q8CDY4
xx41tr|Q91ZB9
xxxxxx49tr|Q96LB1
x
x
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x
x
x
x
x
x
x
x
x
TM3
xx42tr|Q91ZC0
xxxxx43tr|Q7TN45
xxxx50gp|AX657510|29160250
xxxx50tr|Q8TDD7
xxxx50tr|Q8TDD6
xxxx50gp|AX646849|28799318
xxxx51tr|Q96LA9
xxxx53tr|Q8TDD9
xxxx53tr|Q8TDD8
xxxx53tr|Q96LB2
xxxxx46gp|AX657514|29160254
xxxxx49tr|Q8TDE0
xxxxx51tr|Q8TDE1
xxxx51gp|AX647081|28800069
xxx51gp|AX923125|40216229
xxxx51tr|Q96LB0
xxxxxx88tr|Q7TN42
xxxxxx88tr|Q8R4G1
xxx47tr|Q91WW3
xxxxxx47tr|Q91ZC6
xxxxx46tr|Q91WW5
xxxx49tr|Q7TN49
xxxxx46tr|Q91YB7
TM7TM6TM5TM4TM2TM1Identity (%)aSequence
Table S2.1 Hit sequences from independent BLAST search of each TM  
a w.r.t. the sequence of mMrgC11 
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xxxxx45tr|Q91ZC5
xx31sp|MRGF_HUMAN
x31sp|MRGF_RAT
x31sp|MRGF_MOUSE
xx31tr|Q8IXE2
xxx42tr|Q7TN46
xx33tr|Q8N7J6
x
x
x
x
x
x
TM3
x40tr|Q7TN44
x29sp|MRG_HUMAN
xx34tr|Q7TN51
x36tr|Q91ZC1
x44tr|Q7TN43
x30tr|Q7TN40
xxx32tr|Q91ZB7
x23tr|Q91ZB5
x34tr|Q7TN41
xx39tr|Q7TN50
xxx42tr|Q7TN47
xxxx42tr|Q91WW2
xx45tr|Q91ZC7
x35tr|Q91ZB8
x37tr|Q8TDS7
xx37tr|Q8NGK7
xxxx40tr|AAH64040
xxxx42tr|Q91WW4
xx xxx42tr|Q91ZC4
x23tr|Q7TN39
TM7TM6TM5TM4TM2TM1Identity (%)aSequence
Table S2.1 (continued)  
a w.r.t. the sequence of mMrgC11 
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inactive93-20-15-0.0358RFa/mMrgA1
682± 37194-62-19-86-74RFa
1255± 47875-47-19-80-71RF
30-29-27-49-75acetylated RdFa
31-40-25-48-82acetylated dRFa
34-45-19-67-97acetylated RFa
inactive84-61-43-60-80FMRdFa
inactive75-56-51-46-78FMdRFa
113± 3788-82-33-90-117FdMRFa
276± 11386-79-35-75-103dFMRFa
168 ± 2690-81-34-83-109FMRFa
EC50, nMDesolvationHbondsVDWCoulombB.E.Ligand
Table S2.3 Calculated binding energy (in kcal/mol) and its component contribution for ligands in mMrgC11; 
the binding energy of RFa in mMrgA1 is also included on the last row for comparison
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Chapter 3 
Molecular Dynamics Simulation of Mouse MrgC11 Receptor with Bound F-
(D)M-R-F-NH2 in Explicit Lipid/Water Environment 
3.1 Introduction 
GPCR belongs to one of the membrane protein families embedded into the lipid bilayers, 
while the intra- and extracellular regions are exposed to the aqueous media. The membrane 
environment influences the function of membrane proteins, through electrostatic and steric 
interaction as well as through the membrane’s internal pressure. Therefore the proper 
environment should be taken into account in the molecular simulation. However the resulting 
calculation, incorporating proteins, lipid bilayers, water molecules and ions needs to handle with 
50,000 atoms even for the small proteins and this large simulation size poses a major 
computational challenge. Thanks to advances in computing power and availability of an efficient 
parallel molecular dynamics (MD) code, computational biologists have succeeded in performing 
the required calculations. Recently an all-atom molecular dynamics simulation of a complete 
virus system composed of 1 million atoms was presented by the Schulten group in the University 
of Illinois at Urbana-Champaign, using a parallel molecular dynamics program NAMD[1]. 
In chapter 2, in order to reduce the computation cost, the minimally required molecular 
components were considered in predicting the protein structure and the binding site. However our 
predicted mMrgC11 receptor structure was sufficiently accurate to identify binding sites for 
selective ligands, i.e. chirally modified tetrapeptides of F-M-R-F-NH2. Therefore our structure 
prediction and docking methods might be good enough to predict the interaction between ligand 
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and GPCR. Nevertheless, it is worth performing MD studies for the mMrgC11/ligand complex 
structure in more realistic environments. These could provide the validation for our predicted 
structure and also information about the dynamic behavior, which might lead to understanding the 
role of conformational change on receptor activation.  
Here we have carried out the all-atom MD simulation for mMrgC11/F-(D)M-R-F-NH2 
complex structure in explicit lipid and water environments, using NAMD 2.5 program[2]. In the 
following sections the detailed simulation procedure and the structural characteristics observed in 
a 7ns simulation run are described, focusing on the behavior of the ligand in the binding pocket 
and the conformational change on the transmembrane (TM) domains. 
3.2 Simulation procedure 
3.2.1 Setup of lipid and water environment 
A molecular graphics program, Visual Molecular Dynamics (VMD) was used for the 
simulation setup. The Biograf file of the final optimized mMrgC11/F-(D)M-R-F-NH2 complex 
structure was split into separate ligand and the receptor files. The hydrogen atoms were removed 
and the structure files were converted into PDB format compatible in VMD. The hydrogen atoms 
were then re-assigned with the estimated coordinates based on entries of internal coordinates 
present in the CHARMM topology dictionary. The N-terminus was acetylated (residue name: 
ACP in the CHARMM topology dictionary) and the C-terminus was capped with the N-
methylamide group (residue name: CT3). The PDB and PSF files for the receptor and the ligand 
were then combined, generating a single PDB and PSF file respectively. 
The complex structure was replaced for the mid-plan perpendicular to the TM helical axis 
to be positioned at z = 0. The equation of the mid-plane (Ax+By+Cz+D = 0) was calculated for 
the receptor using MembComp program[3]. Briefly, the hydrophobic center which showed the 
maximum hydrophobicity on the hydrophobicity profile was previously determined for each TM 
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helix. The plane of intersection was aligned to these seven points utilizing a least square approach. 
The origin of the plane was the geometric center of the centers defined for each helix. With this 
equation, the coordinates of the complex structure were transformed. Here the plane was moved 
to z = 0 and the vector normal to the plane became the z-axis. Also the origin of the plane was set 
to the geometric center of TM α-helices.  
Next, the complex structure was then superimposed on the 75 Å x 75 Å slab of a solvated 
palmitoyl-oleoyl-phosphatidylcholine (POPC) lipid bilayer patch and the lipids and water 
molecules overlapping with the protein were removed (POPC within 1 Å and waters within 5 Å 
of the protein). The system was fully solvated with water by adding a ~30 Å thick slab from an 
equilibrated water box. The VMD autoionize plugin was then used to randomly place the ions 
necessary to neutralize the system. The resulting system was composed of 47,651 atoms; 4,180 
receptor atoms, 74 ligand atoms, 4,288 lipid atoms, 39,087 water atoms and 10 chlorine atoms.  
3.2.2 Molecular dynamics simulations 
All simulations were performed with the parallel molecular dynamics code NAMD 2.5[2] 
using the CHARMM22 force field[4, 5] for proteins, the CHARMM27 parameters for the lipids 
and the TIP3P water model[6]. The simulated system was kept at constant temperature of 310 K 
by using Langevin dynamics for all non-hydrogen atoms, with a Langevin damping coefficient of 
1 ps-1. A constant pressure of 1 atm was maintained by using the Langevin piston method with a 
period of 200 fs and decay timescale of 200 fs.  
Simulation was carried out with an integration time step of 1 fs. The bonded interaction 
was computed every time step; short-range nonbonded interaction every two time steps; and long-
range electrostatic interaction every four time steps. A cutoff of 12 Å was used for van der Waals 
and short-range electrostatic interactions and a switching function started at 10 Å for van der 
Waals interactions to ensure a smooth cutoff. The simulation was performed under periodic  
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Figure 3.1 Fully solvated mMrgC11/F-(D)M-R-F-NH2 complex in the membrane. It shows the final system 
built for NAMD run. The receptor (cyan) is shown in cartoon representation, the ligand (mauve) in VDW, 
lipids (yellow for carbon) in licorice and waters in line.  
~30Å 
~40Å 
~30Å 
~70Å
~70Å 
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boundary condition with full electrostatics employed by using the Particle Mesh Ewald (PME) 
method.  
Prior to full dynamics, the system was subjected to 5,000 steps of conjugate gradient 
energy minimization, followed by 100 ps of equilibration, while the coordinates of the 
receptor/ligand complex were fixed. In the equilibration, the system was gradually heated up 
from 0 K to 310 K by using Langevin dynamics with a damping coefficient of 5 ps-1 and the 
target temperature reached after ~7 ps. The system was again subjected to 5,000 steps of 
conjugate gradient energy minimization without any restraint. In energy minimization, the 
nonbonded interaction and electrostatic interaction were computed every time step. Lastly, the 
full dynamics simulation was carried out as described above. 
The simulation was performed on a Linux-based cluster of Dual Intel Xenon 2.4 (or 3.06) 
GHz processors with 1 GB of memory per CPU. The first and second minimization took about 3 
and 4 hours respectively with a single 3.06 GHz processor and the equilibration about 8 hours 
with 6 3.06 GHz processors. The 7 ns production run took about 17 days with 12 2.4 GHz 
processors.  
3.3 Results and discussion 
3.3.1 Comparison between initial and final structures 
The final structure after a 7 ns equilibration was minimized with conjugate gradient for 
5,000 steps. The minimized mMrgC11/F-(D)M-R-F-NH2 complex structure was superimposed 
with the initial structure by aligning TM Cα atoms of the receptor. The RMSD for TM Cα atoms 
was 2.50 Å. As expected, the loop regions were floppier (RMSD = 7.00 Å) and the most dramatic 
change was the closure of the binding site by the extracellular loop 2 (EC2). The formation of the 
‘lid’ in the binding site by the EC2 was observed in bovine rhodopsin structure where the 
disulfide bond formed between two Cys residues in EC1 (closer to TM3) and EC2 stabilizes the  
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Figure 3.2 The mMrgC11/F-(D)M-R-F-NH2 complex structure after 7 ns run. (a) Two complex structures at 
0ns (cyan) and 7ns (green) are superimposed by aligning TM Cα atoms between them. The ligands are 
colored in black for 0ns and in red for 7 ns. The water, lipid and ion molecules are removed for clarity. (b) 
The ligands are in close-up after the residues in 5 Å binding pocket are aligned (RMSD for ligand = 2.48 Å). 
(c) Two ligands at 0 and 7 ns are aligned with heavy atoms (RMSD = 1.83 Å).   
 
closed conformation of the EC2[7]. These Cys residues are conserved in several GPCRs 
including amine receptors, and the presence of a ‘plug’ in the binding crevice was also suggested 
in the β2 adrenergic receptor from the inaccessibility of quenchers to a fluorescent ligand[8]. The 
mMrgC11 receptor does not have the corresponding Cys residues and no disulfide bond is 
expected. However two oppositely charged residues, Lys96 (EC1) and Glu169 (EC2) are located 
at the similar sites and induce the closed conformation of EC2. If formation of a plug by EC2 is a 
general feature for all GPCRs, a key event in receptor activation would involve significant 
conformational change of EC2 allowing for rapid access of a ligand to the binding pocket.  
 81
The tetrapeptide ligand moved by ~1.5 Å towards the exracellular regions after 7 ns 
equilibration, but not out of the binding pocket as shown in Figure 3.2(b). This kind of upward 
movement was also observed for the epinephrine agonist in the β2-adrenergic receptor after 4ns 
of MD simulation in the presence of full membrane and water[9]. This behavior was distinct from 
rigidity shown in an antagonist case.  
The conformation of F-(D)M-R-F-NH2 was examined by aligning the heavy atoms of the 
ligand (Fig. 3.2(c)). Two Phe and Arg were relatively rigid since interactions with four aromatic 
residues (Tyr110, Phe190, Trp162 and Tyr256) and two Asp residues (Asp161 and Asp179) 
restrained their movement as predicted in chapter 2. The Met was labile and its side chain 
underwent a large conformation change, leading to 1.83 Å of RMSD for the ligand.  
3.3.2 Dynamic behavior in receptor conformation during MD simulation 
The RMSD of Cα atoms in the receptor was evaluated every 10 ps and plotted in Figure 
3.3. Since the loop parts were much flexible, only the Cα atoms in TM regions were used in 
alignment. The RMSD plot indicates that the TM regions became well equilibrated after 7 ns. To 
explore conformational fluctuation for each TM, the corresponding Cα atoms were aligned 
respectively and then the RMSD of each TM was computed along the time. All TMs showed the 
similar plot (monotonous decrease) to Figure 3.3(a) of the whole TM regions. The large 
conformational change after 7 ns simulation was observed for TM6 and 7 (the RMSD values are 
2.33 Å and 2.36 Å respectively). This conformational flexibility may be relevant to GPCR 
activation. The ligand binding is thought to trigger a cascade of structural changes in the receptor 
molecule that are capable of inducing activation of the associated G proteins. Here flexibility 
actually means low conformational barrier, leading to an ultimate structural change. The 
conformational change in TM6 of the rhodopsin or the β2 adrenergic receptor was supported by 
several structural and photophysical experiments[10, 11]. Also the EPR study in rhodopsin  
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Figure 3.3 The RMSD fluctuation of Cα atoms with respect to the final 7 ns structure. The RMSD is 
calculated every 10ps by aligning the Cα atoms in TM regions. (a) The TM regions are selected. The RMSD 
values in table are calculated for the initial structure after aligning each TM respectively. (b) The whole loop 
part is selected in graph and each loop in table for RMSD calculation.  
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suggests that movement of the cytoplasmic end of TM7 relative to TM1 may occur in response of 
photoactivation[12].  
The dramatic conformation change in loop regions was clearly demonstrated in the RMSD 
plot of Figure 3.3(b). Based on the RMSD value for each loop region (see table next to the RMSD 
plot), we can see that the extracellular loops underwent a larger conformational change. The most 
prominent change was for EC2 from an open to the closed conformation. The complete closure 
occurred after 6 ns and stayed until the end of simulation. Some conformational fluctuation was 
observed for EC1 and EC3 during the simulation. The dynamic behavior of the extracellular loop 
might be obvious since the ligand is bound in the upper half of TM regions from the extracellular 
region and directly perturbs the conformation of the residues close to the ligand.  
Overall the significant change in the conformation of the receptor was seen in the 
mMrgC11/F-(D)M-R-F-NH2 complex structure. Since F-(D)M-R-F-NH2 is an agonist, the 
conformational change (from the inactive conformation to the active one) might be an apparent 
consequence.         
3.3.3 Binding mode of F-(D)M-R-F-NH2 after equilibration 
The binding mode of the tetrapeptide F-(D)M-R-F-NH2 after 7 ns equilibration is shown in 
Figure 3.4. The C-terminus amide group maintains the hydrogen bond with the side chain of 
Asp161 (TM4). The C-terminus F is still positioned in a stabilizing aromatic and hydrophobic 
environment formed by Tyr110 (TM3), Phe190 (TM5), Leu186 (TM5) and additionally Ile107 
(TM3). The R is stabilized through the electrostatic interaction with Asp161 and an additional 
hydrogen bond with the side chain of Thr183 (TM5). However Asp179 in TM5 moved a little 
away from the R, but within the range where the electrostatic interaction was still effective 
(distance between NH1of R and OD2 of Asp179 = 6.41 Å). The water molecules actually 
intervened in interaction between Asp179 and the ligand, and mediated a hydrogen bond between 
the side chain of Asp179 and the backbone carbonyl group of the ligand (Fig. 3.5). The  
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Figure 3.4 The 5 Å binding site of F-(D)M-R-F-NH2 in mMrgC11 receptor. The intermolecular hydrogen 
bonds (calculated with explicit hydrogens using the same criteria as in Figure 2.4) are indicated by the 
dotted lines. A residue whose side chain participates in the hydrogen bond is specified in red, while one 
whose backbone is involved is in blue. The residues showing good hydrophobic interactions are specified in 
black. The top of each picture corresponds to the extracellular regions.  
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Figure 3.5 Water molecules in 5 Å binding pocket. The water-involved hydrogen bonds are indicated by the 
dotted line. 
 
carboxylate group of Asp179 was solvated with more water molecules and also stabilized by the 
positively charged quaternary amine group of a lipid molecule (distance between N of quaternary 
amine and OD1 of Asp179 = 4.16 Å). This relatively weak interaction of Asp179 compared to 
Asp161 might be validated by our experimental observation in chapter 2. For the D161A mutant, 
four of the six agonists were rendered inactive, while the remaining two were only active at 100 
times higher concentrations. Similarly, the D179A mutant showed no affinity for the three 
tetrapeptide agonists, while the other three were activated only at 10 times higher concentration 
of the ligand. This indicates that Asp161 should interact more effectively with the agonists than 
Asp179.  
The N-terminal F remained sandwiched between Trp162 (TM4) and Tyr237 (TM6) (the 
closest C-C distances between two aromatic rings are 4.64 Å and 3.39 Å respectively). Two more 
aromatic residues in TM6, Tyr242 and Phe244 (located close to the extracellular loop) came into  
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Figure 3.6 The RMSD fluctuation for ligand heavy atoms. (a) The residues in 5 Å binding pocket are aligned 
and then the RMSD for the ligand is computed. (b) The ligand parts are aligned each other. The real line is 
for the RMSD with respect to the final structure after a 7 ns equilibration and the dotted one for that with 
respect to the initial structure.  
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the binding pocket (the closest C-C distances between two aromatic rings are 4.22 Å and 3.40 Å 
respectively) and yielded the additional favorable aromatic interaction with the N-terminal F.  
The water molecules filled the void in the binding pocket, forming hydrogen bonds with 
polar atoms, and some of them mediated an intermolecular hydrogen bond between the receptor 
and the ligand as observed for Asp179. The backbone atoms of Phe166 (TM4) and Phe239 (TM6) 
form the water-mediated hydrogen bonds with the side chain of R and the N-terminus of the tetra-
peptide respectively.  
3.3.4 Time profile of receptor-ligand interactions 
Ligand conformation in the binding site 
The RMSD of the ligand was evaluated every 10 ps in MD simulation. In Figure 3.6(a), the 
residues within the 5 Å binding pocket were used in alignment to give information about the 
ligand configurations in the binding site throughout time. The ligand was configurationally 
flexible and the RMSD of the final 7 ns minimized structure was 2.48 Å with the initial structure.  
The ligand conformation itself fluctuated throughout the MD simulation and the RMSD 
values were ~1.5-2.0 Å with respect to the initial conformation. This indicates that the major 
contribution of configurational change shown previously is the conformational variation of the 
ligand itself. From the correlation between two RMSD plots (Fig. 3.6(a) and Fig. 3.6(b)) we can 
see that the ligand is confined within the binding pocket for 7ns, but exhibits conformational 
flexibility. 
Intermolecular hydrogen bonds 
The intermolecular hydrogen bonds between the receptor and the ligand were determined 
with the same criteria used in chapters 2 and 4 (see Fig. 4.3) for the initial and the final 
minimized structures. The distance between the donor and acceptor atoms was computed for 
every hydrogen bond pair and plotted along the time in Figure 3.7.  
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Figure 3.7 Time profile of intermolecular hydrogen bond distance. The distance is measured every 10 ps 
(grey). The moving average per 100 ps is in black. The hydrogen bond pair is indicated in this way: receptor 
part-ligand part with the index of [residue name][residue number][atom name participating in H-bond]. The 
ligand (carbon in purple) and the receptor residue (carbon in green) involved in the hydrogen bond is shown 
in stick at the picture. The corresponding hydrogen bond is indicated in the dotted line. 
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Figure 3.7 (continued) 
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Figure 3.7 (continued) 
 91
                          
2.0
2.5
3.0
3.5
4.0
4.5
0 1000 2000 3000 4000 5000 6000 7000
time (ps)
di
st
an
ce
 (a
ng
st
ro
m
)
D161OD2-R3NH1
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
0 1000 2000 3000 4000 5000 6000 7000
time (ps)
di
st
an
ce
 (a
ng
st
ro
m
)
D161OD2-R3NH2
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
0 1000 2000 3000 4000 5000 6000 7000
time (ps)
di
st
an
ce
 (a
ng
st
ro
m
)
D161OD1-F4NT
 
Figure 3.7 (continued) 
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The hydrogen bonds with the residues in TM6 (i.e. between the N-terminus and Tyr237 
(Y237O-F1N) and between the backbone amide group and Leu238 (L238-M2N)) were 
interrupted for the first 2ns and then became stable. This observation indicates that some 
conformational rearrangement in (or near) TM6 occurs during these time frames. This fluctuation 
is well correlated with entry of Phe244 into the binding site as will be shown in Figure 3.8. The 
intrusion of Phe244 as well as Tyr242 perturbs the initial conformations, but the favorable 
interactions previously present are recovered after re-organization. 
The direct hydrogen bond of the ligand with Asp179 became loose at the early stage due to 
a water molecule stepping in between them. However Asp179 still made contact with the ligand 
through the water-mediated hydrogen bond and electrostatic interaction. The side chain of R 
mostly interacted with the side chain of Asp161 in the ideal configuration after equilibration. The 
torsion χ2 of the side chain in Asp161 was shown to be in relatively low barrier and the C-
terminus amide group of the ligand switched a hydrogen bond partner between two carboxylate 
oxygen atoms of Asp161 after ~5 ns.  
The hydrogen bond between the side chain of Thr183 and the side chain of R remained 
stable throughout the simulation period. 
Inter-aromatic interaction 
The time evolution of the centroid-to-centroid distance between two interacting aromatic 
rings was explored. The interaction of Tyr110 (TM3) and Phe190 (TM5) with the C-terminus F 
kept steady during 7 ns simulation. As mentioned previously, two more aromatic residues in TM6, 
Tyr242 and Phe244 participated in interaction with the N-terminal F after equilibration. Tyr242 
came close at the early time step, but it did not interfere in the overall conformation of the 
binding site. However intrusion of Phe244 actually affected the present binding mode (note that 
Tyr237 and the N-terminal F become apart and back together) and then after conformational 
rearrangement all favorable aromatic interactions were recaptured.  
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Figure 3.8 Time profile of centroid-to-centroid distance between two aromatic residues. F1 and F4 denote 
the N-terminal and C-terminal F of the tetrapeptide ligand respectively. The distance is measured every 10 
ps (grey). The moving average per 100 ps is in black. The ligand (carbon in purple) and the receptor residue 
(carbon in green) are shown in stick at the picture. For tryptophan, the center of the six-membered ring is 
considered. 
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Figure 3.8 (continued) 
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The centroid distance at 7 ns showed that Trp162 (TM4) moved a little away from the 
ligand, and the closet C-C distance between aromatic rings of Trp162 and the N-terminal F was 
4.64 Å. However Trp162 was not completely out of interaction with this F.      
 The stability of aromatic interactions identified in the previous prediction implies the 
accuracy of our predicted structure for the binding site. The new interactions with Tyr242 and 
Phe244 indicate that the explicit membrane and water simulation might be necessary to obtain 
correct conformations for residues on the boundary of the TM and the loop. 
3.3.5 Time profile of inter-helical interactions 
The nonbond distances between residues on different helices were analyzed to understand 
how the dynamics in the explicit lipid and water environment affect the inter-helical interactions. 
The inter-helical hydrogen bonds were identified for the initial and the final 7 ns minimized 
structure (Fig. 3.9) and the distances for these hydrogen bond pairs were measured throughout the 
MD simulation. The comparison of two hydrogen bond networks demonstrates some dynamic 
behavior on the inter-helical interactions. The initial hydrogen bond network was subjected to re-
arrangement during the MD simulation. We can also see some hydrogen bond pairs preserved 
after 7ns; Tyr63 (TM2) (one of the residues conserved in the Mrg receptor family (with 39 
sequences available on Swiss-Prot and TrEMBL))–Ser112 (TM3) and Arg215 (TM6)–Val277 
(TM7). Moreover the hydrogen bond between Tyr63 and Ser112 remained stable throughout the 
MD run as shown in Figure 3.10 and it may play a role in maintaining helix packing.  
The hydrogen bond between Asn66 (TM4) and Trp151 (TM4) (the highly conserved 
residues in the family A of GPCRs that form an interhelical hydrogen bond in rhodopsin) became 
loose, but not totally apart. Asn66 partly formed a hydrogen bond with Ser115 (TM3) during the 
MD run.  
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Figure 3.9 Interhelical hydrogen bond networks in the mMrgC11 receptor. It is viewed form the extracellular 
region. The interhelical hydrogen bonds (dashed lines) are specified with residues participating in hydrogen 
bond. (a) for the initial structure. (b) for the 7ns minimized structure. The HBPLUS program was used to 
calculate hydrogen bonds (maximum D-A distance = 3.9 Å, minimum D-H-A angle = 90.0°).  
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Figure 3.10 The time profile of the distance between residues residing in different helices. The same index 
rule ([residue name][residue number][atom name]) is used as in Figure 3.7.   
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Initially Asn44 (TM1) (highly conserved in the family A GPCRs) formed a hydrogen bond 
with the Ser268 carbonyl group of the backbone in TM7 as shown in Figure 3.9. This hydrogen 
bond was loosened for the early 500 ps (this may be an equilibration period needed for the protein 
structure to be adjusted from perturbation of the lipid and water molecules) and then the pair 
remained close enough for the hydrogen bond formation. At t = 0, Asp71 (TM2) that forms an 
inter-helical hydrogen bond with this Asn in rhodopsin was in the proximity, but was not in 
hydrogen bond contact in the mMrgC11 receptor. In the MD run the distance between Asp71 and 
Asn44 became larger, leading to ~9-10 Å. Instead Asp71 moved close to TM7 and formed a 
stable hydrogen bond with Ser267. The approaching of TM2 and TM7 in the activated state was 
suggested for the angiotensin receptor II type 1 from mutation-induced constitutive activation, 
and later the in situ measurement of TM2 movement in the angiotensin receptor was also 
reported[13, 14]. Based on our simulation, it might be proposed that TM2 first moves further 
from TM1 on activation and then towards TM7. During 7ns, the concerted formation of hydrogen 
bonds in TM1, TM2 and TM7 that exists in the inactivated rhodopsin structure[7, 15] was not 
observed in our predicted mMrgC11 receptor, suggesting that the receptor structure was in the 
activated conformation. 
Lastly we examined the distance between Tyr110 (TM3) and Leu234 (TM6). Tyr110 was 
one of the residues interacting with the ligand and underwent conformational fluctuation. This 
kind of flexibility between TM3 and TM6 may help induce the receptor activation.   
3.4 Summary and conclusions 
We performed the all-atom MD simulation of mMrgC11/F-(D)M-R-F-NH2 structure in the 
explicit lipid and water environment. The analysis of the 7 ns MD trajectory clearly demonstrated 
that our predicted structure of the mMrgC11 receptor and its binding site of F-(D)M-R-F-NH2 
was stable in the full membrane system. The conformational flexibility of the side chain and 
small structural change in TM regions were present, but no significant instability was detected. 
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Moreover the initial interactions of the ligand with the key residues (Asp161 and four aromatic 
residues, Tyr110, Phe190, Trp162 and Tyr237) were preserved throughout the entire MD run 
except for Asp179 in TM5. Nevertheless Asp179 interacted with the ligand through water-
mediated hydrogen bond and electrostatic interaction. These findings validate our structure 
prediction method, indicating that the MembStruk predicted structures are fairly accurate.  
In addition we observed some dynamic behavior in protein structure. In the TM regions, 
TM6 and TM7 showed relatively large conformational change and it suggested the possibility of 
their implication in receptor activation. The loops underwent large structural fluctuations, and the 
most dramatic change was seen in EC2. Interestingly the electrostatic interaction of two 
oppositely charged residues, Glu169 (EC2) and Lys96 (EC1) pulled them each other, resulting in 
the closed conformation of EC2 that is similarly shown in rhodopsin. Two more aromatic 
residues in TM6, Tyr242 and Phe244 were newly identified to contact the N-terminal F of the 
ligand after the equilibration, securing the ligand in the binding site. They could be additional 
mutation candidates to be tested for the further validation. These observations indicate that the 
explicit membrane and water simulation might be necessary to obtain correct conformations for 
the loops, including residues on the boundary of the TM and the loop.  
An extended simulation along with incorporation of G protein into our receptor structure 
where the intracellular loops are now fully equilibrated could be explored to examine the 
reciprocal effect of the G protein and the mMrgC11 receptor on the conformational change in 
activation. It would definitely provide the better understanding on the GPCR activation process. 
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Chapter 4 
Virtual Ligand Screening of Chemical Libraries for Mouse MrgC11 
Receptor: Combination of QSPR and Docking Methods1 
4.1 Introduction 
High-throughput screening (HTS) of chemical libraries is the widely adopted method for 
finding novel lead compounds in drug discovery. It enables a large number of compounds to be 
screened using highly automated, robotic techniques. Although HTS makes it possible in 
principle to test all available compounds, it is not necessarily feasible for a number of practical 
reasons. One of reasons is the cost of such screenings: even though the robotics and 
miniaturization have significantly reduced the unit cost, the huge number of compounds now 
available from many companies means that the overall expense can be significant. Moreover, as 
the available databases get larger and larger, the hit rates in HTS dramatically decrease. A 
possibility to avoid these problems is not to screen the whole compound set in the library 
experimentally, but only a small subset, which is likely to bind to the target protein receptor. This 
pre-selection can be performed by virtual screening (VS), which uses computer-based methods to 
select most promising compounds from the ligand databases for experimental assays. Virtual 
screening can be carried out by searching databases for molecules fitting either a known 
pharmacophore (ligand-based) or a three-dimensional structure of macromolecular target 
(structure-based). In the case of GPCRs, the limited availability of the structural data has forced 
the computational design of ligands to heavily rely on ligand-based drug design techniques. 
                                                 
1 This work was carried out in collaboration with the Tropsha group of the University of North Carolina. 
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Indeed, the natural ligands can provide a good starting point, leading to useful pharmacophore 
models that can be used for virtual screening to identify lead structures with novel scaffolds[1]. 
The application of this method has been successfully demonstrated in the discovery of subtype 
selective agonists to the somatostatin receptor[2] and non-peptide antagonists to the urotensin II 
receptor[3]. Structure-based screening should be potentially more powerful than the ligand-based 
method since by exploiting structural information taken directly from the active site, it is possible 
to discover ligands with both diverse chemotypes and binding modes. However, it still suffers 
from docking/scoring inaccuracy, and in addition it requires the knowledge of the 3D structure of 
the target protein. Therefore, it has mostly been applied to targets for which a high resolution X-
ray crystal structure is known. However, along with the deciphering of human genome, 
computational chemists are facing an overwhelming number of potential targets for which very 
little experimental 3D information is available. Therefore it will be very important in the near 
future to be able to use not only X-ray or NMR structures, but also protein models for structure-
based virtual screening of chemical libraries.  
The structure-based virtual screening mainly relies on a fast and accurate docking/scoring 
function that can be used to identify the correct binding mode. Theoretically, the most accurate 
estimate of the binding affinity can be obtained using force-field based methods. Examples 
include free energy perturbation (FEP)[4] or linear interaction energy (LIE) approaches[5]. 
However, the computational cost of such methods is too high to afford calculation in a high-
throughput fashion.  Therefore the huge chemical libraries should be filtered through a rapid pre-
screening tool to identify the most promising compounds prior to engaging more computationally 
intensive docking approaches. The ligand-based similarity searching technique could be used for 
this purpose. In this approach, the ligand structures are typically represented by multiple chemical 
descriptors and the statistical data modeling techniques are used to establish quantitative 
correlation between descriptors and target properties of interest, such as binding constants or 
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specific biological activities[6]. Recently the Tropsha group in the University of North Carolina 
had developed a novel structure-based chemoinformatics approach to search for complimentary 
ligands based on receptor information (CoLiBRI)[7]. CoLiBRI is based on a representation to 
characterize both receptor active sites and their corresponding ligands in the same universal, 
multidimensional, chemical descriptor space. Mapping of both binding pockets and 
corresponding ligands onto the same multidimensional chemistry space would preserve the 
complementarity relationships between the binding sites and their respective ligands.  
In this study, we carried out virtual screening for the mouse MrgC11 receptor, one of 
orphan GPCR receptors as an effort to identify small molecule ligands that behave as selective 
agonists or antagonists. Despite of the success of orphan GPCR-natural ligand pairing through 
reverse pharmacology many scientists focused on discovering new drugs appear to be bypassing 
the conventional deorphanizing step due to the difficulty in developing peptide libraries to look 
for the ligand. They perform initial high-throughput assays to find synthetic small-molecule 
agonists, which then can be used to explore the physiological aspects of the receptor. Here we 
first pre-screened compounds in the chemical database using the CoLiBRI and the resulting 
candidates were subsequently docked using the MSCDock method. The ‘hit’ compounds from 
docking were experimentally tested with the intracellular calcium release assay. In the following 
sections, we describe the computational methods in details and discuss the screening results. 
4.2 Materials and methods 
4.2.1 Pre-screening of compounds in chemical libraries 
Pre-screening the compounds of the chemical libraries was carried out using the CoLiBRI 
program. CoLiBRI is based on the quantitative structure-property relationship (QSPR) method. It 
generates the molecular descriptors that capture key properties of the molecules, using the 
transferable atom equivalent (TAE)/RECON method. The TAE/RECON method that was 
developed by Breneman and co-workers[8] rapidly generates molecular electron density  
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Table 4.1 Electron-density-derived TAE descriptors; ρ(r) represents the electron density distribution[9] 
 
Integral Electronic Properties 
Energy 
Electronic population 
Volume 
Surface area 
Surface electronic properties 
(extrema, surface integral averages and histogram bins are available for each property) 
SIEP Surface integral of electrostatic potential  
EP Electrostatic potential ∫∑ ′− ′′−−= rr rdrRr ZrEP )()( ρα αα  
DRN Electron density gradient normal to 0.002 e/au
3 
electron-density isosurface 
n⋅∇ρ  
G Electronic kinetic energy density ))(2/1()( * ψψ ∇⋅∇−=rG  
K Electronic kinetic energy density ))(2/1( *22* ψψψψ ∇+∇−=K  
DKN Gradient of the K electronic kinetic energy density normal to surface n⋅∇K  
DGN Gradient of the G electronic kinetic energy density normal to surface n⋅∇G  
F Fukui F+ function scalar value )()( rrF HOMOρ=+  
L Laplacian of the electron density )()()()( 2 rGrKrrL −=−∇= ρ  
BNP Bare nuclear potential ∑ −= α ααRr ZrBNP )(  
PIP Local average ionization potential ∑= i ii rrrPIP )()()( ρ ερ  
 
 
distributions and evaluates the electronic surface properties, which are used for generating 
descriptors. It contains a library of the atomic types in a form which can transfer electron density 
properties. The RECON program reconstructs the electronic density properties of a molecule by 
assigning the closest match from a library of atom types for each atom in the molecule. The 
additivity principle is applied to calculate molecular descriptors by summing up the individual 
descriptor type values for all atoms in the molecule, using the RECON method. Therefore it is 
possible to derive pseudo-molecular descriptors for any group of atoms, e.g., active site fragment, 
making the TAE descriptors well suited for our approach. Table 4.1 shows a complete list of TAE 
descriptors. The local average ionization potential (PIP) of the molecule, one example of the 
electronic surface properties is shown onto its 0.002 e/au3 (electrons per cubic Bohr) electron- 
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Figure 4.1 TAE local average ionization potential (PIP) surface property and its histogram distribution[9]. 
density surface in Figure 4.1. The distribution of this property is then presented as a histogram 
such as that shown on the right side of the figure. Each bin of the histogram is used as a 
descriptor, as well as statistical information such as maximum, minimum, and average of each 
surface property. 
A computational geometry technique known as Delaunay tessellation is utilized to isolate 
receptor atoms that make contacts with bound ligands. Let us consider a collection of randomly 
distributed points in 2D (Fig. 4.2). By analogy, the red and blue dots represent the ligand atoms 
and the receptor atoms in the binding site, respectively. Delaunay tessellation partitions the space 
occupied by these points into a set of space filling, irregular triangles (tetrahedrons in 3D) with 
the original points as vertices. Therefore this method identifies all nearest neighbor triplets of 
vertices, including two types of interfacial triplets as shown in Figure 4.2: one ligand atom point 
and two receptor atom points; two ligand atom points and one receptor atom point. Applied to the 
3D receptor-ligand complex case, it will generate three types of interfacial quadruplets: one 
ligand atom and three receptor atoms; two ligand atoms and two receptor atoms; three ligand 
atoms and one receptor atom. Therefore it provides a way of detecting all receptor atoms that are 
nearest neighbors of ligand atom. The TAE descriptors are then generated for a pseudo-molecule 
composed of these receptor atoms.  
Using the TAE/RECON method, multiple descriptors as listed on Table 4.1 are generated 
for the receptor binding sites and their corresponding ligands so that each chemical entity is  
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represented as a vector in a multidimensional TAE/RECON chemical space.  Since every 
descriptor may not be important for determining receptor-ligand complementarity, the subset of 
descriptors that best reflect this complementarity is determined, using a leave-one-out (LOO) 
cross-validation approach, in which each data value is left out in turn and a model derived using 
the remainder of the data.  The overall procedure for selecting an optimal subset is as follows: 
(1) A subset of nVar descriptors (nVar is a predefined number between 1 and the 
total number of available descriptor) is randomly selected.  
(2) One of the receptors is chosen in the training set and the k nearest 
neighboring (kNN) receptors are selected in the nVar-dimensional descriptor 
Figure 4.2 Delaunay tessllation of a collection of random points in 2D (modified from reference7) 
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space of the binding site. The coordinates of the chosen receptor’s virtual 
ligand in the ligand space are predicted based on the relative orientation of 
ligands known to bind with the kNN receptors. This step is repeated until 
every receptor in the training set is eliminated once and all the receptor’s 
virtual ligands are predicted. This resulting set of virtual ligands is called a 
CoLiBRI model. 
(3) The predictive mean rank (PMR) for the model is calculated. It is related to 
the chemical similarity of the virtual ligands to the known ligands. The 
similarities are evaluated as Euclidean distances in the nVar-dimensional 
descriptor space:  
∑
=
−=
Varn
d
jdidji XXDist
1
2
, )( , (Eq. 4.1) 
where Xid and Xjd are the dth selected descriptor for ligand i and j. The higher rank 
means the larger deviation of the model.   
(4) Step 2 and 3 are repeated for all possible k values 
( pairsreceptor -ligand ofnumber  totalk2 ≤≤ ). The k values that leads to 
the lowest PMR value is chosen as optimal. 
(5) The selection of nVar descriptors is optimized based on simulated annealing. 
For a model built using randomly-sampled nVar descriptors, the value of the 
fitness function, the inverse of its PMR value is calculated. By changing a 
fraction of the currently used descriptors to other randomly selected of nVar 
descriptors, a new CoLiBRI model is generated for the new trial set (repeat 
steps 1 to 4) and the new corresponding fitness function is calculated. The 
new trial set is accepted or rejected based on the Metropolis criterion. This 
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Monte Carlo approach is continued as the temperature is lowered until the 
termination condition is satisfied. 
At the end, both an optimum k value and an optimal subset of nVar descriptors are determined and 
produce a model with the best predictive ability. More detailed mathematical expression is 
described in reference 7.  
Now the CoLiBRI model is ready to be used for the ligand screening. First the target 
receptor is positioned in the selected descriptor subspace and its k nearest neighboring receptors 
from the training set are found. The known ligands of these k nearest neighboring receptors are 
then used to estimate the location of the target receptor’s virtual ligand in the descriptor space in 
the same way as step 2 above. All ligands in the chemical library are ranked based on their 
distance to this predicted virtual ligand point (using Eq. 4.1), and the ligands with the smallest 
distance are considered as the most probable hit.  
In our study the CoLiBRI models were generated for the dipeptide binding site using the 
same training set (670 complex structures from PDBbind[10]) used in reference 7 plus the 
predicted mMrgC11/R-F-OH complex structure.  
4.2.2 Chemical libraries 
Three sets of chemical libraries were screened in this study; 
(1) The first set: An older version of the database from ChemDiv with 451,345 
compounds was pre-screened using the CoLiBRI method. The multiple CoLiBRI 
models that predict complementarity were generated, varying the nVar value, a 
number of selected descriptors used in generating a CoLiBRI model as described 
in section 2.1. The compound within the top 1,000 by at least one model was 
selected and total 3,900 compounds were collected for the next docking step. 
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(2) The second set: It was taken from a newer version (fall, 2004) of the database 
from ChemDiv with 513,000 compounds. We selected compounds that were 
consistently predicted to be within the top 1,000 by all models. This resulted in 
442 hits. 
(3) The third set: The 23 drug compounds known for producing pain relief were 
docked without any pre-screening. It includes some opiates (e.g. Demerol), local 
anesthetics (e.g. Lidocaine) and capsaicin (an agonist of vanilloid receptors in 
dorsal root ganglion (DRG)). All possible protonation states were considered, 
leading to a total of 43 ligand structures for docking. 
 For the pre-screened compounds from the first and second set, hydrogen atoms were added and 
Gasteiger charges[11] were assigned using Concord program. No further optimization was carried 
out before docking. For the third ligand set, Gasteiger charges were assigned and the structures 
were optimized in gas phase using conjugate gradient minimization using the DREIDING force 
field (FF)[12] on Cerius2[13].  
The pre-screening of ChemDiv database for the di-peptide binding site was performed in 
collaboration with the Tropsha group of the University of North Carolina.  
4.2.3 Molecular docking 
MSC-Dock program was used for docking the pre-screened ligands. We used the Dock-
Diversity Completeness protocol (DDCP). As described in chapter 2, DDCP attempts to generate 
a complete set of ligand configuration families with a fixed coordinate diversity. In this study the 
diversity was set to 0.6 Å. The rejection ratio (defined as the fraction of new configuration that 
belongs to previously generated families to the fraction that leads to a new family) was set to 2.2. 
The 50 families were selected with the best energies (by DOCK4.0 energy score) in the first 
phase and an average of six members in each family was generated in the second enrichment  
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phase. The final ~300 configurations were ordered by DOCK4.0 energy score and re-clustered 
with 0.6 Å of diversity to generate a new set of families. The top 5 family heads (a member with 
the best energy in each family) were conjugate gradient minimized (100 steps or 0.1 kcal/mol/Å 
of RMS force) with the ligand atoms movable and the receptor atoms fixed. Then the binding 
energies were then calculated for these 5 optimized ligand-receptor complex configurations. The 
calculated binding energy (BE) is defined by  
BE = E (ligand in fixed protein) – E (ligand in water),  
where the E (ligand in fixed protein) is the potential energy of the ligand calculated in the ligand-
receptor complex with the coordinates of the receptor fixed. This potential energy includes the 
internal energy of the ligand and the interaction energy of the ligand with the receptor. E (ligand 
in water) is the potential energy of the free ligand in its docked conformation (snap bind energy) 
and its solvation energy calculated using the analytical volume generalized born (AVGB) 
continuum solvation method (cavity_params_1.3)[14]. The final best ligand-receptor structure 
was selected as the one with the most negative binding energy. 
4.2.4 Selection of final hits 
The ligands in the final docked conformation were sorted by three criteria; the binding 
energy, the van der Waals interaction energy and the energy of hydrogen bond between the 
> 90° 
> 90° < 3.9 Å
> 90° 
< 2.5 Å
D
H
DD
DD A
AA
Figure 4.3 Geometric criteria for the hydrogen bonds. D is the donor heavy atom, H the hydrogen, A the 
acceptor, DD donor antecedent (i.e. an atom two covalent bonds away from the hydrogen) and AA 
acceptor antecedent. 
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receptor and the ligand. The intermolecular hydrogen bond was determined by the geometric 
criteria shown in Figure 4.3[15] and its energy was evaluated using the DREIDING FF. For the 
first ligand set, the top 100 ligand compounds were chosen by each sorting criterion. Then we 
selected the compounds that were consistently within the top 100 by at least two criteria. This led 
to total 52 compounds. These selected compound structures were further optimized in the protein-
ligand complex. The side chain conformation of receptor residues within 5 Å from the ligand was 
optimized using the SCREAM program and then the entire receptor-ligand complex structure was 
conjugate gradient minimized with 0.1 kcal/mol/Å of RMS force. This receptor-ligand complex 
was further refined using one cycle of annealing MD heating from 50 K to 600 K and cooling 
down back to 50 K in 50 K steps, with 1 ps of equilibration between temperature jumps. Here 
only the ligand and the receptor side chains within 5 Å of the binding pocket were allowed to 
move during the annealing cycle. At the end of the annealing cycle, the system was minimized to 
an RMS force of 0.3 (kcal/mol)/Å. The binding energy was then re-calculated for the final 
complex structure in the same way as described above. 
The compounds in the second set were also sorted by three same criteria and the common 
compounds within the top 40 were selected. The 40th best binding energy is the halfway between 
the highest one and zero. This resulted in 21 compounds, which were optimized further as in the 
first set.  
The pain-related compounds in the third set were sorted by their binding energy and the top 
10 compounds were chosen, then the same post-optimization was carried out. 
Both the protein and the ligand were described using the DREIDING FF and the protein 
charges were from CHARMM22[16]. All calculations used the MPSIM program[17], with 
nonbond interactions evaluated using the cell multipole method[18]. All simulations were 
performed in gas phase with the dielectric constant of 2.5. 
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After post-optimization, the residues of the receptor having either an intermolecular 
hydrogen bond or good van der Waals contact with the ligand were identified. By putting the 
priority on compounds having good contacts with the key residues—Tyr110 (TM3), Asp161 
(TM4) and Asp179 (TM5)—26 compounds were finally chosen for experimental test. They 
included four outliers in the docking step to expand diversity and two pain-related compounds, 
capsaicin and ibuprofen. 
4.2.5 Intracellular calcium release assay 
The intracellular calcium release assay experiment was carried out to test activity for 26 
compounds (the details are described in chapter 2). One of the known peptide agonists, F-M-R-F-
NH2 (EC50 = 168nM) was used as a control compound. To test agonistic activity, cells 
expressing stably mMrgC11 receptor proteins were treated with compounds in two different 
concentrations, 100 μM and 10 μM. To check antagonistic activity, cell sample was pre-
incubated for >5min with a compound in 100 μM and 10 μM concentration and then were treated 
with 1 μM of F-M-R-F-NH2. The inhibitory constant 50% (IC50), the concentration reducing the 
activity of 400 nM F-M-R-F-NH2 by half was measured for the compounds showing the 
antagonistic effect in two ways. First, cells were pre-incubated with a compound in various 
concentrations and F-M-R-F-NH2 was added later. Secondly, the compound was added to the cell 
sample together with F-M-R-F-NH2 at the same time and the intracellular calcium release was 
measured. 
4.2.6 Virtual screening of tetra-peptide binding site 
The virtual screening for the tetra-peptide binding site was independently carried out in a 
similar way. Since the loops were in the ensemble of conformations as shown in chapter 3, the 
extracellular loops in the mMrgC11 receptor were not included in screening. The dataset of 800 
ligand-receptor complexes from the PDBbind Database (PDB entry codes are listed in the 
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supporting information of reference 7) was divided into the training (used for model building; 525 
structures) and the test (used for model validation; 275 structures) sets using the sphere exclusion 
method[19]. In building CoLiBRI models, six predicted Mrg complex structures were included in 
the training set; mMrgC11/(D)F-M-R-F-NH2, mMrgC11/F-M-R-F-NH2, mMrgC11/F-(D)M-R-F-
NH2, mMrgC11/R-F-NH2, mMrgC11/R-F-OH and rat MrgA/adenine complex. The CoLiBRI 
models differ depending on the number of descriptors (4 to 40) and the content of a given number 
(10 content variations). Among these 370 models the top 100 models were chosen based on the 
PMR values for the test set of 275 receptors.  
The first set of chemical library used in the previous dipeptide case was screened for the 
mMrgC11 receptor optimized with the bound F-(D)M-R-F-NH2, which is the best known tetra-
peptide agonist. Five F-M-R-F-NH2 peptides (three agonists and two non-agonists), R-F-NH2 and 
R-F-OH were included into the ChemDiv database, leading to total 451,352 compounds. The top 
1,000 compounds were selected for each model. The models having (D)F-M-R-F-NH2, F-M-R-F-
NH2 and F-(D)M-R-F-NH2 as a hit after screening were identified, resulting in 92 out of 100 
models. The 4,735 compound hits from the ChemDiv database were predicted by at least one of 
92 models and the 16 compound hits were consistently predicted by all 92 models. However F-
M-(D)R-F-NH2 was also consistently recognized as a hit for all 92 models (false positive), 
indicating that the CoLiBRI model is not sensitive enough to completely distinguish between the 
chirally modified tetrapeptide agonists and non-agonists. Nevertheless identification of three 
agonists as hits provides some validation of the CoLiBRI models used in this study. 
The 774 compound hits which were consistently predicted by at least 50 models were 
chosen for the next docking step. We also used MSC-Dock with the same parameters except for 
the diversity of 1.0 Å since the size (number of atoms) of hit compounds in the tetra-peptide 
binding site is larger than those in the di-peptide binding site.  
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Following the same scoring method and selection criteria (the top100 were selected for 
each criterion – binding energy, van der Waals interaction and hydrogen bond energy (the 
calculated binding energy = -41.77 to 431.47 kcal/mol; the 100th is approximately halfway 
between -41.77 to 0)), final 55 compounds were identified out of 774. Then these 55 complex 
structures were optimized in the same way as described section 2.4. 
We docked F-(D)M-R-F-NH2 with the same docking parameters and scoring method. The 
RMSD of the best configuration was 0.29 Å with respect to the previously predicted “true” bound 
configuration, validating our docking procedure. 
4.3 Results and discussion 
D16114.17 
7.38 
9.99 
Y110
D179
Figure 4.4 5 Å binding pocket of mMrgC11 receptor optimized with the di-peptide agonist, R-F-OH. 
Three key residues (Y110, D161 and D179) are identified and inter-residue distances are specified in 
Å for those residues.  
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4.3.1 Hit compounds from virtual screening 
Figure 4.4 shows the 5 Å binding site of the mMrgC11 receptor complexed with one of 
dipeptide agonists, R-F-OH. This dipeptide optimized structure was used for both pre-screening 
and docking. Three key residues were previously identified in the R-F dipeptide binding. Tyr110 
had a good π-π interaction with F of the dipeptide, and two Asp residues, Asp161 and Asp179 
interacted favorably with the sidechain of R and the N-terminus. The final hit compounds after 
virtual screening were listed in Figure S4.1 for the first ligand set and in Figure S4.2 for the 
second one. The ligand atoms forming hydrogen bonds with the receptor were specified. The 
contribution of each receptor residue to the van der Waals interaction was evaluated and the 
residues for which the absolute value of the interaction energy was larger than 3 kcal/mol were 
identified. Most of ligands had at least one aromatic ring, which replaced the phenyl ring of R-F 
dipeptide and interacted with nonpolar residues present inside the pocket such as Tyr110, Phe190 
and Leu186. Some of ligands formed a hydrogen bond with Asp161 or/and Asp179, but none of 
the hydrogen bond partners were similar to the arginine sidechain. 
By comparing the hit compounds from the first set with those from the second set, we 
could see that selection of the compounds consistently predicted by all CoLiBRI models provided 
a ligand with the higher binding energy showing better chemical contacts (i.e. contacts with all 
key residues) although the hit compounds showed less diversity. MOL282 (the ligand with the 
best binding energy in the second set) showed better binding by 6 kcal/mol than Mol2190 (the 
best one in the first set) and made contacts with Tyr110, Asp161 and Asp179. 
Among the pain-related compounds, capsaicin and ibuprofen showed the best binding 
energy in docking. The binding energies were -45.11 and -43.14 kcal/mol respectively. The van 
der Waals interaction mainly contributed to the binding energy. Capsaicin formed a single 
hydrogen bond with Asp161 and ibuprofen does not have any contact with three key residues. 
4.3.2 Experimental activity test 
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Table 4.2 Inhibitory constant 50% (IC50) of hit compounds (unit: μM) 
 A B 
MOL282 46.5 ± 2.2a 74.6 ± 0.1b 
capsaicin 26.0 ± 2.7a N.A. 
capsazepine 19.2 ± 5.9b N.A. 
dihydrocapsaicin 46.6 N.A. 
N-vanillylnonamide 69.7 ± 17.7b N.A. 
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Figure 4.5 Compounds showing the inhibitory effect (a) from the hit compound set of VLS and (b) among 
the tested capsaicin analogs. 
 
The agonistic activity for total 26 compounds (24 from the virtual screening plus capsaicin 
and ibuprofen) were tested using the intracellular calcium assay. The mMrgC11 receptor was 
activated by none of them up to 100 μM concentration. However some of them showed the 
inhibitory effect – blocking the activity of the known agonist, F-M-R-F-NH2. Two compounds, 
MOL282 and capsaicin shown in Figure 4.5(a) blocked the activity of F-M-R-F-NH2. The 
measured IC50s of MOL282 are 47 μM for pre-incubation case and 75 μM for simultaneous 
addition (Table 4.2). It means that MOL282 binds to the mMrgC11 receptor kinetically at the rate 
A –  pre-incubate a compound and then add 400 nM of F-M-R-F-NH2, B –  add a compound and 400 nM of 
F-M-R-F-NH2 at the same time. 
a mean ± SEM from triplicate independent measurements, b duplicate measurements 
N.A.: no significant decrease in activity of F-M-R-F-NH2 agonist is observed in >200 μM concentration. 
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comparable to F-M-R-F-NH2. However capsaicin could not block the activity of the agonist when 
it was added together with the agonist at the same time, indicating that it is a slow binder than F-
M-R-F-NH2.  
MOL282 was predicted to have the best binding energy from our virtual screening, and this 
experimental result provides the strong evidence that our predicted mMrgC11 structure is 
accurate enough to screen chemical libraries for potential ligands. Capsaicin is a well-known 
agonist of vanilloid receptor type 1 (VR1), which functions as a molecular integrator of painful 
chemical and physical stimuli[20]. Although Dong et al. claimed that mMrgAs and mMrgD were 
expressed in the VR1- sensory neurons[21], we could observe that capsaicin was able to inhibit 
the activity of a known agonist in the mMrgC11 receptor. Next we extended the experiment to 
capsaicin analogs, and five commercially available analog compounds were tested (capsazepine, 
dihydrocapsaicin, olvanil, N-vanillylnonamide and eugenol). Among five, three compounds 
showed antagonistic effect at the tens micromolar concentration. Their chemical structures are 
shown in Figure 4.5(b). 
4.3.3 Refined docking of MOL282 and design of its derivatives 
We docked the lead compound, MOL282 again into the mMrgC11 receptor in a more 
refined docking scheme. The conformations of MOL282 were extensively explored using the grid 
sampling method. Five torsion degrees of freedom were sampled by 60° steps from the initial 
optimized structure, leading to total 7,776 conformations. These conformations were ranked by 
the force field energy in gas phase and clustered with 1.0 Å of diversity. This resulted in the set of 
final 87 conformations. Each conformation was docked independently into the same binding 
region without further optimization.  
The MSC-Dock with DDCP was used for docking as described in section 2.3. Here the top 
25 families (instead of 5) were chosen and optimized with the receptor coordinates fixed. They 
were ranked by binding energy and then the top 10 configurations were determined. These 10  
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Figure 4.6 Histograms of energy and RMSD distribution for 7,776 conformations of MOL282 in grid 
search. The pair-wise RMSD is calculated with heavy atoms only.  
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Figure 4.7 The 5 Å binding pocket of MOL282 in mMrgC11 receptor. The hydrogen bond and inter-aromatic 
ring distance are specified in Å. 
 
receptor/ligand complex structures were further optimized with the conjugate gradient 
minimization while all atoms were movable. The final structure was then chosen with the best 
binding energy. Therefore we ended up with 87 optimized complex structures. No further 
optimization such as the sidechain replacement and annealing MD was carried out.  
The best binding configuration across the 87 optimized structures is shown in Fig. 4.7. All 
three key residues interact with the ligand; Asp161 and Asp179 form hydrogen bonds with the 
ligand and Tyr110 participates in the π-π interaction with one of aromatic rings. Trp162, Leu241 
and Tyr250 form the hydrogen bonds with the carbonyl group and the other hydroxyl groups of 
the ligand. However the ligand had the strain energy of  ~15 kcal/mol (energy in gas phase with  
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Figure 4.8 Suggested better binders derived from MOL282. The binding energy is in kcal/mol. 
 
the dielectric constant of 2.5) in the docked conformation. Most strain resulted from the twist in 
θ1 torsion of Figure 4.7 (θ1=180° in the global minimum). To stabilize this twisted configuration, 
the substitution of a bulky group for the ortho hydrogen was suggested as shown in Figure 4.8(a). 
This bulky group also enhanced the van der Waals interaction with the receptor, leading to the 
increase of the binding energy. However as it became too bulky to occupy the void space in the 
binding pocket, it interfered binding (see the table in Fig. 4.8(a)).  
Since nitrogen in C=N bond of MOL282 does not play a role in binding, C=N double bond 
was replaced by C-C single bond to reduce the strain seen in the docked configuration of 
MOL282 (Fig. 4.8(b)). This derivative of MOL282 binds to the mMrgC11 receptor similarly to 
MOL282, except that one of hydrogen bond partners was switched from Tyr250 to Lys99. The  
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Figure 4.9 The 5 Å binding pocket of mMrgC11 receptor optimized with the tetra-peptide agonist, F-(D)M-R-
F-NH2. Six key residues identified in the previous prediction are shown in stick. The spheres representing 
the binding site of F-(D)M-R-F-NH2 are colored by magenta. 
 
strain energy of the ligand in the docked configuration decreased by ~7 kcal/mol and the snap 
binding energy slightly increased by ~5 kcal/mol, leading to the similar relaxed binding energy 
where the strain penalty was taken into account.  
4.3.4 Virtual screening for F-(D)M-R-F-NH2 bound site 
The 5 Å binding site of F-(D)M-R-F-NH2 is shown in Figure 4.9. Compared with the di-
peptide binding site in Figure 4.4, the site is obviously wider. The buried surface was calculated 
using the Connolly MS program from Quantum Chemistry Program Exchange (QCPE) with a 
probe radius of 1.4 Å and a surface density of 5 dots/Å2. The area for the buried part of F-(D)M-
R-F-HN2 was 466 Å2, which was larger than 263 Å2 for R-F-OH. The N-terminal F-(D)M part 
was extended towards TM6 and TM7, covering the additional TM regions. Tyr237 (TM6) is one 
of the key residues newly identified in the tetra-peptide binding site. 
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Figure 4.10 The 5 Å binding site of the best three hit compounds (a) comp242755 (b) comp241282 (c) 
comp391008. The intermolecular hydrogen bond is indicated by the dotted line and the aromatic interaction 
by the two-sided arrow. 
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The chemical structures of the final 55 hit compounds are shown in Figure S4.3, where the 
residues making a hydrogen bond or having a good van der Waals interaction (interaction energy 
with a ligand is greater than 3 kcal/mol) are identified together. Most are bulky since the surface 
area is considered as one of the descriptors, and relatively nonpolar compounds. They belong to 
the different class of compounds compared with those screened previously in the di-peptide case.  
The detailed binding modes of the compounds with the best (comp242755), the second best 
(comp241282) and the third best (comp391008) binding energy are described in Figure 4.10. In 
comp242755, three aromatic rings interact with Trp162 (TM3), Phe180 (TM5) and Tyr237 
(TM6). The t-butyl group has a favorable hydrophobic interaction with Tyr110 (TM3). The side 
chains of Trp162 (TM4) and Asp179 (TM5) are involved in the formation of hydrogen bond. 
However the hydrogen bond with Asp179 is unlikely if the carboxylate group in the benzoic acid 
part of comp242755 is deprotonated (pKa of benzoic acid = 4.20 for water at 25 °C). Since the 
buried receptor site might provide the different dielectric medium, the neutral form of 
comp242755 could be taken into account. 
In comp24282, two key residues, Asp161 and Asp179 form hydrogen bonds with the 
ligand. Only two residues are shown to have good van der Waals interaction, but the ligand form 
two more hydrogen bonds with Trp162 (TM4) and Leu238 (TM6). 
The comp391008 interacts with the receptor mainly through the hydrophobic interactions. 
The aromatic groups are well stacked with Phe190 (TM5), Tyr110 (TM3), Trp162 (TM4) and 
Phe180 (TM5). Asp161 and Asp179 do not interact with the ligand and are stabilized through the 
hydrogen bond or electrostatic interaction with Thr183 and Lys99 respectively as shown in the 
apo protein. 
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Although the hit compounds do not form as many hydrogen bonds as F-(D)M-R-F-NH2, 
the nonpolar character would relieve the desolvation penalty in aqueous solution to help binding 
to the buried pocket of the receptor.  
4.4 Summary and conclusions 
The virtual screening with the combination of QSPR and docking method was carried out 
for the predicted mMrgC11 receptor. The antagonist ligand, MOL282 (IC50 = 46.5 μM) that had 
the best calculated binding energy was identified by mining ChemDiv database for the di-peptide 
binding site. The interactions with Asp161, Asp179 and Tyr110 shown in the agonist binding 
were also observed in MOL282. The novel ligands were derived from MOL282 in getting rid of 
the strain energy in its docked conformation. The identification of MOL282 as a hit provides the 
strong validation of our predicted binding site and low trial and error in the experiment (only 24 
compounds were tested) demonstrates efficiency of our virtual screening method.  
 The different class of compounds was identified in virtual screening for the tetra-peptide 
binding site, having a large contribution of van der Waals interaction to the binding affinity. The 
experimental test of some of the top compounds would be needed to provide further validation. 
The hit compounds identified in this study are certainly good staring points in designing 
new agonists or antagonists for the mMrgC11 receptor, and variation on the functional group in 
the series of ligands could be used to characterize the binding pocket. Moreover chemical 
characteristics of the hit compounds could provide some clues in deorphanizing Mrg receptors.   
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Supporting Figures 
 
 
Figure S4.1 Hit compounds from the first ligand set after docking.
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Figure S4.1 (continued) Hit compounds from the first ligand set after docking. 
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Figure S4.1 (continued) Hit compounds from the first ligand set after docking. 
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Figure S4.1 (continued) Hit compounds from the first ligand set after docking. The ligands whose names 
are enclosed by rectangular box were tested in experiment. The number in parenthesis corresponds to the 
calculated binding energy in kcal/mol. Residue in blue makes a hydrogen bond through its side chain with 
the atom indicted by the blue arrow. The residue in red has backbone atoms involved in the hydrogen bond. 
The residues in box have good van der Waals interactions with a ligand (E > 3 kcal/mol). 
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Figure S4.2 Hit compounds from the second set after docking. 
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Figure S4.2 (continued) Hit compounds from the second set after docking. 
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Figure S4.3 Hit compounds after virtual screening for the tetra-peptide binding site. 
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Figure S4.3 (continued) Hit compounds after virtual screening for the tetra-peptide binding site. 
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Figure S4.3 (continued) Hit compounds after virtual screening for the tetra-peptide binding site. 
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Figure S4.3 (continued) Hit compounds after virtual screening for the tetra-peptide binding site. The 
residues involved in the intermolecular hydrogen bonds or the van der Waals interactions are indicated in 
the same way as Figure S4.1.  
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Chapter 5 
Prediction of the 3D Structure of Rat MrgA G Protein-Coupled 
Receptor and Identification of its Binding Site1 
5.1 Introduction 
Rat MrgA is one of a few Mrg receptors for which the small molecular (non-peptide) 
agonists have been identified. It has been shown to be activated by adenine (and not guanine). 
Indeed adenine activates rMrgA with a Ki value of 18 nM, potentially identifying it as the 
endogenous ligand[1]. In this chapter we predict the 3D structure of the rMrgA receptor, and we 
report the ligand binding site for adenine and related ligands. This work builds upon our previous 
studies in which we first predicted the 3D structures of mouse MrgC11 (mMrgC11) and MrgA1 
(mMrgA1) receptors using the MembStruk computational method[2, 3]. These structures were 
validated by predicting the binding sites and energies for several tetrapeptides, identifying key 
residues, and then experimentally confirming the expected changes in binding resulting from 
mutations of these residues, as described in chapter 2.  
For this study on rMrgA, we use these validated mMrgC11 and mMrgA1 structures as 
templates to predict through homology modeling the 3D structure of rMrgA receptor (it is 49 % 
and 77 % sequence identical to the mMrgC11 and mMrgA1 sequences). Then we used this 
structure of rMrgA in conjunction with the HierDock computational procedure to predict the 
binding site of all nine ligands to the rMrgA receptor for which experimental data are available. 
                                                 
1 Portions of this chapter have been submitted from the Journal of Computational Chemistry for publication. 
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rMrgA RTLIPNLLIIISGLVGLTGNAMVFWLLGFRLARNAFSVYILNLALADFLFLLCHIIDSTL 60 
mMrgA1 TILIPNLMIIIFGLVGLTGNGIVFWLLGFCLHRNAFSVYILNLALADFFFLLGHIIDSIL 60 
mMrgC11 PILTLSFLVLITTLVGLAGNTIVLWLLGFRMRRKAISVYILNLALADSFFLCCHFIDSLL 60
* .::::*   ****:** :*:***** : *:*:*********** :**  *:*** * 
rMrgA LLLKF--SYPNIIFLPCFNTVMMVPYIAGLSMLSAISTERCLSVVCPIWYRCRRPKHTST 118 
mMrgA1 LLLNV--FYP-ITFLLCFYTIMMVLYIAGLSMLSAISTERCLSVLCPIWYHCHRPEHTST 117
mMrgC11 RIIDFYGLYAHKLSKDILGNAAIIPYISGLSILSAISTERCLCVLWPIWYHCHRPRNMSA 120
::..   *.       : .  :: **:***:**********.*: ****:*:**.: *: 
rMrgA VMCSAIWVLSLLICILNRYFCGFLDTKYEKDNRCLASNFFTAACLIFLFVVLCLSSLALL 178 
mMrgA1 VMCAVIWVLSLLICILNSYFCGFLNTQYKNENGCLALNFFTAAYLMFLFVVLCLSSLALV 177
mMrgC11 IICALIWVLSFLMGILDWF-SGFLGETHH--HLWKNVDFIITAFLIFLFMLLSGSSLALL 177
::*: *****:*: **: : .***.  :.  :     :*: :* *:***::*. *****: 
rMrgA VRLFCGAGRMKLTRLYATIMLTVLVFLLCGLPFGIHWFLLIWIKIDYGKFAYGLYLAALV 238 
mMrgA1 ARLFCGTGQIKLTRLYVTIILSILVFLLCGLPFGIHWFLLFKIKDDFHVFDLGFYLASVV 237 
mMrgC11 LRILCGPRRKPLSRLYVTIALTVMVYLICGLPLGLYLFLLYWFGVHLHYPFCHIYQVTAV 237
*::**. :  *:***.** *:::*:*:****:*:: ***  :  .       :* .: * 
rMrgA LTAVNSCANPIIYFFVG 255 
mMrgA1 LTAINSCANPIIYFFVG 254 
mMrgC11 LSCVNSSANPIIYFLVG 254
*:.:**.*******:** 
TM1 TM2
TM3
TM4 TM5
TM6
TM7
 
Figure 5.1 Sequence alignment provided as an input for the homology modeling of rMrgA. The N-terminus 
(11 residues) and C-terminus (38 residues) were omitted because for such class A (rhodopsin-like) GPCRs 
especially for small ligands, they generally do not play a role in the binding of the ligand[4]. 
 
 We also compare the putative binding site of rMrgA receptor with those of other known adenine-
related GPCRs like adenosine receptors or purinergic receptors. 
5.2 Materials and methods  
5.2.1 Molecular modeling of receptor structure 
We used MODELLER6v2[5] to build a homology model for the 3D structure of rMrgA 
receptor using the 3D structures for mMrgC11 and mMrgA1 as templates. The sequences of 
rMrgA receptor (TrEMBL accession number: Q7TN49) was aligned with mMrgC11 (TrEMBL 
accession number: Q8CIP3) and mMrgA1 (TrEMBL accession number: Q91WW5) using 
Clustal-W (version 1.82)[6] as shown in Figure 5.1. The sequence identity of rMrgA with 
mMrgC11 is 49%, while that for mMrgA1 is 77%, for the entire sequences. The TM regions have 
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44% to 76% identity (totaling 56%) between rMrgA and mMrgC11 and 77% to 88% identity 
between rMrgA and mMrgA1 (totaling 83%).  
After predicting the overall 3D structure of rMrgA, the side chain conformations were re-
assigned using the SCWRL3.0 side chain replacement program (~1.4 Å diversity)[7] and 
hydrogen atoms were added using the POLYGRAF software. The all-atom structure was 
optimized with the conjugate gradient minimization technique to an RMS in force of 0.5 
kcal/mol/Å. Subsequently this minimized receptor structure was used as the starting point for gas 
phase NVT molecular dynamics (MD) simulations (using an internal dielectric constant of 2.5) at 
300 K for 10 ps to account for changes in the backbone conformation. The conformation with the 
lowest total energy in the trajectory was selected and minimized to an RMS force of 0.5 
(kcal/mol)/Å with conjugate gradients. All simulations used the DREIDING force field (FF)[8] 
with charges from CHARMM22[9] in the MPSim code[10]. The cell multipole method[11] was 
used for calculation of non bond interaction. 
5.2.2 QM calculation of ligand tautomers 
We docked to rMrgA the 9 molecules shown in Figure 5.2 (including adenosine 
phosphates), for all of which there are measured binding constants. The structures for these 
molecules were constructed using the Cerius2 build module[12]. The ligand conformations were 
minimized using conjugate gradients with the DREIDING FF and GASTEIGER charges[13]. For 
ligands with a significant number of torsions, such as 6-benzylaminopurine (6BAP), adenosine 
and adenosine phosphates, the X-ray crystal structures were obtained from the cambridge 
structural database and used as the starting conformation for docking without further optimization. 
For 1-methyladenine (1MA) and 6BAP, several tautomeric forms are possible in addition 
to the direct substitution at N1 or N6 of adenine. For these systems we built all such tautomeric 
forms (see Figure 5.2) and calculated their relative stabilities using quantum mechanics (QM) 
(Jaguar v5.5 software[14]) to determine the dominant tautomeric form. The geometries were first  
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Figure 5.2 Ligand compounds used in docking studies for the rMrgA receptor. They are placed in order of 
experimental binding affinity from top-left to bottom-right. No binding was detected experimentally for the 
ligands of the third row. For 1-methyladenine (1MA) and 6-benzylaminopurine (6BAP), the most stable 
tautomeric forms are shown together. 
 
optimized in the gas phase using the B3LYP flavor of Density Functional Theory with the 6-
31G** basis set. The vibrational frequencies for thermodynamic quantities were calculated at the 
same level. The calculated frequencies were scaled by the factor 0.9614 appropriate for 
B3LYP/6-31G*. All thermodynamic quantities were computed at 298.15 K, based on standard 
ideal-gas statistical mechanics and the rigid-rotor harmonic oscillator approximations. We 
calculated the solvation energy in water using the Jaguar Poisson-Boltzmann methodology with 
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standard parameters (dielectric constant H2O = 80.37, solvent probe radius RH2O = 1.40 Å, and 
Dreiding van der Waals radii of atoms) for the final optimized QM structure. These results are in 
Table S5.1 of the supplementary information. 
5.2.3 Prediction of the adenine binding site 
Scanning the receptor to determine the putative binding region 
To select the putative binding region, we used adenine (the best binder) to scan the entire 
receptor structure of rMrgA. To do this we first calculated the molecular surface using autoMS 
utility in DOCK4.0[15] with the default values for surface density (3.0 dots/Å2) and probe radius 
(1.4 Å). Then we used SPHGEN in DOCK4.0 to generate spheres from each surface point to fill 
up the void space in the receptor. The receptor was partitioned into 41 cubic boxes each with 
sides of 10 Å such that all void spheres were included. The spheres inside each box were taken as 
an input for DOCK4.0 to define the docking region. The scoring energy grids of the protein were 
calculated using GRID in DOCK4.0, with a grid spacing of 0.3 Å and a nonbond cutoff distance 
of 10 Å. For each of the 41 regions, we performed rigid docking with the anchor search option in 
DOCK4.0. For each region, we sampled orientations until 100 passed the bump test and then we 
selected the ten top scoring orientations. For each of these 10 from each of the 41 boxes, we used 
MPSim to minimize the ligand conformation with the receptor coordinates fixed to obtain the 
final energy scores. Here we used the Dreiding FF. After scoring with MPSim, we calculated the 
percentage of buried surface for each of these 410 orientations using the Connolly MS program 
from Quantum Chemistry Program Exchange (QCPE). Of these, 103 had over 90 % of buried 
surface. From these we selected the best orientation for each box. Out of the 41 boxes, this led to 
seven possible binding regions with good energy and >90% buried surface. We then clustered the 
spheres near these seven regions, to obtain the two distinct putative binding sites shown in Figure 
5.3. 
Docking adenine and guanine into the predicted putative binding sites  
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1 2 3 4 5
region1
region2
 
Figure 5.3 Putative binding sites predicted from the HierDock scanning procedure. Region 2 is in the 
TM3456 region that we find to bind adenine-like agonists. Region 1 is in the TM1237 region (it does not play 
a role in binding agonists, but might for antagonists). 
 
The HierDock protocol was used to predict the binding site and energy of adenine to both 
binding regions. In the study on rMrgA we also used the modified HierDock protocol (MSC-
Dock) described in chapter 2. Here we used a rejection ratio of 2.2 to define completeness 
(leading to 2,453 families that past the bump tests). We then enriched the top 75 families until 
there was an average of six members in each family (passing the bump tests). Then we scored 
these using MPSim (Dreiding FF) and selected the 30 best scoring family heads. These were 
minimized (conjugate gradients) using MPSim (50 steps or 0.1 kcal/mol/Å) with ligand movable 
and the receptor atoms fixed. Then the 5 best scoring ligands (total energy) were selected and the 
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side chain conformations of the residues of the receptor within 5 Å of the bound ligand were 
reassigned using the SCREAM side chain replacement program (This uses a side chain rotamer 
library of 1,478 rotamers with 1.0 Å resolution, with all atom DREIDING energy function to 
evaluate the energy for the ligand-receptor complex). The binding energies were then calculated 
for these 5 optimized ligand-receptor complex structures as the difference between the energy of 
the ligand in the fixed receptor and the energy of the ligand in solution. The energy of the free 
ligand was calculated for the docked conformation and its solvation energy was calculated using 
analytical volume generalized Born (AVGB) continuum solvation method[16]. The dielectric 
constants for the continuum solvation method were set to 78.2 for the external region and to 1.3 
for the internal region.  
Guanine shows no binding in the experiments (worse than ~100 μM). We docked it to the 
two putative binding regions determined from scanning the receptor (shown in Fig. 5.3). 
5.2.4 Refinement of the binding mode of adenine 
To account for changes in the backbone structure of the receptor due to ligand binding, we 
started with the docked structure and carried out annealing MD simulations allowing the ligand 
and residues within 10 Å in the binding pocket to move (with other residues fixed). The 
procedure was to heat the system from 50 K to 600 K and then to cool it back down to 50 K in 
steps of 50 K. The system was equilibrated for 1ps between changes in temperature. At the end of 
the annealing cycle, the system was minimized to an RMS force of 0.3 (kcal/mol)/Å and the side 
chains of the residues within 5 Å from the ligand was reassigned again with SCREAM. 
5.2.5 Docking of other adenine derivatives 
After optimizing the structure for adenine in the receptor, we re-clustered the spheres to 
define the binding site. Spheres within 1.0 Å from any atom in the docked adenine were selected 
out of the entire spheres generated for the final receptor structure that was previously optimized 
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with adenine. We then used the HierDock procedure described above to dock the adenine 
derivatives.  
5.3 Results and discussion 
5.3.1 Characteristics of receptor structure 
The sequence identity of rMrgA receptor with bovine rhodopsin is ~18 % for TM regions 
(the averaged value obtained with the independent alignments for each TM). The RMSD of the 
coordinates of the Cα atoms between these two receptors is 3.72 Å in TM regions[17].  
The RMSD of rMrgA with mMrgA1 (83 % sequence identity for TM regions) is 0.41 Å in 
the TM regions and the RMSD with mMrgC11 (56 % sequence identity for TM regions) is 2.59 
Å in the TM regions. The predicted 3-D structure of rMrgA is shown in Figure 5.4(b) where it is 
superimposed with the predicted structures of mMrgA1 and mMrgC11. 
Figure 5.5 shows the interhelical hydrogen bond network in TM regions formed in the 
rMrgA receptor; 
The Asn31 (TM1) makes hydrogen bonds with the side chain of Asp58 (TM2) and the 
backbone carbonyl of Cys256 (TM7) at the same time and contributes to the interhelical stability 
among TM1, TM2 and TM7. This Asp-Asn pair is highly conserved across the family A of 
GPCRs, corresponding to Asp83 and Asn55 in bovine rhodopsin. There is a similar pattern in 
rhodopsin structure[18] where a carbonyl group of A299 in the backbone of TM7 is as the 
common hydrogen bond acceptor for Asn55.   
The Tyr95 (TM3) is conserved throughout the Mrg receptor family (although 5 of 36 have 
a Phe conservative replacement at this position). Here the hydroxyl group of Tyr forms an 
interhelical hydrogen bond with a backbone carbonyl group of C218 in TM6.  
The highly conserved Asn53 (TM2) and Trp136 (TM4) form a hydrogen bond as observed 
in rhodopsin (Asn78 and Trp161).  
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Figure 5.4 Predicted 3D structure of rMrgA receptor.  
(a) Adenine (in spheres) is docked in rMrgA receptor. The residues within 5 Å of adenine are shown as 
sticks. (b) The rMrgA receptor (red) is overlapped with mMrgA1 (blue) and mMrgC11 (green). The top part 
shows the view from the extracellular side, while the bottom part shows the side view (with the extracellular 
part on top).  
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Figure 5.5 Interhelical hydrogen bonds (dashed lines) in rMrgA receptor, as identified using HBPLUS[19] 
(maximum D-A distance = 3.9 Å, minimum D-H-A angle = 90.0°). 
 
One more hydrogen bond pair exists between Ala46 (TM2) and Thr129 (TM4) near the 
intracellular region.  
In addition, the positively charged residue Arg147 (TM4) is oriented slightly towards the 
lipids and might contact with the negatively charged head group of the lipid molecule. We find 
that it forms the hydrogen bonds with Cys86 and Thr89 in TM3 that are one helical turn apart.  
The highly conserved proline residues in TM6 and TM7 across the family A of GPCRs 
correspond to Pro221 (TM6) and Pro258 (TM7) in rMrgA receptor. They lead to bends of 15° 
and 18° in the α-helix structure. 
The Pro94 (TM3) in rMrgA receptor corresponds to the double Gly in the middle of 
rhodopin. In both cases this leads to bending (19° for rMrgA and 13° for rhodopsin), making the 
overall backbone conformation of TM3 in these two receptors similar.  
A major difference between rMrgA and most other family A GPCRs is that there is no Cys 
in the extracellular loop (EC) 2 or at the top of TM3. In rhodopsin and other amine receptors 
there are highly conserved cysteine residues in TM3 and in the EC2 that form a disulfide linkage 
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that constrains the structure of EC2. Thus for rMrgA receptor we find that EC2 has an open 
random coil conformation. (In rhodopsin this loop has a closed beta sheet structure). 
5.3.2 QM results of ligand tautomers 
The QM results of the free energies for the different tautomeric forms of 1MA and 6BAP 
are shown in Table S5.1. We find that in solution the free energy of 1MA1 is 1.87 kcal/mol lower. 
The relative abundance with respect to the tautomer with the lowest free energy was calculated 
from the free energy using the equation; 
( )RTGtautomertautomer sollowest Δ−= exp][ ][ , 
where R is the gas constant (1.986 cal/mol·K) and T is the temperature (298.15 K). Thus we 
predict that the relative abundance of 1MA2 is only ~4 % of 1MA1. (In contrast 1MA1 is less 
stable than 1MA2 by 3.5 kcal/mol in the gas phase.) 
There are three tautomers for 6BAP, but 6BAP1 is the most stable both in gas phase and in 
aqueous solution. Here the others forms have negligible abundance.  
These calculations suggest that the majority species for 1MA or 6BAP have direct 
substitutions at the N1 or N6 of adenine. Therefore these forms were chosen for the docking 
studies.   
5.3.3 Binding modes of adenine and other ligands 
Location of the binding site 
MSC-Dock predicts the adenine binding site lie between TM3, TM4, TM5 and TM6 as 
shown in Figure 5.4. This TM3-4-5-6 pocket (corresponding to region 2 in Fig. 5.3) is predicted 
to provide the binding site for the agonists to a number of other GPCRs (including dopamine, 
adrenergic, histamine). In addition the adenine is in a region similar to the β-ionone ring of 11-cis 
retinal in bovine rhodopsin (but the adenine leans more towards TM4 instead of TM6).  
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The scanning step also found a second binding site, denoted as region 1 in Figure 5.3. This 
other site is located in the interhelical hydrogen bond network between TM1, TM2 and TM7. In 
this site both adenine and guanine make a hydrogen bond with the highly conserved Asp58 in 
TM2, but the binding pocket is mostly hydrophobic except for this Asp residue. We found that 
the calculated binding energy of adenine in region 1 is only 66 % of that in region 2. The binding 
energy of guanine in region 1 was 73 % of that for adenine in region 2. Thus we conclude that 
this site is not the site for agonist binding (it could play a role for antagonists).  
As discussed in section 3.1, Asp58 (TM2) plays a key role in stabilizing the TM1, 2, 7 triad, 
and it may be the site at which Na+ binds for the allosteric regulation observed in human 
adenosine A1 receptor and α2A adrenergic receptor[20, 21], making it unlikely to serve as the 
agonist binding site. 
Based on these results we ruled out region 1 as a possible binding site. 
Predicted Binding site of Adenine  
Adenine is reported as the potential endogenous ligand for rMrgA receptor by Bender et 
al.[1]. The binding mode is detailed in Figure 5.6(a). The most critical residues for binding are 
Asn88 TM3 and Asn146 TM4. They each form bidentate hydrogen bonds with adenine, locking it 
tightly inside the pocket. The hydrogen bond partners of Asn146 are the same nitrogen atoms of 
adenine that participate in the DNA base pair. In addition Phe83 in TM3 and His225 in TM6 have 
good π stacking interactions with the purine ring. These features characterizing adenine binding 
site agree well with the empirical observations by Nobeli et al. to explain the molecular 
discrimination of adenine and guanine ligand moiety in complexes with proteins[22]. They 
observed that the protein aromatic residues stabilize an environment in which the ligand would 
have π stacking interaction with the side chain of these residues and that His is much more 
favorable for adenine. They found that amino acids with side chains like Asn that can form  
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Figure 5.6 Predicted 5 Å binding pockets of adenine (top) and guanine (bottom) in the rMrgA receptor. The 
residue labels are colored according to the binding energy contributions from non bond interaction with the 
ligand:  
red: greater than 10 kcal/mol contribution (best),  
green: between 10 and 4 kcal/mol,  
blue: worse than 4 kcal/mol (worst).  
The hydrogen bonds are indicated by dotted lines with the distance between the donor and acceptor atoms. 
The number in parenthesis indicates the TM containing the residue.  
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simultaneously a donor hydrogen bonds and an acceptor hydrogen bond are favored for binding 
adenine.  
The residues within the binding pocket in Figure 5.6 are grouped by color according to the 
intermolecular interaction energy with the ligand (red is strongest, blue is weakest). Here the 
intermolecular interaction energy includes Coulomb, van der Waals, and hydrogen bond terms. 
The most important are Asn88 and Asn146, which comes from strong hydrogen bond interactions. 
Met92 has moderate van der Waals interaction with adenine. 
Predicted binding site of guanine 
Changing the docked adenine structure to guanine, we find that the hydrogen bond donor 
and acceptor in the side chain of Asn146 does not match with the counterparts in guanine, 
resulting in a dramatic decrease in the predicted binding affinity (by 16 %) for guanine in this 
configuration. However N2 of guanine forms a new weak hydrogen bond with sulfur of Cys150.  
Independently docking guanine, leads to a structure in which the guanine has the different 
orientation shown in Figure 5.6(b). Here its hydrogen bond interactions with Asn146 are not 
optimal. The carbonyl group of the Asn146 side chain loses a hydrogen bond partner and the 
Asn146 amine group does not make a good hydrogen bond. However the guanine retains similar 
interaction with the other residues.  
Thus the predicted structure of rMrgA, explains the dramatic difference in bonding 
between adenine and guanine. Adenine can bind to both Asn in the active site leading to good 
hydrogen bonds for N1, N3, N6, and N9. In contrast guanine in the same configuration could 
make only half of these. As a result guanine binds in an alternate site where the sidechain of 
Asn88 form hydrogen bonds with the N1 and O6 atoms of guanine and Asn146 form a weak 
hydrogen bond with N7, but with binding that is 78 % weaker than for adenine. However if Tyr95 
that is found nearby N2 and N3 of guanine is mutated to Gln, formation of two more  
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Table 5.1 Decomposition of total intermolecular interaction (kcal/mol) between ligand and rMrgA receptor, 
calculated for the residues within 5 Å of the ligand; the numbers in parentheses are the values relative to 
adenine 
 
Ligand Coulomb VDW Hbonds TOTAL 
Adenine -2.37 (100) -11.63 (100) -28.17 (100) -42.17 (100) 
1MA -1.20 (50) -16.16 (138) -23.87 (84) -41.23 (97) 
6BAP -0.35 (14) -29.90 (257) -12.58 (44) -42.82 (101) 
HPX -3.06 (129) -12.64 (108) -13.95 (49) -29.65 (70) 
Guanine -3.27 (137) -14.26 (122) -16.59 (58) -34.12 (80) 
Adenosine -1.23 (51) -22.84 (196) -12.95 (45) -37.02 (87) 
 
 
hydrogen bonds would be expected and might enhance the binding affinity in spite of the loss in 
van der Waals interactions. Indeed the predicted binding energy of guanine in the Tyr95Gln 
mutant is comparable to that of adenine in the wild type (99.9 % of adenine binding). 
The total intermolecular interaction energy and its each component in the 5 Å binding 
pocket are tabulated in Table 5.1. 
Predicted binding site of medium binders 
For 1MA (Ki=4.4 μM) we also calculated two binding modes, one by perturbing adenine to 
1MA, the other with independent docking. The binding modes of 1MA are described in Figure 
5.7. The perturbed structure built by direct substitution at N1 in the docked adenine leads to a big 
clash between the bulky methyl group and Asn146. The independently docked 1MA is locked 
between Asn88 and Asn146 through hydrogen bonds with these two residues. However, this 
leads to slightly weakened bonding with Asn146 due to the loss of one of hydrogen bonds. This 
leads to a predicted binding affinity 83% of that to adenine. The methyl substituent of 1MA 
resides in the good hydrophobic environment.  
For 6BAP, another mild binder (Ki = 58 μM), we find a docking orientation similar to that 
of 1MA. Here the large benzyl substituent has a close contact with Tyr95 with good π stacking 
interactions making the van der Waals term the dominant non bond interaction. 6BAP also forms  
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Figure 5.7 The 5 Å binding pockets for various ligands in the rMrgA receptor. The same color scheme is 
used as for Figure 5.6. (a) 1-Methyladenine, (b) 6-Benzylaminopurine, (c) Hypoxanthine, (d) Adenosine. 
 
hydrogen bonds with Asn88 and Asn146, but the interaction with Asn146 is weaker than for 
adenine or 1MA. The loss of this interaction is partly compensated by the increased van der 
Waals interactions as shown in Table 5.1. The result is a binding affinity of 92 % of that of 
adenine. 
Predicted binding site of poor binders 
Hypoxanthine, one of the bad binders, makes nice contacts with Asn146 but has weak 
interactions with Asn88. Its hydrogen bond energy is comparable to 6BAP in Table 5.1, but the  
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Figure 5.8 The 5 Å binding pockets of adenosine phosphates in the rMrgA receptor. (a) AMP, (b) AMP, (c) 
ADP, (d) ATP. 
 
van der Waals interaction energy is insufficient to overcome the decreased hydrogen bond energy. 
The result is a binding affinity of 71 % of that of adenine. 
For adenosine, we find that only Asn88 makes good hydrogen bond contacts with the 
ligand, with no other residues having good specific interactions. The result is a binding affinity of 
71 % of that of adenine. 
Predicted binding site of adenosine phosphates 
Adenosine mono- and tri-phosphates (AMP and ADP) are observed to have binding 
constants to rMrgA in the range of 20-60 μM concentration. Our predicted structure is in Figure 
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5.8. We find that the adenine moiety forms good two hydrogen bonds with Asn88, but they have 
different glycosyl torsion angles. In both cases the sugar ring has a contact with Asn146. We find 
that the phosphate group points toward extracellular region and is stabilized by Arg147 in TM4 
(on the boundary between the inside-bundle region and the membrane). This is only the positively 
charged residue located on the upper half of TM regions (excluding a Lys233 at the end of TM6). 
This further validates our prediction of binding site.  
For neutral ligands such as adenine, the side chain of Arg147 leans more toward the 
membrane regions which might allow it to contact the head group of lipid as seen in the apo 
protein in Figure 5.5. However when the phosphate comes into the binding pocket, the Arg147 
would move toward the pocket. 
For adenosine diphosphate (ADP), the sugar ring interacts with Asn146 in the similar way 
to AMP but the adenine base does not interact strongly with Asn88 (see Fig. 5.8(c)). The 
phosphate group shows strong interaction with Arg147 and Thr89. 
Comparison of calculated binding energy to ln Ki 
The predicted binding energies for the various ligands are compared in Figure 5.9 with the 
experimental competition binding constant (inhibition constant) reported by Bender et al.[1] Of 
the nine compounds whose binding constants have been measured, we examined only the six 
neutral ligand with the fewest torsional degrees of freedom for docking (since the adenosine 
phosphates are highly negative-charged, the entropic effect in binding is no longer negligible and 
the uncertainty in calculated solvation energy increases). Figure 5.9 shows the good correlation 
between our calculated binding energy and the experimental inhibition constant, ln Ki. The 
calculating binding energy is for the minimized structure at 0 K, which ignores entropic effects. 
Except for adenosine all ligands are rigid with similar shapes so that the entropic contributions 
should be similar. This good correlation strongly validates our predicted structures and binding 
configurations. 
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Figure 5.9 Comparison of calculated binding energies (left legend) with the experimental inhibition constants 
(right legend) for rMrgA ligands as described in the method section, the calculated energies are for the 
minimized structure (0K) without entropic contributions. 
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Table 5.2 Computational alanine-scanning results (SCAM) for adenine/rMrgA (energies in kcal/mol)a  
  I.E.(WT) ΔI.E.(Ala)   
Asn88 -17.787 17.161 41% 
Asn146 -12.819 12.275 29% 
Met92   -4.741   2.844   7% 
Phe83   -1.545   1.433   3% 
His225   -1.505   1.349   3% 
Leu174   -0.665   0.432   1% 
Tyr95   -0.422   0.344 0.8% 
Ile96   -0.450   0.333 0.8% 
Phe178   -0.298   0.265 0.6% 
Cys150   -0.494   0.207 0.5% 
Thr170   -0.273   0.168 0.4% 
Met91   -0.321   0.161 0.4% 
Arg147   -0.360   0.091 0.2% 
Pro85   -0.393   0.086 0.2% 
Leu177   -0.102   0.066 0.2% 
a The intermolecular interaction energy (IE) for the wild type (WT, no mutation) is shown for all residues 
within 5 Å of the ligand. After mutating the residue to Ala and minimizing, we recalculated the IE of the ligand 
to this Ala, IE(Ala). The percentage change in binding of the mutant relative to the calculated total binding of 
WT is shown in the last column. These results show that the Ala mutations track well the calculated ligand-
residue IE and confirm the important role of Asn88 (3), Asn146 (TM4), Met92 (TM3), Phe83 (TM3), and 
His225 (TM6) to the binding of adenine.  
 
Effect of computational alanine-scanning mutations (SCAM) in the binding pocket 
For the best binder, adenine, we carried out alanine scanning to assess the importance of 
various residues to binding. The residues within 5 Å of the ligand were each independently 
mutated to Ala and the energy for the ligand-protein complex was reoptimized (conjugate 
gradient minimization). Prior to the minimization we used SCREAM to reselect the side chain 
conformations of the other residues within 5 Å of the ligand. The results are summarized in Table 
5.2.  
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As expected, the Asn88Ala and Asn146Ala mutations significantly reduce the binding 
affinity due to the loss of the hydrogen bonds. Mutation of either Phe83 or His225 abolishes the 
favorable van der Waals contacts. 
The close correspondence between the contributions predicted for the wild type and the 
change in bonding calculated with the mutation to Ala, indicates that good estimates can be made 
without optimization of the coordinates.  
5.3.4 Comparison of the adenine binding site in rMrgA to the nucleotide binding sites in 
adenosine receptors and purinergic receptors 
We can compare the binding site of adenine to rat MrgA with the binding site of human A1 
and A2A to adenosine (hA1A and hA2AA) receptors and human P2Y1 to purinergic (hP2Y1) 
receptor. These receptors all bind adenosine or ATP, with the adenine moiety in common, and all 
have been studied both experimentally and with modeling. The sequences of the adenosine 
receptors and the purinergic receptor were aligned separately with that of rMrgA receptor. The 
whole sequences were aligned first with Clustal-W while ensuring that specific highly conserved 
residues are matched to each other in the alignment: Asn at position 20 in TM1, Asp at position 
13 in TM2, Arg in DRY sequence of TM3, Trp at position 12 in TM4, Pro at position 19 in TM6, 
Pro in NPXXY of TM7 (the number is counted from the starting residue of each TM in Figure. 
5.10). Using the TM prediction of rMrgA receptor, the sequences for each TM were aligned 
independently. The averaged sequence identity of rMrgA receptor is ~22 % for hA1A receptor 
and ~20 % for hA2AA receptor (considering only TM regions). For hP2Y1 receptor, the TM 
sequence identity to rMrgA is ~24 %. The resulting TM sequence alignment is shown in Figure 
5.10 where the key residues in adenosine receptors and P2Y1 receptor identified from the binding 
or functional assay experiments are bolded and underlined[23, 24]. 
Recall that for rMrgA the adenine binding site mostly contacts with Asn88 (TM3), Asn146 
(TM4) and Leu174 (TM5), with His225 (TM6) interacting closely with adenine.  
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MRGA_RAT   RTLIPNLLIIISGLVGLTGNAMVFWLLG 28 
AA1R_HUMAN FQAAYIGIEVLIALVSVPGNVLVIWAVK 28
AA2A_HUMAN GSSVYITVELAIAVLAILGNVLVCWAVW 28
P2YR_HUMAN QFYYLPAVYILVFIIGFLGNSVAIWMFV 28
MRGA_RAT   AFSVYILNLALADFLFLLCHIIDST 25 
AA1R_HUMAN ATFCFIVSLAVADVAVGALVIPLAI 25 
AA2A_HUMAN VTNYFVVSLAAADIAVGVLAIPFAI 25
P2YR_HUMAN GISVYMFNLALADFLYVLTLPALIF 25
MRGA_RAT   FLPCFNTVMMVPYIAGLSMLSAISTERC 28
AA1R_HUMAN TCLMVACPVLILTQSSILALLAIAVDRY 28 
AA2A_HUMAN GCLFIACFVLVLTQSSIFSLLAIAIDRY 28
P2YR_HUMAN MCKLQRFIFHVNLYGSILFLTCISAHRY 28
MRGA_RAT   KHTSTVMCSAIWVLSLLICILNRYFCGF 28 
AA1R_HUMAN PRRAAVAIAGCWILSFVVGLTPMFGWNN 28 
AA2A_HUMAN GTRAKGIIAICWVLSFAIGLTPMLGWNN 28
P2YR_HUMAN KKNAICISVLVWLIVVVAISPILFYSGT 28
MRGA_RAT   LASNFFTAACLIFLFVVLCLSSLALLVR 28 
AA1R_HUMAN EFEKVISMEYMVYFNFFVWVLPPLLLMV 28
AA2A_HUMAN LFEDVVPMNYMVYFNFFACVLVPLLLML 28
P2YR_HUMAN FIYSMCTTVAMFCVPLVLILGCYGLIVR 28
MRGA_RAT   RLYATIMLTVLVFLLCGLPFGIHWFLLIWIK 31
AA1R_HUMAN KIAKSLALILFLFALSWLPLHILNCITLFCP 31
AA2A_HUMAN HAAKSLAIIVGLFALCWLPLHIINCFTFFCP 31
P2YR_HUMAN KSIYLVIIVLTVFAVSYIPFHVMKTMNLRAR 31
MRGA_RAT   AYGLYLAALVLTAVNSCANPIIYFFVG 27 
AA1R_HUMAN PSILTYIAIFLTHGNSAMNPIVYAFRI 27 
AA2A_HUMAN PLWLMYLAIVLSHTNSVVNPFIYAVRI 27
P2YR_HUMAN VYATYQVTRGLASLNSCVDPILYFLAG 27
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TM2
TM3
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Figure 5.10 Sequence alignment of rat MrgA receptor with other receptors known to bind adenine 
components of ligands: human A1 and A2A adenosine receptors and human P2Y1 purinergic receptor. The 
residues predicted to play an important role in ligand binding are in boldface and underlined.   
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In the putative A2A binding site, the adenine moiety is recognized by TM3, TM5 and 
TM6[23]. The binding regions in TM3 overlap significantly throughout four receptors but we 
could not find any residue from adenosine or purinergic receptor that directly matches with 
Asn88 in rMrgA receptor. However, Gln92 in TM3 of hA1AR has the same functional group as 
Asn (shorter by one methylene) which was found to interact with the adenosine adenine 
moiety[25]. Asn146 in TM4 is a key residue in the adenine binding in rMrgA, but no similar 
residue is identified as a key residue in TM4 of adenosine or purinergic receptor. Arg157 in TM4 
interacts with phosphate group of adenosine phosphates in rMrgA while Lys (TM6) and Arg 
(TM7) are involved in P2Y1 receptor.  
In conclusion, although similar residues recognize adenine, there is very little similarity in 
the location of the binding site of adenine in rMrgA receptor compared to adenosine and 
purinergic receptors. This suggests that rMrgA belongs to non-adenosine or non-purinergic 
receptor families even though adenine binds well and activates the receptor. 
5.3.5 Comparison to other MrgA orthologs 
We examined the sequences of the 8 mouse orthologs of rMrgA receptor to determine 
whether some might be good candidates for possible adenine binding receptors. These are 
collected together and compared to rMrgA in Figure S5.1. Among the eight mouse MrgA 
(mMrgA) receptors, we find that the mMrgA2 receptor has Asn residues at the same two 
positions in TM3 and TM4 as in rMrgA receptor. However, Bender et al. tested activation of the 
mMrgA2 receptor with adenine and found no activation[1]. Perhaps this is because mMrgA2 
receptor does not have a proline in the middle of TM3 analogous to the Pro94 of for rMrgA 
receptor that we found to induce the bend in TM3. The change in the conformation of TM3 might 
put the Asn in TM3 of mMrgA2 receptor in the wrong orientation to bind sufficiently tightly with 
adenine to cause activation, explaining the lack of binding or activation by adenine mMrgA2 
even though it has the same pair of Asn as rMrgA, This could be tested by mutating the Pro94 of 
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rMrgA to Val as in mMrgA2 to see if this causes a loss in activity or by mutating the Val94 of 
mMrgA2 to Pro to see if this leads to activity for adenine. 
On the other hand, mMrgA5 receptor contains Pro in TM3 at the same position as in 
rMrgA and the Asn146 of rMrgA is also conserved. However, the Asn88 in TM3 of rMrgA is 
replaced with Tyr in mMrgA5 receptor. Here we suggest that mutation of Tyr87 to Asn in 
mMrgA5 might lead to adenine binding. 
5.4 Summary and conclusions 
We predicted the 3D structure of rMrgA receptor using homology to our MembStruk 
predicted mMrgA1 and MrgC11 structures and we predicted the binding sites for adenine and its 
derivatives using HierDock. The putative binding site is within TM3, 4, 5 and 6 with Asn88 in 
TM3 and Asn146 in TM4 serving as key residues in binding adenine. This Asn146 is 
homologous to Asp161 in mMrgC11 receptor that we previously identified as a key residue 
which was then validated experimentally. The side chain of Asn146 plays the role of the thymine 
in the same way as in the Watson-Crick hydrogen bond geometry of the A-T DNA base pair. It 
forms a bidentate hydrogen bond with both the N1 and N6 atom of adenine. The availability of 
the hydrogen bonds with these two Asn residues correlates with the binding affinity of the ligand.  
These studies of the rMrgA receptor provide targets for mutagenesis experiments to further 
identify or validate important features in the binding site. This predicted binding site could be 
used to identify other small molecule ligands.  Experimental tests of such ligands might help 
identify the endogenous ligand. 
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Supporting figures and tables 
Figure S5.1 Multiple sequence alignment of rat MrgA with mouse MrgAs using Clustal-W 
sp|Q7TN49|MRGA_RAT        --------MDKTIPGSFNSRTLIPNLLIIISGLVGLTGNAMVFWLLGFRLARNAFSVYIL 52
sp|Q91WW5|MGA1_MOUSE      --------MDNTIPGGINITILIPNLMIIIFGLVGLTGNGIVFWLLGFCLHRNAFSVYIL 52
sp|Q91WW4|MGA2_MOUSE      --------MDETLPGSINIRILIPKLMIIIFGLVGLMGNAIVFWLLGFHLRRNAFSVYIL 52
sp|Q91WW3|MGA3_MOUSE      --------MNETIPGSIDIETLIPDLMIIIFGLVGLTGNAIVFWLLGFRMHRTAFLVYIL 52
sp|Q91WW2|MGA4_MOUSE      MAPTTTNPMNETIPGSIDIETLIPNLMIIIFGLVGLTGNVILFWLLGFHLHRNAFLVYIL 60
sp|Q91ZC7|MGA5_MOUSE      --------MDKPLWKYGHLDS-DPKLMIIIFRLVGMTGNAIVFWLLGFSLHRNAFSVYIL 51
sp|Q91ZC6|MGA6_MOUSE      ------------MHRSISIRILITNLMIVILGLVGLTGNAIVFWLLLFRLRRNAFSIYIL 48
sp|Q91ZC5|MGA7_MOUSE      --------MDETSPRSIDIESLIPNLMIIIFGLVGLTGNAIVLWLLGFCLHRNAFLVYIL 52
sp|Q91ZC4|MGA8_MOUSE      --------MDKTILGSIDIETLIRHLMIIIFGLVGLTGNAIVFWLLGFHLHRNAFLVYIL 52
.*:*:*  ***: ** :::*** * : *.** :***
sp|Q7TN49|MRGA_RAT        NLALADFLFLLCHIIDSTLLLLKFSYPNIIFLPCFNTVMMVPYIAGLSMLSAISTERCLS 112
sp|Q91WW5|MGA1_MOUSE      NLALADFFFLLGHIIDSILLLLNVFYP-ITFLLCFYTIMMVLYIAGLSMLSAISTERCLS 111
sp|Q91WW4|MGA2_MOUSE      NLALADFLFLLSSIIASTLFLLKVSYLSIIFHLCFNTIMMVVYITGISMLSAISTECCLS 112
sp|Q91WW3|MGA3_MOUSE      NLALADFLFLLCHIINSTVDLLKFTLPKGIFAFCFHTIKRVLYITGLSMLSAISTERCLS 112
sp|Q91WW2|MGA4_MOUSE      NLALADFLFLLCHIINSTMLLLKVHLPNNILNHCFDIIMTVLYITGLSMLSAISTERCLS 120
sp|Q91ZC7|MGA5_MOUSE      NLALADFVFLLCHIIDSMLLLLTVFYPNNIFSGYFYTIMTVPYIAGLSMLSAISTELCLS 111
sp|Q91ZC6|MGA6_MOUSE      NLALADFLFLLCHIIASTEHILTFSSPNSIFINCLYTFRVLLYIAGLSMLSAISIERCLS 108
sp|Q91ZC5|MGA7_MOUSE      NLALADFLFLLCHFINSAMFLLKVPIPNGIFVYCFYTIKMVLYITGLSMLSAISTERCLS 112
sp|Q91ZC4|MGA8_MOUSE      NLALADFFYLLCHIINSIMFLLKVPSPNIILDHCFYTIMIVLYITGLSMLSAISTERCLS 112
*******.:**  :* *   :*..      :   :  . : **:*:******* * ***
sp|Q7TN49|MRGA_RAT        VVCPIWYRCRRPKHTSTVMCSAIWVLSLLICILNRYFCGFLDTKYEKDNRCLASNFFTAA 172
sp|Q91WW5|MGA1_MOUSE      VLCPIWYHCHRPEHTSTVMCAVIWVLSLLICILNSYFCGFLNTQYKNENGCLALNFFTAA 171
sp|Q91WW4|MGA2_MOUSE      VLCPTWYRCHRPVHTSTVMCAVIWVLSLLICILNSYFCAVLHTRYDNDNECLATNIFTAS 172
sp|Q91WW3|MGA3_MOUSE      VLCPIWYHCRRPEHTSTVMCAVIWVLSLLICILDGYFCGYLDNHYFNYSVCQAWDIFIGA 172
sp|Q91WW2|MGA4_MOUSE      VLCPIWYRCRRPEHTSTVLCAVIWFLPLLICILNGYFCHFFGPKYVIDSVCLATNFFIRT 180
sp|Q91ZC7|MGA5_MOUSE      VLCPIWYRCHHPEHTSTVMCAAIWVLPLLVCILNRYFCSFLDINYNNDKQCLASNFFTRA 171
sp|Q91ZC6|MGA6_MOUSE      VMCPIWYRCHSPEHTSTVMCAMIWVLSLLLCILYRYFCGFLDTKYEDDYGCLAMNFLTTA 168
sp|Q91ZC5|MGA7_MOUSE      VLCPIWYHCRRPEHTSTVMCAVIWIFSVLICILKEYFCDFFGTKLGNYYVCQASNFFMGA 172
sp|Q91ZC4|MGA8_MOUSE      VLCPIWYRCHRPEHTSTAMCAVIWVMSLLISILNGYFCNFSSPKYVNNSVCQASDIFIRT 172
*:** **:*: * ****.:*: **.:.:*:.**  *** .      * * :::  :  
sp|Q7TN49|MRGA_RAT        CLIFLFVVLCLSSLALLVRLFCGAGRMKLTRLYATIMLTVLVFLLCGLPFGIHWFLLIWI 232
sp|Q91WW5|MGA1_MOUSE      YLMFLFVVLCLSSLALVARLFCGTGQIKLTRLYVTIILSILVFLLCGLPFGIHWFLLFKI 231
sp|Q91WW4|MGA2_MOUSE      YMIFLLVVLCLSSLALLARLFCGAGQMKLTRFHVTILLTLLVFLLCGLPFVIYCILLFKI 232
sp|Q91WW3|MGA3_MOUSE      YLMFLFVVLCLSTLALLARLFCGARNMKFTRLFVTIMLTVLVFLLCGLPWGITWFLLFWI 232
sp|Q91WW2|MGA4_MOUSE      YPMFLFIVLCLSTLALLARLFCGGGKTKFTRLFVTIMLTVLVFLLCGLPLGFFWFLVPWI 240
sp|Q91ZC7|MGA5_MOUSE      YLMFLFVVLCLSSMALLARLFCGTGQMKLTRLYVTIMLTVLGFLLCGLPFVIYYFLLFNI 231
sp|Q91ZC6|MGA6_MOUSE      YLMFLFVVLCVSSLALLARLFCGAGRMKLTRLYVTITLTLLVFLLCGLPCGFYWFLLSKI 228
sp|Q91ZC5|MGA7_MOUSE      YLMFLFVVLCLSTLALLARLFCGAEKMKFTRLFVTIMLTILVFLLCGLPWGFFWFLLIWI 232
sp|Q91ZC4|MGA8_MOUSE      YPIFLFVLLCLSTLALLARLFSGAGKRKFTRLFVTIMLAILVFLLCGLPLGFFWFLSPWI 232
:**:::**:*::**:.***.*  . *:**:..** *::* *******  :  :*   *
sp|Q7TN49|MRGA_RAT        KIDYGKFAYGLYLAALVLTAVNSCANPIIYFFVGSFRHQ-KHQTLKMVLQRALQDTPETA 291
sp|Q91WW5|MGA1_MOUSE      KDDFHVFDLGFYLASVVLTAINSCANPIIYFFVGSFRHRLKHQTLKMVLQNALQDTPETA 291
sp|Q91WW4|MGA2_MOUSE      KDDFHVLDVNFYLALEVLTAINSCANPIIYFFVGSFRHQLKHQTLKMVLQSALQDTPETA 292
sp|Q91WW3|MGA3_MOUSE      APGVFVLDYS---PLLVLTAINSCANPIIYFFVGSFRQRLNKQTLKMVLQKALQDTPETP 289
sp|Q91WW2|MGA4_MOUSE      NRDFSVLDYILFQTSLVLTSVNSCANPIIYFFVGSFRHRLKHKTLKMVLQSALQDTPETP 300
sp|Q91ZC7|MGA5_MOUSE      KDGFCLFDFRFYMSTHVLTAINNCANPIIYFFEGSFRHQLKHQTLKMVLQSVLQDTPEIA 291
sp|Q91ZC6|MGA6_MOUSE      KNVFTVFEFSLYLASVVLTAINSCANPIIYFFVGSFRHRLKHQTLKMVLQSALQDTPETP 288
sp|Q91ZC5|MGA7_MOUSE      KGGFSVLDYRLYLASIVLTVVNSCANPIIYFFVGSFRHRLKHQTLKMVLQSALQDTPETH 292
sp|Q91ZC4|MGA8_MOUSE      EDRFIVLDYRLFFASVVLTVVNSCANPIIYFFVGSFRHRLKQQTLKMFLQRALQDTPETP 292
:      .  *** :*.********* ****:: :::****.** .******  
sp|Q7TN49|MRGA_RAT        ENTVEMSSSKVEP 304
sp|Q91WW5|MGA1_MOUSE      KIMVEMSRSKSEP 304
sp|Q91WW4|MGA2_MOUSE      ENMVEMSSNKAEP 305
sp|Q91WW3|MGA3_MOUSE      ENMVEMSRNKAEP 302
sp|Q91WW2|MGA4_MOUSE      ENMVEMSRSKAEP 313
sp|Q91ZC7|MGA5_MOUSE      ENMVEMSRNIPKP 304
sp|Q91ZC6|MGA6_MOUSE      ENMVEMSRNKAEL 301
sp|Q91ZC5|MGA7_MOUSE      ENMVEMSRIKAEQ 305
sp|Q91ZC4|MGA8_MOUSE      ENMVEMSRSKAEP 305
:  ****    :  
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Table S5.1 The Gibbs free energies (kcal/mol) calculated from QM for various tautomeric forms of 1MA and 
6BAP (numbered as shown in Figure 5.2) 
Ligand Ggas a Gsol b ΔGsol c Relative abundanced 
1MA1 -317838.40 -317864.54 0.00 1 
1MA2 -317841.98 -317862.67 1.87 0.043 
6BAP1 -462806.01 -462822.66 0.00 1 
6BAP2 -462797.65 -462818.90 3.76 0.0017 
6BAP3 -462788.10 -462812.30 10.36 2.5E-08 
a Calculated using QM energy and vibrational frequencies for gas phase 
b Calculated using Poisson-Boltzmann solvation in water 
c relative to the most stable state 
d abundance at 300K relative to the most stable  
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Appendix A 
Stability of Oxidized Base and its Mispair in DNA: Quantum 
Mechanics Calculation and Molecular Dynamics Simulation 
Abstract 
 5-formyluracil (FoU) is a potentially mutagenic lesion of thymine (T) produced in DNA by 
ionizing radiation and various chemical oxidants. The quantum mechanics (QM) calculation to 
compute pairing energies of FoU with a purine base was performed at the B3LYP/6-
31G**//B3LYP/6-31G**++ level, considering various possible tautomeric, rotameric and ionized 
form of FoU. The pairing energies of FoU in keto form with either adenine (A) or guanine (G) are 
comparable to those of T. Although the tautomerism to enol provides triple hydrogen bonds with 
G, the energy penalty is not fully compensated by the extra hydrogen bond energy. These QM 
results lead to the conclusion that the ionization at N3 position of FoU would mainly account for 
the increased mispairing rate of FoU since the deprotonated FoU preferentially form H-bonds 
with G rather than A and therefore FoU has one more extra possibility of base pairing. The 
following molecular dynamics (MD) simulations for DNA dodecamers with normal A:T base 
pair, A:FoU base pair and G:FoU base mispair showed that hydrogen bonds in FoU paired with 
adenine remained stable in the duplex during the whole simulation, while G:FoU dodecamer 
showed slightly larger structural fluctuation since it contains non Watson-Crick pairs in the 
middle. The formyl group of FoU in the anti conformation affects the hydration pattern around 
the DNA structure. A water molecule that makes a bridge of H-bond between O7 of FoU and 
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O2P of phosphate seems to be responsible for the well-ordered solvent structure. The interesting 
result is that, even though the formyl group is located on the major groove side, its presence 
actually results in severe narrowing of minor grooves. No significant change in helical and 
backbone parameters is shown for A:FoU and G:FoU dodecamer except for the large shear in G-
FoU pairs, which is obvious in Wobble-type geometry.  
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A.1 Introduction 
The modification on DNA bases induces the formation of base mispairing during 
replication, which is fatal in keeping the genetic integrity in living organism. 5-formyluracil 
(FoU), one of well-known DNA base lesions is the oxidation product of thymine (T) by ionizing 
γ-radiation, Fenton-type reactions, and quinone-mediated UV-A photosensitization[1-3]. Privat 
and Sowers proposed that the electron-withdrawing formyl group increases the stability of the 
deprotonated form of FoU, which could exist in a non-negligible amount since FoU has a lower 
pKa value close to physiological pH than T[4]. The deprotonated form of FoU would be 
mispaired with guanine (G) in a canonical Watson-Crick geometry. In the following replication 
process, G might form a correct pair with C and this leads to miscoding (i.e. starting with T, it 
ends up with C). Masaoka and co-workers also observed that the miscorporation ratio with 
deoxyguanosine monophosphate (dGMP) increased when FoU on the DNA template was 
substituted for T and this ratio also increased with increasing pH[5]. It supports the idea proposed 
by Privat and Sowers that the deprotonated form of FoU plays a key role in mispair mechanism. 
The general repair steps carried out by DNA repair enzymes are detection, recognition and 
removal of mutagenic lesions from DNA. The pathway most commonly employed to remove 
incorrect bases (like uracil) or damaged bases (like 3-methyladenine) is called base excision 
repair (BER)[6]. Initially individual DNA glycosylases are targeted to distinct base lesions, which 
are flipped and cleaved out by the enzymes (damage-specific step) and then a damage-general 
step restores correct DNA base sequences. Several DNA glycosylases responsible for repair of 
FoU have been suggested, but the repair mechanism on the molecular level is not well understood 
yet. In Escherichia coli, FoU is reported to be removed from a DNA by the AlkA enzyme with 
efficiency comparable to that of 7-methylguanine, a good substrate for AlkA[7]. It was proposed 
that the electron deficient bases flip out from the DNA duplex to form strong π-donor/acceptor 
interaction with electron-rich aromatic amino acids present in the active site of AlkA. The MutS 
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proteins involved in methyl-directed mismatch repair also recognize FoU paired with G, but do 
not recognize it with A. The MutS complex with FoU:G inhibited the activity of AlkA to FoU 
and thus two independent repair pathways might exist[8]. Zhang et al. performed the trapping 
assay with NaBH4 that is the clue for formation of Schiff base intermediate with NH2 group in the 
enzyme at the abasic site[9]. They observed the trapped complex for the Nth, Nei and MutM 
protein in E. coli and also the cleaved bases for these enzymes. With the AlkA protein, no 
trapping was observed, but the repair mechanism by it cannot be excluded since other pathways 
without forming the Schiff base intermediate are plausible. 
Even though the repair processes help maintain the genetic integrity, the cells are always 
vulnerable to having base lesions and the following mispairing. The presence of a non-natural 
base such as FoU would cause the structural changes in DNA double helix. When neutral FoU is 
mispaired with G and forms the non-canonical hydrogen bond; i.e. in this case, the Wobble type, 
this local change in H-bonding geometry can cause the overall changes in DNA double helix 
structure. One of the well-known examples showing the sequence-dependent conformational 
characteristic is the narrowing of minor grooves in the middle AT-tracts of DNA double helix. It 
is suggested that the N3 of A and O2 of T in AT base stacks form the electronegative pocket and 
then the counter cations, e.g., Na+, are bound to that site and pull two bases closer together. 
Several studies have been carried out to show the correlation between the width of minor grooves 
and the location of counter ions in the simulation[10, 11]. One of the reasons why the width of the 
minor groove matters is that some drugs actually bind to the minor groove. For example, the 
antitumor antibiotic netropsin binds to the B-DNA double helix, especially at the AT base pair 
regions, without intercalating[12]. The hydration pattern is also critical for the stability of DNA 
structure and this pattern strongly depends on the sequence of DNA. The hydration spine in the 
AT-tracts is a good example[13]. Sometimes the hydration pattern also plays a crucial role in 
protein-DNA interaction. The similar hydration patterns of the protein-DNA interface in the trp 
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repressor-DNA complex and the naked DNA target were seen and it is proposed that both protein 
and DNA specially recognize each other’s hydration pattern[14]. 
In this report, we examine the stability of FoU in free base pair system and when 
incorporated in DNA double helix. We compute pairing energies of various free DNA base pairs 
with the density functional theory, focusing mainly on mispairing of FoU with G. We also 
consider pairings of deprotonated form and enol tautomer of FoU with G in all possible 
hydrogen-bonding geometries. In order to see how stable the oxidized base and the following 
mispairs are in DNA double helix and how they affect the overall DNA conformation, the 
molecular dynamics (MD) simulations for DNA dodecamers with normal A:T base pair, A:FoU 
base pair and G:FoU base mispair are then carried out. 
A.2 Computational Methods 
A.2.1 Quantum Mechanics (QM) calculation of pairing energies in free DNA base systems 
All QM calculations were performed using the Jaguar v4.1 quantum chemistry 
software[15]. The geometries for 1-methyl pyrimidine, 9-methyl purine bases and all pyrimidine-
purine base pairs were first optimized in the gas phase at the B3LYP/6-31G** level. The 
vibration frequencies for thermodynamic quantities were also calculated at the same level. Then 
the 6-31G**++ basis set was used for the final geometry optimization starting from the 6-31G**-
optimized geometry. Since the calculation of vibration frequencies is a quite time consuming, the 
diffuse function was not included in the first step. To validate the exclusion of the diffuse 
function in the calculation of vibration frequencies, we have considered the following 
combinations of basis sets and compared the calculated enthalpies of base pairing with 
experimental ones:  
(1) 6-31G**/6-31G** (No diffuse function is included in both steps.) 
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(2) 6-31G**/6-31G**++ (The preliminary geometry optimization and the calculation of 
frequencies are done with 6-31G** basis set and then the geometry is re-optimized with 6-
31G**++ basis set.) 
(3) 6-31G**++/6-31G**++ (The diffuse function is included in both steps.) 
No scaling factor was adopted in the frequency calculation. All thermodynamic quantities 
were computed at 300 K, based on standard ideal-gas statistical mechanics and the rigid-rotor 
harmonic oscillator approximation. The enthalpy (or free energy) for each species is defined as: 
) () ( 300030000300300 KKKKK GorHZPEEGorH →→ ΔΔ++= , 
where the E0K is the total energy of the molecules at 0 K calculated from QM, ZPE is the zero-
point energy and, ΔH0→300K (or ΔG0→300K) is the change of enthalpy (or free energy) from 0 K to 
300 K.  
The single point energy calculation was carried out for the free energy of solvation in 
water, Gsolv, for the final optimized structure at the B3LYP/6-31G**++ level. The solvation free 
energies are computed with a self-consistent reaction field method by solving the Poisson-
Boltzmann equation. For the dielectric constant of water, we used εH2O = 80.37 which is at 20 
°C[16]. The probe radius was set to 1.40 Å. We used the default values for the van der Waals 
radii of atoms[17]. The free energy of the system in aqueous solution is given by 
solvKaq GGG += 300 . 
The calculations of pairing free energies were performed for various DNA base pairs, 
focusing on mispairing of FoU with G. Pairing of deprotonated form or enol tautomer of FoU 
with G was also considered in all possible hydrogen-bonding geometries. In this calculation, the 
basis set superposition error (BSSE), which is the artificial lowering in the complex energy 
relative to that of the separated monomers since the complex basis set is larger than that of each 
 174
monomer, should be taken into account. Since the free bases undergo the conformational change 
upon pairing, their relaxation energy terms were also incorporated into the estimation of the 
BSSE correction[18]. Therefore, the following BSSE-correction energy, EBSSE, should be added to 
the “raw” pairing energy, ΔE0K: 
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where a and b are the basis sets for corresponding bases, A and B, and the A, B and AB on the 
subscript represent the geometries where the energies for the species inside the parenthesis were 
computed. The final equation form for BSSE-corrected free energies in gas and in aqueous 
solution is followed as: 
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A.2.2 Molecular dynamics (MD) simulation of DNA dodecamer system containing the FoU 
The DNA dodecamer containing FoU has been crystallized recently[19]. It was a 
Dickerson-type dodecamer with the sequence d(CGCGAAT(FoU)CGCG) where one of the 
middle thymines was replaced with 5-formyluracil. The starting structure for our MD simulation 
was taken from one of these crystal structures (PDB ID: 1G8V). Three sets of simulations were 
carried out; one with normal Dickerson sequence, another with the FoU crystal structure and the 
other where A paired with FoU in the crystal structure was replaced by G. The formyl group in 
FoU could have a syn or an anti conformation to C4 atom. In the crystallographic study, the 
formyl group of one FoU adopts a syn conformation, but the other is distorted between the syn 
and anti conformation with almost equal occupancies. For our dodecamers, the formyl group of 
the FoU at each strand was assigned to be in the different conformation. The AMBER6 program 
 175
package was used for the simulations[20]. However, the FoU is a non-natural DNA base and the 
AMBER6 does not provide the charges and force-field (FF) parameters for it. Therefore we 
generated the charges and FF parameters with the consistent way used in the development of the 
PARM94 in AMBER. 
Determination of charges and FF parameters for FoU 
We took the thymine nucleoside structure (DTN) in AMBER6 as the initial structure and 
then changed the methyl group at the C5 position to formyl group. For the enol tautomeric form, 
the carbonyl group at C4 was converted to the hydroxyl group. We built the syn and the anti 
conformation of the formyl group separately. With those structures, the geometry optimization 
was performed at the HF/6-31G* level using Jaguar v4.1. The electrostatic potential (ESP) was 
calculated for the final geometry and was used as an input for the RESP module in AMBER6 to 
obtain the charges[21]. In AMBER6, sugar atoms have intermolecularly equivalent charges with 
the exception of C1’ and H1’ atoms. Those atoms were constrained to have the same charges 
given in AMBER6 during charge fitting. The sum of charges for hydrogen and oxygen in the 
hydroxyl group at the 3’ and 5’ terminal of nucleoside was constrained. The force-field atom 
types of modified part were assigned using the Antechamber module in AMBER7[22]. The 
consistent atoms with thymine kept the same force-field atomic types as in thymine. The common 
force-field parameters with thymine was taken from the Cornell et al. force field[23] given in 
AMBER6 and non-available parameters there were from the “general amber force field” 
(gaff.dat).  Table A.3 summarizes the FF atomic types and the charges used in this simulation. 
MD simulation procedures 
The DNA dodecamer was embedded in a rectangular box of TIP3P water molecules 
extended by 10 Å in each direction of a DNA solute where there were approximately 4000 water 
molecules. The sodium cations were added to neutralize the system at the electronegative points 
determined by the electrostatic potential that was calculated at the crude grid points. Some water 
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molecules clashed with cations were replaced with those ions. Most cations were located near the 
negatively charged phosphate groups. First, the minimization was performed with the DNA under 
the harmonic constraint (500 kcal/molÅ2) while only waters and sodium ions movable to relieve 
the bad contact between DNA solute and waters or cations. In the next, the constant pressure MD 
was carried out with isotropic position scaling during 25 ps while the system was gradually 
heated from 0 K to 277 K under 1 bar with the DNA still constrained (500 kcal/ molÅ2). Near the 
end of the simulation the density of the system reached ~1 g/cc. One more 25 ps constant pressure 
MD was done at constant temperature of 277 K. While releasing the constraint of the solute, the 
whole system was minimized. Then without any constraint, the whole system was gradually 
heated up from 0 K to 277 K under the constant pressure of 1 bar. After the system was fully 
equilibrated in this way, the long-term constant volume MD simulation was performed. All the 
MD simulations were done with 2 fs integration step. The particle mesh ewald (PME) method 
was used for the long-range electrostatic interaction. The cutoff distance of 9 Å was used for van 
der Waals interaction of Lennard–Jones type. 
The helical parameter analysis was done using the Curves 5.2 program[24]. The O7 of 
formyluracil was removed during analysis because the presence of O7 alters the definition of base 
axis system on the pyrimidine and affects the helical parameters especially related to bases. 
A.3 Results and discussion 
A.3.1 QM calculations of base pairing energies 
 
Figure A.1 shows the hydrogen bonding patterns of FoU and deprotonated FoU with A or 
G. They are final QM-optimized structures obtained by the method described in the previous 
section. While the keto tautomer of FoU forms the hydrogen bonds of Watson-Crick type with A, 
the enol tautomer forms the Wobble type. The enol tautomer can form the Watson-Crick type of  
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mispairing with G through three hydrogen bonds. For the deprotonated FoU, both types of 
hydrogen bonding are possible with G. 
The enthalpies of base pairing in gas phase for the canonical AT and GC pairs are shown in 
Table A.1. It can be seen that the exclusion of diffuse function on the frequency calculation does 
not make any difference on calculation of enthalpies. In all three cases, the calculated values 
agree fairly well with experimental ones, even though the slight improvement on the pairing 
enthalpy of GC is shown when the 6-31G**++ basis set is used for the final geometry 
optimization. In the case of the anion species like the deprotonated FoU, the diffuse function  
(a) 
(b) 
(c) 
Figure A.1 Hydrogen bonding patterns of FoU with purine bases; QM-optimized structures, (a) A-
FoU(keto) Watson-Crick, (b) G-FoU(keto) Wobble (left) and G-FoU(enol) Watson-Crick (right), (c) G-
FoU(deprotonated) Watson-Crick (left) and Wobble (right). 
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Table A.1 Base pairing enthalpies in gas phase at 300 K for GC and AT calculated using B3LYP DFT 
method with three combinations of basis set§ 
 
 6-31G**/ 6-31G** 
6-31G**/ 
6-31G**++ 
6-31G**++/ 
6-31G**++ Exptl
a 
 AT (Watson-Crick) -10.9 -10.5 -10.6  
  AT (Hoogsteen) -11.5 -11.1 -11.1 -13.0 
 GC (Watson-Crick) -24.4 -23.3 -23.4 -21.0 
 
a Reference [25], § unit: kcal/mol 
 
should be included and the 6-31G**/6-31G**++ combination has been chosen for all other 
calculations in this study.  
When the FoU is paired with A, the pairing free energies slightly increase in solution phase 
as well as in gas phase, compared with those of A-T Watson-Crick pair. Since the formyl group is 
an electron-withdrawing group, the inductive effect makes the charges on the pyrimidine ring 
deficient, and the hydrogen bond would become stronger if the FoU plays a role as a hydrogen 
donor. However, the FoU forms two hydrogen bonds with A both as a donor and as an acceptor. 
Therefore such an enhancement would be nullified and the pairing energy of A-FoU would 
become similar to that of AT. From the fact of the slight stabilization in A-FoU, it can be said that 
the hydrogen bond between H3 in FoU and N1 in A plays a more important role in the A-FoU 
pairing as previously shown by Kawahara et al.[26]. 
The FoU and G can form two hydrogen bonds in the Wobble geometry and their pairing 
free energy is comparable to that of FoU-A pair. The T-G pair also has the similar strength of 
hydrogen bond to T-A pair. It shows that the FoU and T can be paired with G as frequently as 
with A when they exist as the free bases.  
Tautomerism of FoU  
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Table A.2 Pairing free energies in gas phase and in aqueous solution calculated using B3LYP DFT method 
with 6-31G**//6-31G**++ basis setsa 
 
 ΔE(BSSE) ΔH300K ΔG300K(g) Gsolv ΔG300K(aq) ΔΔG300K(aq)keto→enol 
TA [WC]e -11.9 -10.5 1.0 10.0 11.0  
TA [H]e -12.5 -11.1 0.5 10.3 10.9  
CG -25.1 -23.3       -9.1 19.8 10.7  
       
FoUA -12.4 -11.1  0.34 10.0 10.3  
FoUG -12.9 -11.5       -0.05 10.3 10.2  
FoU´Gb -25.9 (-14.8)c -25.2 (-14.4)c -12.4 (-1.4)c 18.9 6.5 (15.9)c   9.4 
       
TG -12.8 -11.3 0.5 10.6 11.1  
T´Gb -27.1 (-15.3)c -26.1 (-14.7)c -13.6 (-1.5)c 19.5 5.9 (15.4)c   9.5 
       
FoU-G [WC]e -23.4 -21.9      -10.1 19.2 9.1 (10.4)c      1.3*d 
FoU-G [W]e -29.0 -27.5      -16.2 25.3 9.1 (10.4)c      1.3*d 
 
a Unit: kcal/mol, b FoU´ and T´: enol tautomers of FoU and T, c ( ): considering energy penalty relative to 
the keto form of neutral FoU, d *: from J. Phys. Chem. A 105 274 (5-formyluracil, T = 298 K, pH = 7.00), e 
WC: Watson-Crick; H: Hoogsteen; W: Wobble 
 
The FoU and T can have enol tautomeric forms. In both FoU and T cases, the keto form is 
energetically more favorable than the enol form as shown in Table A.2 and the calculated 
equilibrium constants of tautomerism, which are defined as the concentration ratio of enol form to 
keto form, are 1.2 x 10-7 and 1.3 x 10-7 at 300 K in aqueous solution for FoU and T, respectively. 
However, one of enol tautomers could form three hydrogen bonds with G as shown in Figure A.1 
and the barrier of tautomerism would be compensated by one extra hydrogen bonding. Actually 
the calculation results show that the pairing of enol form with G in gas phase is slightly favorable 
even after considering energy penalties (11.1 kcal/mol in E0K for FoU and 11.8 kcal/mol in E0K 
for T with respect to the keto form). On the other hand, it becomes unfavorable in aqueous 
solution because of large cost of solvation energy on pairing. If we assume that the DNA bases 
would be in the lower dielectric environment in oligonucleotides than in water, the pairing of enol 
form with G would be energetically plausible in the biological system. 
Deprotonated form of FoU   
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The smaller pKa of 5-formyl deoxyuridine predicts the existence of N3-deprotonated, 
negative species on a larger amount at the physiological pH[4]. At pH = 7 and T = 300 K, the 
7.6% of 5-formyl deoxyuridine would dissociate into negative deoxyuridinium ion and proton 
while only 0.2% dissociates for deoxythymidine. The deprotonated FoU plays a role only as a 
hydrogen acceptor and therefore the pairing with A is expected to be extremely weak. Two 
possible geometries of pairing between FoU- and G are shown in Figure A.1. The first one 
(geometry I) corresponds to Watson-Crick geometry, which could be optimal since it does not 
distort the overall backbone geometry in the normal DNA. The interesting thing is that both 
geometries have a big stabilization on pairing in gas phase and their pairing free energies are 
comparable to that of the triple hydrogen-bonding pair such as GC. In the geometry I the 
repulsion between two electronegative oxygens destabilizes the hydrogen bonding, and actually 
the purine and pyrimidine rings are no longer co-planar in this structure. The extra stability in the 
pair of deprotonated FoU with G could come from the ion and ion-induced dipole interaction 
since the permanent dipole for the isolated guanine does not point toward the negatively charged 
FoU. In aqueous solution, the solvation energy for the isolated FoU- is quite huge and the final 
free energy in solution becomes comparable to those of neutral G-FoU Wobble pair and A-FoU 
Watson-Crick pair. Considering that the base pair is not fully exposed to water in the 
oligonucletide, these results support the mechanism that the ionization could allow formation of 
mispair with G during DNA replication and it would induce the transition mutation at the 
oxidized T site. 
A.3.2 MD simulations of dodecamers 
In the present MD simulation, we consider the most dominant keto form of FoU. The 
deprotonated FoU that might play a role in mispairing during the DNA replication step would 
turn into the thermodynamically most stable keto species. 
AMBER force field parameters of FoU 
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Table A.3 The AMBER type force field parameters of 5-formyluracil – keto form (top) and enol form (bottom) 
 
 
 
N3
C2
N1
C2
C3
C4
O4
O2
C7
C1'
H7
O7
H2
H3
H1'
 
 
 
 
 
 
 
 
 
N3
C2
N1
C2
C3
C4
O4
O2
C7
C1'
H7
O7
H2
H1'
H4
 
charges atom label FF atomic type (anti) (syn) 
C1' CT  0.166  0.142 
H1' H2  0.137  0.155 
N1         N* -0.010 -0.001 
C6  CM -0.196 -0.280 
H6 H4  0.298  0.286 
C5  CM -0.055 -0.041 
C7         C  0.396  0.396 
O7         O -0.518 -0.455 
H7  HA  0.067  0.001 
C4         C  0.412  0.522 
O4         O -0.527 -0.512 
N3  NA -0.295 -0.393 
H3         H  0.305  0.319 
C2         C  0.496  0.555 
O2         O -0.554 -0.573 
charge atom label FF atomic type (anti) (syn) 
C1'         CT  0.205  0.182 
H1' H2  0.104  0.121 
N1 N* -0.110 -0.083 
C6  CM -0.072 -0.178 
H6  H4  0.243  0.237 
C5   CM -0.106 -0.094 
C7          C  0.343  0.348 
O7 O -0.491 -0.457 
H7   HA  0.074  0.038 
C4   CA  0.620  0.715 
O4   OH -0.614 -0.587 
H4   HO  0.469  0.454 
N3   NC -0.738 -0.775 
C2          C  0.787  0.800 
O2 O -0.592 -0.600 
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(Unit: kcal/mol) 
 
 
 
 
 
 
 
  AMBER FFa QMb 
A:T - 15.1 -11.9 
G:C -29.0 -25.1 
A:FUA -14.3 -12.4 
A:FUS -14.3 -12.5 
G:FUA -16.3 -12.9 
G:FUS -16.4 -12.7 
  AMBER FF
a QMb X-rayc 
A:T Watson-Crick   
N1-N3 2.85 2.91 2.82 
N6-O4 2.79 3.01 2.95 
G:C Watson-Crick   
N1-N3 2.85 2.98 2.95 
N2-O2 2.74 2.94 2.86 
O6-N4 2.78 2.83 2.91 
A:FUA Watson-Crick   
N1-N3 2.86 2.89  
N6-O4 2.80 2.90  
A:FUS Watson-Crick   
N1-N3 2.86 2.88  
N6-O4 2.81 3.08  
G:FUA Wobble   
N1-O2 2.75 2.95  
O6-N3 2.80 2.77  
G:FUS Wobble   
N1-O2 2.74 2.83  
O6-N3 2.80 2.98  
(Unit: Å) 
a dielectric constant = 1; scaling of 1-4 vdW interaction = 0.5; scaling of 1-4 electrostatic interaction = 0.83; 
for deoxynucleosides b gas phase calculation; BSSE corrected; for 1-methylpyrimidines and 9-
methylpurines c From experimental X-ray crystallographic data [26]. 
Table A.4 The base pairing energies and the distances between H-bond donors and acceptors for the 
base pairs involved in the dodecamers of this work (FUA : anti conformer, FUS : syn conformer) 
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Figure A.2 Fluctuation in the root mean square deviation of coordinates (CRMSD) of DNA dodecamer 
containing FoUs (1G8V.pdb) during 1 ns simulation after equilibration; a : CRMSD with respect to the 
minimized DNA structure, b : CRMSD with respect to the mean structure over 220–1020 ps. 
 
The force field (FF) atomic types and charges for FoU developed for this study are 
tabulated in Table A.3. To validate these parameters the base paring energies and geometries 
obtained with AMBER FF are compared with those from QM calculations as shown in Table A.4. 
The overall pairing energies are a little overestimated even in the cases of the canonical AT and 
GC pair, although this might result from the extra non-bond interaction between sugar rings in 
nucleosides. However, the extent of the overestimation for the pairs with formyluracil is 
comparable to the GC and AT cases. The hydrogen bond distances agree well with each other and 
the differences are within 0.3 Å. To check the stability of the DNA conformation during the MD 
simulation with newly implemented charges and FF parameters for FoU, the time evolution of the 
root mean square deviation of coordinates (CRMSD) was calculated for the dodecamer X-ray 
crystallographic structure containing FoU (1G8V) in Figure A.2. The CRMSD value with respect 
to the mean structure is 1.24 ± 0.24 Å and it is comparable to the one calculated for the DNA 
system with normal base sequence. 
Hydrogen bond distance 
The stability of DNA structure is directly related to the hydrogen bonds (H-bonds) between 
two base pairs. The bond distances between H-bond donor and acceptor atoms were measured  
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Figure A.3 The time profile of H-bond distance between N1 from G and O2 from FoU; (a) for the syn 
conformer of FoU at the 5th position and (b) for the anti conformer of FoU at the 8th position. 
 
every 1 ps after 220 ps during the production period. For the DNA with the normal Dickerson 
sequence, the distances are within 3.1 Å in most times except for the bases at the terminal. The 
base pairs at the 5’ terminal started unraveling around 420 ps and formed the H-bonds back in 50 
ps later. The H-bonds at the 3’ terminal broke around 620 ps and stayed unraveled until the end of 
the simulation. The floppiness of the bases at the terminal is usual since they have only the one-
side stacking interaction. In the case of the dodecamer with A:FoU pairs, a similar phenomena 
were observed. The FoU in the middle of the dodecamer does not cause any instability in H-
bonds and the DNA kept the stable conformation during the simulation. However, when the FoU  
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is paired with G, the large fluctuation in H-bonds for the G:FoU pair was observed, especially in 
the case of FoU with the formyl group in the anti conformation. For the syn conformer, the H-
bonds were pretty steady. 
DNA hydration 
When the methyl group in thymine is substituted with the formyl group, this extra oxygen 
(O7) can play a role as a hydrogen bond acceptor. Figure A.4 shows the radial distribution 
function, g(r) of oxygens in water solvent. 
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Figure A.4 [(a), (b)] Normalized radial distribution functions g(r) of water-oxygen [(c), (d)] and the 
number of waters in the solvation shell obtained by integrating g(r). The thick black line, the thick gray 
line and the thin black line show g(r) of the target atoms, O7 of FoU in the G:FoU case, O7 of FoU in the 
A:FoU case and H7 of T in the A:T case respectively. (a) and (c) : the formyl group of FoU is anti at the 
8th base pair position; (b) and (d) : the formyl group is syn at the 5th base pair position. g(r) was 
normalized by the water of 1 g/cm3. ∫= drrrgn 2)(4πρ , where ρ is 0.033 molecules/Å3 for water of 1 
g/cm3. 
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Figure A.5 The snapshot of guanine and formyl uracil with the formyl group in anti conformation (at 301 ps). 
The water makes a hydrogen bond bridge between O7 of FoU and O2P of the phosphate group. The O-O 
distance between water and O7 is 2.7 Å and the other O-O distance between water and O2P is 2.5 Å.  
 
The first sharp peak that is not prominent in the thymine case is observed for the FoU case, 
especially when the formyl group is in the anti conformation. It shows that the waters around the 
oxygen of formyl group in anti are well ordered. This is because the water can make a bridge 
between O7 of FoU and O2P or O5’ from the backbone when the formyl group is anti as shown 
in Figure A.5. In the syn conformation, the O7 is located away from these oxygen atoms and the 
O4 of FoU is too close to O7 atom for a water to make H-bond bridge. When g(r) is integrated 
over the first coordination shell (r ~ 3.3 Å) for FoU at the 8th position of G:FoU and A:FoU case, 
the number of waters is approximately 1.8 for both cases. We can clearly see that the more water 
molecules are around the FoU than the thymine. 
Groove widths 
The widths of the major and minor grooves for Dickerson crystal structure (PDB ID: 
1BNA) and FoU crystal structure (PDB ID: 1G8V) were calculated using Curves program. They 
have the same crystal symmetry. If we ignore that the different experimental condition where the 
crystals were grown might affect the conformational differences, Figure A.6 shows definitely 
sequence-dependence of the groove widths. Although the overall shapes in the graphs are similar  
 187
 
 
 
 
 
 
 
 
to each other, the widths of minor grooves for the FoU case become slightly narrower and the 
major grooves get wider.  
The groove widths averaged over the MD simulation from 220 ps to 1020 ps are shown in 
Figure A.7. Since they are isolated DNA molecules immersed into the water box and less 
constrained, the absolute values of widths are larger than in the crystal structure. The dodecamer 
with the normal Dickerson sequence has an asymmetric distribution in minor groove throughout 
the sequence even though the sequence itself is symmetric. However, the dodecamer with FoU:A 
has a symmetric pattern, and the different conformation of formyl group does not seem to affect 
the width of minor groove. The replacement of T with FoU results in the significant decrease in 
the width of the minor groove. In the FoU:G case, the minor groove becomes narrower around the 
5th base pair position where the syn FoU is located and on the other hand the minor groove 
becomes wider at the 8th base pair position where the anti FoU is located. The major grooves 
become narrower for the A:FoU DNA and this change is more prominent on the side of anti FoU. 
There is a huge increase in the width of the major groove near the 5th base pair for the G:FoU 
DNA.  
Figure A.6 The widths of minor (a) and major (b) grooves. The solid line is for the crystal structure 
with 5-formyluracil (1G8V) and the dotted line is for Dickerson crystal structure (1BNA). The positions 
where the sequence differences are shown are circled. 
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Helical parameters 
The global base-base parameters are analyzed and shown in Figure A.8. These parameters 
could be the indication of the stability in hydrogen bonding. The G:FoU DNA dodecamer has the 
large shearing at the 5th and 8th position where G:FoU mispairs are located. The G and FoU have 
the Wobble geometry and they are sliding each other compared to the pyrimidine-purine pair in 
Watson-Crick geometry. Therefore the large values in shear parameter reflect the Wobble 
geometry of G:FoU pair. Since the measurement is done in the 5’→3’ direction, they have the 
opposite sign even though the sequence is symmetric. The conformation of formyl group does not 
make any difference in shearing. 
Large buckling is detected at the 4th and 9th base pair in the A:FoU DNA dodecamer, 
compared with the case of normal Dickerson sequence. These pairs that flank the central AATT 
sequence have respectively positive and negative buckles that bend the center of these base pair 
away from the central tetramer. This may contribute to severe narrowing of the minor grooves in 
the A:FoU dodecamer. The similar huge positive buckling is shown only at the 4th base pair  
Figure A.7 The minor (a) and major (b) groove widths averaged over the MD simulation from 220 ps 
and 1020 ps. The diamond, square and triangle symbol are for the normal, A:FoU and G:FoU DNA 
dodecamer, respectively. The syn FoU is at the 5th position and the anti FoU is at the 8th position as 
indicated by circles. 
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Figure A.8 The global base-base parameters. They are averaged values over the MD simulation from 
220 ps and 1020 ps. The diamond, square and triangle symbol are for the normal, A:FoU and G:FoU 
DNA dodecamer, respectively. 
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position in the G:FoU mispair case and it is reflected as the asymmetric narrowing of minor 
groove in the central part of the G:FoU dodecamer.  
The large positive opening in base pair means opening in the major groove and thus 
narrowing of the minor groove. The deviation from the normal Dickerson sequence case that 
might explain the significant narrowing in the dodecamers with FoU present is not small, and in 
all three systems the width of minor groove shows the negative correlation with opening. Figure 
A.9 shows the correlation between the H-bond distance of N1-O2 at the 8th base pair in G:FoU 
dodecamer and the opening. In most times, the N1-O2 distance is near 2.9 Å and the opening 
fluctuates by 10º around zero. When the N1 and O2 get apart, the opening becomes more 
negative. This loose H-bond at the 8th base pair contributes to the larger width of minor groove 
than one at the 5th base pair as shown in Figure A.7.   
Backbone parameters 
The torsion angles for a polydeoxyribonucleotide chain and the pseudorotation phase angle 
P of a sugar ring are calculated for three dodecamer systems. The distinct sequence-dependent 
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Figure A.9 The plot of N1-O2 distance versus the opening at the 8th G:FoU pair. The snapshot 
was taken every 1 ps during 220-1020 ps of MD simulation. 
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aspects are not seen here. The preferred sugar puckering modes are O4’-endo, C1’-exo and C2’-
endo that correspond to the “south” conformations. The structures keep B-type DNA 
conformations over the MD simulation. The phase angle P and the δ torsion (C5’-C4’-C3’-O3’) 
at the 7th base residue and the 16th base residue show a little correlation with the opening of G 
and FoU base at the 8th base pairs. The 7th and 16th bases are right ahead of this G:FoU pair in 
the 5’→3’ direction. The correlation coefficients for the P and δ torsion of the 7th base are 0.36 
and 0.36, respectively. For the 16th base, they are 0.32 and 0.34 for the P and δ torsion.  
A.4 Summary and Conclusion 
We calculated pairing free energies of various free DNA base pairs at the B3LYP/6-
31G**//B3LYP/6-31G**++ level, focusing on mispairing of 5-formyluracil which is an oxidative 
form of thymine. The free energy of keto FoU with G is comparable to that with A in both gas 
phase and solution phase while the pairing of enol FoU with G in solution phase is most 
unfavorable due to large cost of solvation free energy on pairing in addition to the barrier on 
tautomerism. The N3-deprotonated FoU forms strong hydrogen bonding with G in gas phase, 
which is energetically comparable to the triple hydrogen bonding of GC pair. The calculation in 
aqueous phase shows that mispairings of both neutral keto and deprotonated FoU with G are as 
probable as normal base pairings. 
Considering that the neutral FoU could be mispaired as frequently as T with G from the 
aspect of energetics, we conclude that the ionization at N3 position of FoU would mainly account 
for the increased misparing rate of FoU since the deprotonated FoU preferentially form H-bonds 
with G rather than A and therefore FoU has one more extra possibility of base pairing. 
The 1 ns MD simulations were then carried out for three DNA dodecamer-explicit water 
systems; one with normal Dickerson-type sequence, another with two thymines replaced by 
formyluracil in the Dickerson sequence and the other where these formyluracils are paired with 
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guanines. Even though the formyl group is on the side of the major groove, its presence actually 
leads to the severe narrowing of the minor grooves. In the case of G:FoU dodecamer, the same 
kind of narrowing was shown especially around the 5th base pair where the syn FoU makes a pair 
with G. The slightly wider minor groove at the 8th base pair position where the formyl group of 
FoU has anti conformation, is correlated with loosening of H-bonds between G:FoU. 
The formyl group of FoU in the anti conformation affects the hydration pattern around the 
DNA structure. A water molecule makes a bridge of H-bond between O7 of FoU and O2P of 
phosphate and it provides the well-ordered water structure. No significant change in backbone 
parameters is shown for A:FoU and G:FoU dodecamer.  
Overall the incorporation of FoU paired with A does not cause the significant structural 
change in DNA double helix except for the narrowing of the minor groove. On the other hand, the 
G:FoU dodecamer shows relatively larger fluctuation since it contains non Watson-Crick pairs. It 
might be worth studying how this kind of conformational distortion affects the interaction with a 
DNA-binding protein, for example like the DNA repair enzyme. More detailed molecular level 
description also should be investigated to explain the effect of the formyl group on the width of 
minor grooves. 
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